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   ABSTRACT     
Abstract 
This body of work provides descriptions of test systems, which can be used for a detailed 
assessment of physical, non-thermal atmospheric pressure plasma (APP) devices with regard 
to bio-medically relevant performance parameters. To establish and perform experiments, two 
different plasma sources were used: the plasma jet type kINPen® MED and a µs-pulsed volume 
dielectric barrier discharge (DBD) device. On the basis of a general physico-technical 
characterization of the two sources, evaluation strategies were developed to comparatively 
study (1) immediate cell damages after APP treatments and (2) to test if APPs cause genetic 
alterations in cellular DNA. Since the dermatological use of APP devices was of major interest 
in this thesis, different human skin fibroblast lines were used for plasma experiments. With the 
test systems, cell-type dependent effects of APP can be compared; moreover, a direct 
comparison of plasma-type dependent effects is also feasible.  
The first part of this thesis presents common test systems for the basic physical 
characterization, which include measurements of electric current, gas temperature and 
resulting thermal output, ultraviolet (UV) radiation, and emission of potentially unhealthy gases. 
Based on these measurements, a risk assessment was possible, which indicate that the two 
sources can be safely used as medical tools, but also exhibit plasma-specific handling and 
application requirements. Furthermore, a number of bio-medically relevant performance 
parameters of the sources were investigated: inactivation efficiency against pathogens, 
cytotoxicity on human skin fibroblasts, and chemical changes of plasma-treated phosphate 
buffered saline (PBS) solution. The results demonstrated that the impact of APPs on cells differ 
due to their different physical and chemical properties. Most, but not all, of the test systems 
presented here were published in the context of a cooperation with other groups as German 
DIN-Specification 91315. 
The second part of the thesis presents test systems for the assessment of long-term damages. 
The genotoxic and mutagenic effects of plasmas on isolated and cellular deoxyribonucleic acid 
(DNA) were examined with different techniques: host cell reactivation assay, DNA separation 
via gel electrophoresis, plasmid shuttle vector assay, and flow cytometry based on staining of 
phosphorylated histone proteins. The assessment of possible plasma-induced long-term 
damages is of utmost importance because some of the plasma components, like reactive 
oxygen species (ROS) and UV radiation, are well known to affect DNA. Particularly in 
dermatological therapies of wounds, potential mutagenic side effects induced by plasma 
application would lead to serious health risks, since the skin of patients will be directly exposed 
to plasma and, thus, also proliferative cells in the wound area.  
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The level of impact of the two plasma sources on cells and isolated DNA was compared. At 
same treatment durations, plasma jet treatments usually induced stronger effects than DBD 
applications. In particular, a higher cytotoxicity and genotoxicity was observed. However, only 
a tendency towards a mutagenic effect was seen. In contrast, in experiments on plasmid DNA, 
which was located inside the cells during plasma treatments, no mutagenic effect was detected 
for either of the two sources. But, an increased formation of double strand breaks in genomic 
DNA could be demonstrated.  
Calculations of plasma doses within given treatment durations revealed that in same time 
periods the plasma jet transfers higher energy densities to the treatment object than the DBD 
plasma. On the other hand, the DBD plasma was shown to generate much higher ROS and 
RNS concentrations during the same treatment time. In some parts these findings can explain 
the observations in this thesis. It is, however, assumed that mainly ROS and UV radiation are 
responsible for the different effects of the two plasma sources.  
With the assays presented here, a valuable basis for a more detailed evaluation of different 
plasma jet systems and volume DBD devices with regard to their medical usability is created. 
Moreover, such APP sources can now be characterized and their desired therapeutic 
applications can be assessed on a standardized, quantitative basis.  
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1. Introduction 
In the last years, intensive research was done on the various effects of biocompatible physical 
plasma on living organisms and tissues whereby the awareness of its beneficial properties in 
medical applications became increasingly clear. From this research, the new and 
interdisciplinary field of plasma medicine evolved. In this field, physicists, engineers, medical 
doctors, and biologists cooperate closely with the purpose of using plasma as a medical tool 
to treat and alleviate symptoms or even cure diseases. One of the first milestones in plasma 
medicine was the production of non-thermal plasma under atmospheric conditions, also known 
as biocompatible or cold plasma. The temperature of such plasmas is usually below 40 °C, 
which is a prerequisite for the treatment of heat sensitive materials, living organisms, or whole 
tissues. Before that, thermal plasmas have been used as standard practice in medicine, e.g. 
to cauterize tissues, coagulate blood, or for sterilization and decontamination of thermally 
stabile materials [1–4]. Now, many studies focus on the effects of components generated in 
non-thermal and biocompatible atmospheric pressure plasma (APP) on living prokaryotic or 
eukaryotic cells, cell structures and components, benign and malignant tissues of plants, 
animals, and humans.  
Particularly in dermatology, plasma is thought to be a new medical hope for the treatment of 
numerous skin diseases. Researchers find more and more evidence that plasma stimulates 
and supports healing processes of the skin in many different ways [5–9]. This is because 
physical APPs contain various biologically and chemically active components, such as reactive 
oxygen species (ROS), reactive nitrogen species (RNS), electrons, ions, and neutral 
molecules. Moreover, artificial optical radiations, which include ultraviolet (UV) radiation as well 
as electric currents, are produced in the plasma. During plasma treatment, all these elements 
are acting simultaneously; they may reinforce or diminish one another by interactions and, 
thus, lead to numerous effects. The plasma cocktail, meaning the composition of the plasma 
elements, strongly depends on the way plasma is produced. Changing the working gas, power 
supply, or electrode configuration greatly influences plasma composition [10]. Nowadays, 
many research groups have developed their own individual plasma source, which is why each 
device has unique physical properties. For this reason, a comparison of experimental results 
based on different plasma sources and different experimental setups is not possible. Only if 
the experimental procedures are standardized, meaning that same test assays, treatment 
conditions, and organism or tissues are used, a comparison of the biological impacts of 
different plasmas is scientifically reasonable. In addition, with regard to medical applications 
of APP sources another aspect is immensely important: the safety in use. Each individual 
plasma component or element bears its own risk factor. General risk factors originating from 
plasma include in particular: plasma temperature, radiation, ROS and RNS, emission of toxic 
— 3 — 
INTRODUCTION      
gases, and electric currents. If plasma temperature is too high, this can cause burns, high 
doses of UV radiation may induce the development of skin cancer, and electrical currents could 
lead to electric shocks. Even though these risks are well-known in the plasma community and 
have already been discussed in several reviews [7–9], basic criteria for the use of medical 
plasma sources and guidelines for their safe use are still missing. 
Aims of the study 
The first aim of this study was to define generally accepted, plasma specific standards and 
basic safety criteria for medical plasma sources. In collaboration with others, this was achieved 
by creating and publishing a German DIN (‘Deutsches Institut für Normung’)-Specification 
document (DIN-SPEC 91315) titled “General requirements for plasma sources in medicine” 
[11]. Physical efficiency measurements and some biological experiments from my thesis are 
part of this DIN-SPEC. In the document test systems are introduced that are appropriate for a 
first, general evaluation of physico-technical performance characteristics of plasma sources 
(i.e. plasma temperature, thermal output, artificial optical radiation, UV radiation, gas emission, 
and electric current), as well as general bio-medically relevant effects (i.e. inactivation 
efficiency against microorganisms, cytotoxicity on human skin cells, and chemical changes of 
plasma-treated liquids). This allows a basic evaluation of the biomedical potential of APP 
sources. In addition, a general characterization will indicate if a plasma device is suitable as 
therapeutic tool and may even reveal the best application field for a specific device; this applies 
especially to new plasma sources in the early stages of their development. Furthermore, based 
on a standard characterization according to DIN-SPEC 91315, biological effects caused by 
different plasmas can be compared. Such tests will provide a quantitative basis to identify the 
best and most appropriate application(s) for individual sources. 
The basic biomedical characterization described in DIN-SPEC 91315 mainly aims at direct and 
at short-term effects of therapeutic plasma applications. However, plasma-induced long-term 
damages are also of great interest, especially in the field of dermatology where the skin of 
patients is exposed to plasma and most treatments require repetitive applications during the 
therapeutic process. Plasma includes components that are widely known to be mutagenic, e.g. 
UV radiation and different ROS. UV radiation is able to generate deoxyribonucleic acid (DNA) 
photoproducts like cyclobutane pyrimidine dimer (CPD) or and pyrimidine-(6-4)-pyrimidone 
dimer (6,4PP) [12–16], while strong oxidative ROS like the hyperoxide anion (O2●-) and the 
hydroxyl radical (OH●) oxidize DNA molecules leading to oxidative DNA lesions, strand breaks, 
or other DNA modifications [17–19]. Moreover, other components of plasma like RNS, and 
discharge currents potentially have an impact on the biological system of a skin cell. Therefore, 
the second major aim of this thesis was to establish test systems to study long-term effects on 
human skin cells induced by plasma applications. Both, the genotoxic and the mutagenic effect 
of APP treatments on human skin fibroblasts was studied using the host cell reactivation (HCR) 
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assay, agarose gel electrophoresis, the plasmid shuttle vector (PSV) assay, and a flow 
cytometry assay based on γ-H2A.X staining. 
The third aim of this project was to develop test systems and experimental settings that can 
be easily adjusted to as many different plasma devices as possible. Therefore, two different 
types of APP sources were chosen: the kINPen® MED as plasma jet device and a µs-pulsed 
volume dielectric barrier discharge (DBD) source. Both types of plasma devices are known to 
be suitable for skin applications and have previously been used for experimental biomedical 
applications [9, 10, 20–25]. On the basis of the assays established in this thesis, a direct 
comparison of these two sources with regard to their physical efficiencies and biomedical 
effects is possible.  
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2. Theoretical Basics 
In this chapter necessary background information about important aspects of this work is 
provided. Since the project was performed in the interdisciplinary field of plasma medicine 
physical, chemical, medical, and, of course, biological knowledge is presented in three main 
sections. The first section ‘Plasma technology’ includes a short introduction of the physical 
term plasma and how it can be produced, followed by a more detailed description of 
biocompatible atmospheric pressure plasmas and important chemical kinetics of plasma-liquid 
interactions. The second section provides dermatological background information about the 
structure and function of the skin and the process of wound healing with a focus on human 
fibroblast cells. In the last section, some of the current research areas in plasma medicine are 
introduced. In addition, the current state of knowledge about beneficial effects of APP for 
dermatological applications is summarized. 
2.1 Plasma technology 
Plasma is defined as partially or completely ionized gas, in which some electrons are separated 
from their atomic union. Viewed as a whole, plasma is electrically quasi-neutral and conductive. 
In 1879 Sir William Crookes first described this state as “radiant matter” [26] followed by the 
introduction of the term plasma by Irvin Langmuir in 1928 [27]. From a cosmological point of 
view, the most matter of the visible universe exists in the physical plasma state; e.g. cosmic 
orbs such as suns and stars, but also solar corona, stellar winds, and shining interstellar 
clouds. On earth, the plasma state is visible as natural phenomena like the aurora borealis or 
lightening in thunderstorms. Plasma can be produced by high energy inputs to a neutral gas; 
e.g. by radiation energy (e.g. UV or thermal excitation), strong electric fields, or kinetic energy 
[28]. Consequently, plasma comprises the highest enthalpy of all physical states (Fig. 1). 
Figure 1: Schematic illustration of the four physical states 
With increasing enthalpy of the system, the physical state of matter of atoms (grey spheres) changes from solid, to 
liquid, to gas, and finally to the plasma state where electrons (negative blue spheres), ions (positive red spheres), 
and neutral atoms coexist. 
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Depending on the production of the plasma, it can exist in two basic forms: non-thermal and 
thermal plasma.  
In thermal or equilibrium plasma electrons, ions, and neutrals have almost the same 
temperature. Due to the high electron temperature (Te) of about 10,000 K, the ion temperature 
(Ti) and the neutral gas temperature (Tn) in such equilibrium plasmas can reach several 
hundred or thousand degrees (Te ≈ Ti ≈ ) [29]. The electron density in thermal plasmas is very 
high (1021-1026/m3) [28]. Via so called inelastic collisions of electrons with heavy particles (ions, 
neutrals) in the gas, reactive species are produced. Simultaneously, elastic collisions of 
electrons and heavy particles increase the plasma temperatures [28]. This kind of plasmas are 
commonly used in industrial processes such as metal cutting and welding or surface coating 
by plasma spraying [30–32], but are also found in mercury or Xenon arc lamps for example.  
Non-thermal or non-equilibrium plasma is characterized by different temperatures of electrons 
(extremely hot) compared to ions and uncharged particles (around room temperature; Te ≫ Ti 
and Te ≫ Tn with Ti ≈ Tn). The electron density is low (< 1019/m3) and mainly inelastic collisions 
and only few elastic collisions of electrons and heavy particles take place [28].  
Plasma can be also classified according to the pressure levels in which the plasma is 
produced: low-, high-, or atmospheric-pressure plasma. In this work only non-thermal plasma 
devices which operate under atmospheric pressure were utilized. 
2.1.1 Biocompatible atmospheric pressure plasma 
Biocompatible APPs are usually generated by electrical excitation of a neutral gas or a gas 
mixture, which produces many different chemically and biologically active components. In 
contrast to low- or high- pressure plasma production, there is no need for complex and cost-
intensive vacuum systems or chambers to maintain the pressure conditions. Accordingly, 
portable APP systems with handheld application devices can be designed.  
APPs for biomedical applications are mostly generated by applying high voltages to electrodes 
facing each other. Due to this arrangement the gas between the electrodes is partially ionized. 
One way to keep the plasma at low temperature is to electrically isolate at least one electrode 
with a dielectric cover [33]. Generated charge carriers (electrodes and ions) are thereby 
prevented from flowing off to the respective electrode and thus accumulate at the dielectric 
layer. This also prevents the generation of arc discharges across the discharge gap [34]. When 
high voltages are applied to the electrodes plasma ignites in so called microdischarges or 
microfilaments, through which the charge carriers are transported to the opposite electrode 
within a few nanoseconds. Microfilaments are spatially and temporally distributed between the 
electrodes and thus lead to a rather inhomogeneous type of discharge [35]. DBD devices with 
such configurations are also called volume DBDs. The electrons and ions generated in the 
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discharge interact with other molecules in the gas generating radicals, metastable products, 
excited molecules, and atoms. Excited molecules, i.e. N2, can spontaneously emit photons 
due to relaxation. This leads to the characteristic glow of plasmas whereby the color of the 
emitted light depends on the gas being excited. 
In this study a volume DBD was used, which runs under burst mode with short high voltage 
pulses in the microsecond range and, therefore, will be called µs-pulsed volume DBD device. 
This source only consists of one electrode covered by a dielectric whereby the treated material 
acts as counter electrode. The air between the electrode and the treated object is ionized to 
produce the plasma.  
The other source used during this project was a plasma jet type. It includes a dielectric layer, 
which separates a pin and a round electrode. Argon gas is directed through the small tunnel 
between the electrodes and a high voltage with a very high repetition frequency of about 1 MHz 
is applied to the electrodes. Rare gases like helium or argon are preferably used for operating 
plasma jet sources, because lower energy inputs are necessary for plasma ignition [36]. 
Moreover, it stabilizes the discharge and species composition generated in the plasma is more 
accurately definable. Through admixture of O2 or other molecules, the production of desired 
reactive species can be controlled [36, 37]. Also, shielding gases can be used to build a defined 
atmosphere around the plasma jet to modify and regulate species mixture in the effluent [38–
40]. However, using ambient air instead of noble gases would increase the amount of 
generated reactive species [41].  
There are other possible configurations of electrodes for plasma devices and a wide range of 
power supplies that can be used to ignite the plasma (from direct current, alternating current, 
radio frequency to microwaves). Furthermore, different operating modes are possible, i.e. burst 
mode and continuous mode, which also will affect plasma physics. More detailed information 
about APP sources preferably used for biomedical applications can be obtained in the following 
comprehensive reviews [8, 10, 42]. 
2.1.2 Plasma chemistry and plasma-liquid interactions 
Chemical kinetics of plasma-liquid interactions is of special interest regarding biological and 
medical studies where tissue or cells are exposed to plasma because they are surrounded by 
an aqueous milieu. In in-vitro studies on cell cultures for example, a thin liquid layer covering 
the cells is often required to prevent dehydration of the cells during plasma treatments [43–
47]. In dermatological treatments of wounds, plasma constituents will initially react with 
molecules in the wound liquid and produce reactive species. In general, highly energetic 
particles in the plasma-liquid interface will react quickly with nearby molecules and, therefore, 
may not directly hit the cells. In contrast, long-living species are more likely to reach the cells 
via diffusion. 
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It was already demonstrated that depending on the composition of the liquid surrounding the 
cells during plasma treatment different cellular responses can be induced [21] showing that 
individual plasma-liquid interactions took place. Moreover, plasma chemistry and, therefore, 
plasma-liquid interactions strongly depend on physical settings of the plasma source and the 
process gas used for ignition of the plasma [48]. In this context, electron temperature has to 
be mentioned as a key parameter that determines which types of reactive species are 
produced and in which concentrations certain species occur. Some researchers use 
computational model simulations to calculate possible reaction paths and predict generated 
species in and around plasmas [40, 49, 50]. 
Even though the two plasma sources used in this project are driven with different working 
gases (kINPen® MED source is driven with argon gas and the µs-pulsed DBD source ignites 
in ambient air) basic plasma chemistry of the two plasmas overlap since both interact with 
same molecules or atoms in ambient air and aqueous solutions. The reactions listed below are 
selected examples for possible reaction paths with important end products in and around the 
plasmas. In order to allow an approximate complete consideration, hundreds of reactions must 
be considered [40, 50]. 
As one of the first reactions, free electrons may react with H2O (Eq. 1-3), N2 (Eq. 4), or O2 (Eq. 
5 and 6): 
e + H2O  H + OH + e,    (1) 
e + H2O  O- + H2,     (2) 
e + H2O  OH- + H,     (3) 
e + N2  e + 2 N,     (4) 
e + O2  O2-,      (5) 
e + O2  O- + O.     (6) 
In case of the plasma jet, Ar in its ground state is being ionized within the plasma by inelastic 
collisions with highly energetic electrons leading to an excited argon gas atom (Ar*; Eq. 7): 
e + Ar  e + Ar*.     (7) 
The energy from excited Ar* can dissociate other molecules in the air surrounding the plasma 
jet (i.e. reacts with H2O, N2, or O2; Eq. 8-10): 
Ar* + H2O  Ar + OH + H.    (8) 
Ar* + N2  Ar + 2 N,     (9) 
Ar* + O2  Ar + 2 O,     (10) 
Furthermore, reactions with other impact partner (IM) in the vicinity of the plasma take place 
that lead to the formation of long-living species in APPs like O3 (Eq. 11) and H2O2 (Eq. 12): 
O + O2 + IM  O3 + IM,    (11) 
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2 OH + IM  H2O2 + IM.    (12) 
Also, other biologically important molecules like different nitric oxides are generated, for 
example NO (Eq. 13 and 14), NO2 (Eq. 15), and NO3 (Eq. 16): 
N + O2  NO + O,     (13) 
N + OH  NO + H,     (14) 
O + NO + IM  NO2 + IM,    (15) 
O + NO2 + IM  NO3 +IM,    (16) 
In liquid environments NO2- and NO3- can also be formed via the products HNO2 and HNO3 
(Eq. 17-19 and Eq. 20-22, respectively): 
NO + OH + IM  HNO2 + IM,    (17) 
HNO2 + OH-  NO2- + H2O,    (18) 
HNO2 + H2O  NO2- + H3O+,    (19) 
NO2 + OH + IM  HNO3 + IM,   
 (20) 
HNO3 + OH-  NO3- + H2O,    (21) 
HNO3 + H2O  NO3- + H3O+.    (22) 
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2.2 Skin structure and function 
The human skin is one of the biggest and functionally seen the most extraordinary organ of 
the body. As barrier to the external world it incessantly communicates and adapts to 
environmental influences, while at the same time protecting us against external damages by 
toxic agents, microorganisms, mechanical insults, and UV radiation. Moreover, it is involved in 
essential body functions like thermoregulation, skin hydration, sensory perception, and 
immune defense [51]. This highly dynamic organ undergoes constant change as cells from 
deeper layers are moving towards upper layers to replace shedding cells. The skin is divided 
into three structural layers (from apical to basal):  
1. The epidermis as the outermost layer serves as chemical and physical barrier between 
the interior and the exterior environment. 
2. The dermis is responsible for oxygen and nutrient supply to the epidermis and gives 
structural support to the skin. 
3. The subcutis is an important storage of fat. 
1. Epidermis 
The epidermis mainly consists of keratinocytes that build a stratified squamous epithelium. 
During the migrating from the basal to the top layer of the epidermis, keratinocytes undergo a 
terminal differentiation including structural and physiological alterations, which usually take 
about 28 to 30 days. The main product that is synthesized by the keratinocytes is keratin. 
According to the types of keratin proteins produced and differences in keratin maturation, five 
separate layers are defined in the epidermis (Fig. 2) [52]: 
1) The stratum basale comprises proliferative keratinocytes that are connected with each 
other by desmosomes. At the base, the cells are attached via hemidesmosomes to a thin 
membrane, which is called the basal laminar. This membrane functionally separates the 
dermis from the epidermis [53, 54]. Melanocytes that produce the pigment melanin to 
provide protection against UV radiation are also present in this layer, as well as 
mechanoreceptor cells; the Merkel cells that often are associated with sensory nerve 
endings. On fingers and toes, these cells are present in particularly large numbers [52]. 
2) In the stratum spinosum keratinocytes are in their early differentiation phase when they 
build characteristic short and spiky extensions of their surfaces. Now, other keratin 
proteins are expressed (Fig. 2). In this layer the majorities of Langerhans cells are located 
but are also present in all other epidermal layers. They are premature antigen-presenting 
dendritic cells that are important for immunological responses of the skin [52]. 
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Figure 2: Schematic illustration of epidermal layers 
Each epidermal layer (right side) comprises keratinocytes in different developmental stages from proliferative cells 
at the basal lamina up to corneocytes that descale from the skin. In each stage (written in bolt letters; left side) 
keratinocytes express different keratin proteins and are characterized by other structural proteins and complexes. 
3) In the stratum granulosum keratinocytes form and accumulate lamellar bodies that contain 
lipids as main component [55]. Furthermore, keratinocytes produce keratohyalin granules 
predominantly filled with the precursor protein profilaggrin [52]. 
4) The stratum lucidum is a very thin layer between the stratum granulosum and corneum, 
which is more pronounced on palms and soles. At this stage, keratinocytes lose their 
nuclei and other organelles [52] and secrete the content of the lamellar bodies via 
exocytosis to form impermeable membrane stacks in the extracellular space that serve as 
water barrier. 
5) Mature keratinocytes form the most apical layer of the epidermis; the stratum corneum. 
Profilaggrin is now dephosphorylated and proteolysed into multiple filaggrin monomers, 
which associate with keratin intermediate filaments to form tight bundles of parallel aligned 
filaments. This process causes a highly insoluble keratin matrix and further compression 
of the cells. Together with a number of other structural proteins, the keratin matrix deposit 
at the cytoplasmic membrane and thereby form the cross-linked cornified envelope. The 
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cells are now terminally differentiated, non-viable, and are called corneocytes connected 
through corneodesmosomes [52]. They are continuously scaled from the skin, a process 
which is called desquamation. 
2. Dermis 
The dermis is a strongly vascularized tissue and highly pervaded by nerves and lymphatic 
systems. It is subdivided into two layers, stratum papillare and stratum reticulare, which cannot 
be sharply distinguished from each other. The stratum papillare is located directly underneath 
the epidermis and owes its name from cone shaped loops of collagen fibers rising as 
connective-tissue papillae into depressions of the epidermis. Melanocytes and high numbers 
of mast cells are found in this layer. At this interface the dermis serves as supply zone for the 
epidermis, which itself does not contain any blood vessels. The stratum reticulare is a denser 
and irregularly arranged connective tissue.  
Figure 3: Structural arrangement of the connective 
tissue in the dermis 
Fibroblasts express the major connective tissue 
components, e.g. hyaluronic acid, collagen, and elastin. 
 
 
Fibroblasts represent the major cell type of the dermis. They synthesize proteoglycans, 
hyaluronic acid, glycoproteins, elastin and collagen (after secretion collagen polypeptide 
chains self-assemble to collagen fibrils in the extracellular space by polymerization process), 
which make up the extracellular matrix (Fig. 3). This provides tear strength and elasticity to the 
skin. Furthermore, the dermis comprises sweat glands, hair follicles and sensory cells, such 
as the Meissner corpuscles (fast-adapting pressure receptors) and Ruffini corpuscles (slowly 
adapting receptors for perception of stretch and shear) [52]. In response to skin injuries 
fibroblasts proliferate and the secretion of cytokines is reinforced, which is why fibroblasts play 
a crucial role in wound healing processes. 
3. Subcutis 
The subcutis is a loosely arranged and fatty connective tissue. It serves as shock absorber, 
and is important for thermal insulation and energy storage. The subcutaneous tissue contains 
numerous blood and lymph vessels, sweat glands and hair roots. Moreover, it is pervaded by 
a dense nervous network, the endings of which are spreading to all layers of skin. The different 
sensory cells transduce stimuli like pain, warmth, cold, and pressure. The sensory cell type 
Pacinian corpuscle is located in the subcutis. They respond to fast changes of stimuli and 
especially are responsible for vibration perception [52]. 
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2.2.1 Stages of wound healing 
Normal wound healing includes highly dynamic but strictly directed biological processes, like 
coagulation, inflammation, matrix synthesis and deposition, angiogenesis, and remodeling 
[56]. Immediately after skin injuries the endogenous immune defense is activated 
simultaneously with various skin cells, including fibroblasts. Numerous growth factors, 
cytokines, and integrins are released that initiate and coordinate the complex healing process. 
Major phases in wound healing are described sequentially. However, only the most important 
cell types and molecular factors, which are affected by plasma applications, are mentioned 
and described. In general, three main phases of wound healing are defined [57]: 
1. Hemostasis and inflammation 
Damage to blood vessels leads to an influx of thrombocytes into the wound region. They clump 
together after contact with collagen to stop the bleeding, which is called coagulation. The 
activated thrombocytes subsequently secrete many different signaling substances, such as 
cytokines that initiate the inflammation process. Chemo-attractants, for example platelet-
derived growth factor (PDGF), interleukin (IL)-1, tumor necrosis factor-α (TNF-α), and 
transforming growth factor (TGF)-β are secreted by thrombocytes. These factors attract 
neutrophil granulocytes, macrophages, fibroblasts, and smooth muscle cells. The growth factor 
TGF-β further activates macrophages to secrete various signal molecules (different fibroblast 
growth factors (FGFs), ILs, PDGF, and TNF-α). In the further course of the inflammation phase, 
neutrophils clean the wound by removing eliminated bacteria, destroyed matrix components 
like collagen, as well as dead cells using matrix metalloproteinase (MMP) and elastase [57, 
58]. Mast cells release specific amines and enzymes that digest surrounding vessels to 
enhance cell migration and transport into the wound. This also causes water deposition and 
typical inflammatory symptoms such as swelling and redness occur [59, 60]. At the same time, 
monocytes differentiate into specific wound macrophages in response to the release of the 
cytokine interferon-γ (IFN-γ) by fibroblasts. They are responsible for further thorough cleaning 
of the wound and additional ejection of PDGF and TGF-β to boost the chemotaxis of fibroblasts 
and muscle cells into the wound bed [61]. To recruit more macrophages and fibroblasts, 
additional chemo-attractants are being released by macrophages: TNF-α, IL-6, granulocyte 
colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor 
(GM-CSF). Subsequently, fibroblasts also release IL-6, G-CSF, and GM-CSF [57]. 
2. Proliferation 
Cell-cell junctions (desmosomes) and cell-substrate junctions (hemidesmosomes) are 
decomposed so that keratinocytes can migrate into the injured tissue in order to rebuild the 
epidermal layers. Fibroblasts also migrate into the wound and begin to proliferate and deposit 
new extracellular matrix components; proteoglycan and fibronectin. Furthermore, fibroblasts 
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are stimulated by macrophages to express IL-6 and FGF10, which leads to the initiation of 
epithelialization by activating proliferation and migration of keratinocytes. In addition, 
fibroblasts but also macrophages release proteases that transform the inactive TGF-β into the 
active form. This in turn stimulates fibroblast proliferation and collagen synthesis and 
simultaneously inhibits the collagenase activity [57, 60]. Active fibroblasts, immune cells, and 
macrophages continue to secret cell-type specific sets of signal molecules (inter alia growth 
factors, integrins, keratins, chemokines, and MMPs) to further sustain the directed remodeling 
of the tissue.  
3. Maturation and remodeling 
In the final phase of wound healing the different skin layers as well as connective tissue and 
blood vessels are completely rebuilt. Macrophages now produce IL-10 that inhibits the invasion 
of neutrophil granulocytes and reduces the secretion of IL-1β, monocyte chemoattractant 
protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, IL-6, and TNF-α [62]. In addition, 
other growth factors (e.g. epidermal growth factor (EGF), TGF-α, vascular endothelial growth 
factor (VEGF), bFGF, and TGF-β) are released by fibroblasts, macrophages, keratinocytes, 
endothelial cells, and thrombocytes required for remodeling of connective tissue, enhanced 
angiogenesis in the wound area, and the correct formation of epidermal layers. Environmental 
factors in the wound bed like pH, oxygen partial pressure, and increased lactate values play a 
major role in the recruitment of new blood vessels [60, 63]. 
2.2.2 Chronic wounds 
Chronic wound conditions occur when wounds do not heal in a proper way. Wounds are 
classified as chronic when they persist for over three months without signs of healing or when 
they are not completely cured after 12 months [64]. They are characterized by a malfunction 
to progress through the normal phases of wound healing and remain in a pathological 
inflammation phase. This leads to a delayed, incomplete, and uncoordinated healing process. 
In most cases chronic wounds are a result of vascular diseases leading to ischemia, such as 
the lower leg ulcer ulcus cruris. Other causes include metabolic, neuropathic, genetic or 
hematological pathology, dermatosa, as well as severe mechanically, thermally, or chemically 
induced skin injuries [65]. Often, chronic wound conditions are accompanied by bacterial 
and/or fungal infections whereby the process of healing is further strongly inhibited [56, 66, 
67]. Bacteria may even build a biofilm shielding the wound. As a result of pathogenic 
overgrowth and infection other complications may arise, like abscess formation, gangrene, or 
sepsis [68]. The abnormal inflammatory profile includes excessive numbers of neutrophils in 
the wound bed that express degradative MMPs and elastase; thus, the concentrations of these 
enzymes are too high in the wound. Moreover, there is an imbalance between MMPs and their 
inhibitor proteins (i.e. tissue inhibitors of metalloproteinase (TIMP)), which favors degradation 
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of collagen and elastase. In addition, also too high numbers of inflammatory cells are present 
in the wound and, therefore, excessive amounts of inflammatory cytokines like TNF-α are 
released [69]. Pro-proliferative factors (e.g. PDGF) and matrix depositing factors (e.g. TGF-β) 
are reduced though [70]. All these factors influence the functionality of fibroblasts. Because of 
the high degradation rate of collagen by MMPs for example, fibroblasts fail in depositing 
enough extracellular matrix. Furthermore, some fibroblasts show an impaired migration 
behavior and a reduced response to growth factors [68]. In general, proteases and radicals 
persist in the wound and mitogenic activity of cells is suppressed. Some fibroblasts differentiate 
to myofibroblasts important for wound contraction in the later phases of wound healing and 
scar formation. Sometimes, deregulated fibroblasts show an uncontrolled and excessive 
synthesis of collagen, which cannot be efficiently deposited in the extracellular matrix leading 
to fibrosis [60].  
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2.3 Plasma medicine (special focus on dermatology) 
The first study, in which an APP glow discharge was used for the bacterial inactivation of 
Pseudomonas fluorescens HK 44, was conducted in 1996 [71]. Because the strong inactivation 
efficiency was evident, many other researchers focused on decontamination and sterilization 
effects of plasma against a broad spectrum of different microorganisms. In the beginning of 
the 21th century more researchers expanded the knowledge about plasma-cell interactions on 
mammalian cells. In 2003 researchers reported that plasma treatments with a plasma needle 
of eukaryotic cells do not necessarily induce cell death but under mild treatment conditions 
rather lead to the detachment of cell-cell and cell-substrate connections [72]. This effect was 
reversible, i.e. after some hours cells attach and connect again. It was suspected that ROS 
and RNS produced in the plasma were mainly responsible for cell detachment by damaging 
cell adhesion molecules like integrins and cadherins.  
Over the next years, more and more plasma researchers focused on detailing dose dependent 
effects of plasma treatments. The term plasma dose refers to the energy density, which is 
transferred to a treatment target and is specified with the unit J/cm2. The plasma dose can be 
either varied by treatment duration with plasma or by changing physical setting like input power 
or voltage, which in turn alter the composition of bioactive components such as the 
concentration of reactive species for example. In the simplest way results of plasma dose 
dependent studies can be summarized as follows: Very high plasma doses result in increased 
numbers of apoptotic and also necrotic cells [73]. Medium doses of plasma can evoke 
apoptosis [74]. Low doses of plasma lead to cell detachment from substrate and dissolved cell-
cell interactions. However, cells remain viable, and after some time reattach and proliferate 
again [74–76]. In some cell types, very low doses even induce higher proliferation rates [44, 
74, 77].  
The controlled induction of apoptosis in eukaryotic cells opened up new therapeutic 
applications for plasma, for example the selective killing of cancer cells [78]. Different cellular 
mechanisms underlying apoptosis were already described, such as DNA damages (including 
strand breaks), cell cycle checkpoint arrest, mitochondrial dysfunction, or up- and down-
regulation of apoptosis affecting proteins, for example an accumulation of the tumor 
suppressor protein p53 [21, 79–84]. Most importantly, studies indicate that cancer cells are in 
general more vulnerable to plasma applications than healthy cells. Therefore, nowadays 
cancer therapy with plasma seems conceivable [81, 85–87]. In-vivo experiments on mice 
indeed demonstrated that plasma applications inhibited tumor growth without damaging the 
surrounding healthy tissue and, therefore, increased the survival rate of the animals [85]. Here 
again, reactive species, especially ROS, are thought to play a major role in triggering apoptosis 
in cancer cells [85, 88–90].  
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Besides cancer medicine, other medical research fields like dentistry, cosmetic medicine, and 
especially dermatology steadily gained interest during the last decade. In dentistry, for 
instance, plasma is used to break up and remove biofilms on implant materials or in root canals 
[91, 92]. Moreover, in combination with H2O2, plasma treatment efficiently is able to bleach 
tooth [93]. Cosmetic plasma applications involve treatments of diseases like acne, as well as 
treatments to improve the aesthetic appearance of the skin, i.e. scars and wrinkles [94–96]. 
Severe bacterial or fungal skin infections that play a fundamental role in widespread skin 
diseases such as atopic dermatitis and other eczema or chronic wounds are of special concern 
in dermatology and, therefore, are in focus of medical plasma therapy. In the following section 
more information on dermatological plasma applications is provided. 
The vast number of new potential therapeutic applications with APPs led to the introduction of 
the new term ‘plasma medicine’ in 2007 with announcing the first ‘International Conference on 
Plasma Medicine’ [97]. The term summarizes all non-destructive plasma treatments of 
mammalian cells and/or tissue to modify cell responses for specific therapeutic purposes. 
Dermatological applications of biocompatible APP (state of knowledge) 
Due to its physical propagation and properties cold APP seems to be perfectly applicable on 
the skin; it adapts to uneven surfaces and can transfer biologically active components into 
small cavities. Some reviews were already dedicated to dermatological plasma applications in 
which a number of skin diseases are suggested that could be beneficially treated with plasma 
treatments [7, 9, 23, 98]. The most important findings regarding beneficial plasma effects for 
dermatological therapies are presented below. 
Differential effects of plasma on eukaryotic and prokaryotic cells 
The well-known strong antimicrobial and antiviral properties of plasma play a crucial role in 
plasma medicine. Given the threat of ever rising bacterial resistance to antibiotics the 
disinfecting and sterilizing properties of APP are of particular interest in plasma medicine. It 
has already been widely demonstrated that within seconds or minutes of plasma application 
the treated skin or material can be efficiently but gently cleaned from bacteria, fungi, viruses, 
and spores [42, 99–104]. Even methicillin-resistant Staphylococcus aureus (MRSA) and other 
resistant pathogens are rapidly inactivated and killed by plasma [105, 106]. Moreover, biofilms 
can be broken up and removed [107]. Because of these remarkable properties, APP is more 
and more used as medical tool for the therapy of highly infected or chronic wound conditions. 
Some clinical trials on ulcers showed a higher reduction of bacterial load and a quicker 
improvement of wounds after plasma treatments than after standard wound care [108–110]. 
Comparing the sensitivity of bacteria and mammalian cells to plasma applications it was 
already occasionally shown that bacteria are more susceptible to same plasma doses than 
eukaryotic cells. In Wende et al. [111] for example, a self-developed in-vitro wound model was 
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developed to study the selective effect of plasma on eukaryotic and prokaryotic cells. 
Therefore, a two dimensional cell culture of keratinocytes was covered with agarose gel, 
scratches were induced, and the scratches were then inoculated with Staphylococcus 
epidermidis (S. epidermidis). After a 40 s exposure to the plasma jet source, keratinocytes 
started to grow into the scratch whereas in untreated control samples scratches even 
increased in size [111]. In another study, a commercially available full thickness reconstructed 
human skin model (EpiDermFT) was used for the same approach. The skin was injured and 
the wounds were infected with Staphylococcus aureus (S. aureus). Tissue samples were 
covered with phosphate buffered saline (PBS) and the liquid plasma electrode of the plasma 
source was held into the PBS for plasma application. 1 and 2 minutes (min) of plasma treatment 
significantly reduced bacterial colonization without causing tissue damage [112]. Furthermore, 
small pieces of porcine skin from biopsies were colonized by two different MRSA strains, 
Escherichia coli (E. coli), or S. aureus to examine the decolonization efficiency of the 
FlatPlasSter (plasma box) and miniFlatPlasSter (portable handpiece) device [105]. Results 
indicated a plasma treatment time dependent and species dependent elimination of the 
different bacterial strains and further revealed neither epidermal, nor dermal abnormalities for 
treatment durations up to 8 min. It is argued that bacteria are less effective in compensating 
high intracellular ROS levels and in repairing ROS and/or UV triggered DNA damages. Also, 
the smaller size of bacteria compared to mammalian cells may be an explanation, because the 
same dose of a toxic agent would lead to a faster injury of small bacterial cells than big 
mammalian cells. To sum up, eukaryotic cells may cope better with external stress induced by 
plasma treatments than prokaryotic cells [113]. 
Plasma-induced increase of cell proliferation 
The antibacterial effect of plasma treatment is not the only reason for an enhanced wound 
healing. In the work of Kalghatgi et al. [44] low doses of plasma (30 s ≙ 3.9 J/cm2) resulted in 
a twofold higher proliferation rate of porcine aortic endothelial cells compared to untreated 
cells. They further demonstrated that the release of FGF2 was elevated in plasma-treated cells 
and, therefore, assumed that proliferation enhancement was promoted by FGF2 release. 
Moreover, their results suggest that the increased FGF2 release resulted from cells with 
sub-lethal membrane damages induced by plasma generated ROS [44]. Similar results were 
obtained by Ngo et al. [77]. The immortalized mouse fibroblast cell line L292 responded to very 
short plasma applications (5, 10, and 15 s) with an about three times higher proliferation rate 
than non-exposed cells. In addition, cell migration increased. Both phenomena were correlated 
with elevated FGF7 release of cells and high ROS levels in cells’ surrounding medium [77]. 
APP treatments also may trigger differentiation in eukaryotic cells. Chondrogenic and 
osteogenic cells that already started their differentiation process could be for example 
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stimulated by plasma to produce intracellular ROS, which likely accelerated the process of 
differentiation [114].  
Acidification due to plasma treatment 
The human skin has a pH between 6 and 4. Such acidic environments are detrimental for many 
bacteria; pH values below 6 inhibit bacterial growth [115]. Thus, the low pH of the skin 
contributes to the natural barrier function. When the skin is injured interstitial fluids with almost 
neutral pH come in contact with the skin and, therefore, increase the pH value in wounds. 
Consequently, the natural pH of this skin area is disturbed, which simultaneously facilitates 
bacterial accumulation. As a natural body response to bacterial colonization the pH shifts back 
to an acidic milieu in wounds. This is one of the reasons why the pH value in general plays an 
important role in wound healing [115, 116]. Studies showed that the inactivation efficiency of 
plasma against bacteria was strongest for acidified solutions in which the bacteria were 
suspended [117–119]. Furthermore, lipid film surfaces taken from human foreheads could be 
acidified by volume DBD plasma application. It was hypothesized that the conversion of NO2 
molecules generated in the DBD plasma into nitric or nitrous acids drives such pH changes 
[120]. This is consistent with another study where non-buffered physiological saline was 
treated with a surface DBD device for up to 30 min (≙ 110 J/cm2), which caused a pH decrease 
from 7 to about 2. Again, it was assumed that RNS like NO are mainly responsible for 
decreasing pH values [117]. Taken together, the acidification property of APPs can be used to 
clean infected wounds and to limit bacterial growth in general. The natural healing process of 
the skin can thereby be supported. 
Plasma-induced changes in gene expressions of wound-related factors 
The few clinical APP studies in which chronic wounds were exposed to plasma showed that 
additional plasma treatments in addition to the standard wound care efficiently decreased 
bacterial contaminations of the wounds, which will support wound healing [108–110]. 
Nonetheless, this is only one mode of action regarding the improvement of healing processes. 
In order to understand the underlying mechanisms of plasma supported wound healing in more 
detail, gene expression analyses of wound healing related proteins were performed.  
In Barton et al. [121] complementary DNA (cDNA) and quantitative real-time polymerase chain 
reaction (qPCR) were used to investigate down- or upregulation of various ribonucleic acids 
(RNAs) in immortal human skin keratinocytes (HaCaT). Results showed an upregulation of a 
number of angiogenesis promoting factors, e.g. VEGF-A which enhances angiogenesis in 
damaged tissues [122, 123] and prostaglandin-endoperoxide synthase 2 (PTGS2) which is 
expressed in early stages of wound healing and activates cell proliferation [124, 125]. In 
addition, elevated RNA levels of the GM-CSF were detected after plasma treatments. GM-CSF 
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enhances keratinocyte proliferation, increases angiogenesis via VEGF upregulation, and leads 
to the recruitment of leukocytes and Langerhans cells [126–128].  
Furthermore, plasma treatments stimulated the up-regulation of heparin-binding EGF-like 
growth factor (HBEGF) [121], which is a protein that can regulate keratinocytes proliferation 
and regeneration upon skin damage [129, 130], MMP-9 that is important for reorganization of 
tissue [131, 132], and FGF10 that is known to stimulate proliferation and migration of 
keratinocytes [133]. The messenger RNA (mRNA) syntheses of the anti-inflammatory cytokine 
IL-6 was mostly influenced by plasma treatments (29-fold upregulation) [121].  
Elevated productions of different cytokines and growth factors were also shown by Arndt et al. 
[46] in cultured primary human dermal fibroblast cells exposed to the MicroPlaSter β device. 
Namely, higher amounts of IL-6, IL-8, MCP-1, TGF-ß1 and TGF-ß2 were observed on mRNA 
and protein levels. This indicates for a plasma-induced enhancement of the immune defense 
during wound healing. In addition, in-vivo animal experiments were conducted in this work 
using mice with artificially generated wounds. A daily treatment of 2 min over a period of 10 
days with the MicroPlaSter β source led to significantly accelerated wound closure in mice. 
Interestingly, increased protein amounts of MCP-1 and IL-6 but no changes in TGF-ß1 and 
TGF-ß expressions were recorded in treated tissues. Morphologically, a thicker epidermal 
layer and denser structure of collagen fibers were observed, which correspond with higher 
mRNA levels of collagen type 1 and alpha-smooth muscle actin (alpha-SMA) in the dermal 
tissue of mice [46].  
Tissue tolerable plasma treatments 
At this time, to the best of my knowledge, no side effects such as burns were detected following 
plasma application. Experiments on mice, ex-vivo studies on porcine skin, and human skin 
biopsies, as well as in-vitro studies on living human cells neither showed histological injuries, 
nor increased amounts of necrotic cells [43, 105, 111, 134–136]. Furthermore, during and after 
clinical trials with patients suffering from chronic wounds no side effects, like pain or 
deterioration of wounds were reported [108–110]. The same has been shown for intact skin 
treatments: Daeschlein et al. [137] applied different plasmas (i.e. pulsed APP jet, non-pulsed 
APP jet, and DBD) to finger cups of volunteers and observed no harmful effects on skin barrier 
functions examined with a transepidermal water loss (TEWL) recording device. This makes 
clear that APP sources can be tuned and adjusted so that plasma applications of the skin are 
well tolerable for humans. Still, adjustments of plasma devices for biomedical use are more or 
less performed after the principle of trial and error. This is because the physical-chemical 
kinetics in the plasma and their resulting biomedical efficiencies are not yet completely 
understood. 
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3. Materials and Methods 
In this chapter first the main structure of the two plasma sources is presented, followed by 
detailed descriptions of cellular, molecular, and functional methods. A complete list of all 
materials is in addition provided in the appendix I.  
3.1 Plasma devices 
The plasma jet device kINPen® MED was developed by neoplas tools GmbH and INP 
(‘Leibniz-Institut für Plasmaforschung und Technologie’) in Greifswald, DE. It consists of a 
pen-shaped hand held device and a control unit for gas and power supply (50 VA at 230 V, 
50 Hz) [138]. The hand-held unit comprises a ceramic capillary tube that includes a metallic 
pin electrode and is surrounded by a ring electrode at the distal tip of the device (Fig. 4a). 
Argon gas (Argon N46, purity of 99.996%; Air Liquid, Düsseldorf, DE) is directed through the 
capillary with a flow rate of 5 standard liter per minutes (slm). High voltages of up to 3 kV (peak 
to peak) are applied to the pin electrode at a repetition frequency of about 1 MHz. The device 
operates in a burst mode with a repetition rate of 2.5 kHz (duty cycle: 50%). The gas is partially 
ionized by high voltages and directed outwards of the hand held device forming a so-called 
effluent at the tip. The effluent propagates into the air in form of bullets. The kINPen® MED was 
the first plasma jet worldwide that obtained a CE-certification as medical device (class IIa) for 
the use on patients.  
The other source used in this thesis was a µs-pulsed volume DBD provided by the HAWK 
(‘Hochschule für angewandte Wissenschaft und Kunst’), Göttingen, DE. This DBD device was 
developed for laboratory use only. However, it is similar to the PlasmaDerm®VU-2010 
(CINOGY GmbH, Duderstadt, DE), which was already used in a clinical trial on the therapy of 
venous leg ulcer [110] and is the first volume DBD device worldwide, which is classified as CE-
certified medical tool in class IIa. The µs-pulsed DBD device comprises a handpiece and a 
power supply (Power Supply 3045/15; EA-Electronic GmbH, Essen, DE). The nozzle of the 
handpiece consists of an electrode (diameter: 10 mm) that is covered by a 1 mm thick ceramic 
dielectric (Al2O3; Fig. 4b). High voltages of about 9.9 kV are applied to this electrode at a 
frequency of 300 Hz. The plasma is ignited when the treatment object is set approximately 
1 mm away from the nozzle so that it can act as counter electrode. As described in Tiede et al. 
[47], PBS solution (cf. appendix I.5) was used as counter electrode in fibroblast experiments. 
Grounding was achieved by installing a copper strip (CFT-25/10M; Conrad Electronic SE, 
Hirschau, DE) near the DBD tip. One end of the copper strip was directed into the PBS solution 
and the other end was connected to an earthing clip in a socket. 
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Figure 4: Schematic illustration of the two plasma sources 
The general and simplified structures of the kINPen® MED nozzle (a) and the tip of the µs-pulsed DBD source (b) 
are presented in geometrical relationship to a treatment object (petri dish). Distances from nozzle and tip to the 
treatment object and the resulting exposure areas of the plasmas are presented.  
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3.2 Cell biological methods 
3.2.1 General cell culture methods 
Cell lines 
Two different adherent human skin fibroblast cell lines were used for establishing and 
performing test assays to evaluate effects of different plasma sources: 
i. GM00637 (GM) 
ii. primary fibroblast (PF) 
During all experiments vital cells were handled under sterile conditions. 
The GM cell line (Coriell Institute, Camden New Jersey, USA) is a SV40 virus-transformed 
immortalized cell line. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
PAA Cölbe, DE) at 37  C, 5% CO2, and a humidity of 90%, and split twice a week into fresh 
175 cm² cell culture flasks (Greiner bio-one, Frickenhausen, DE) at a ratio of 1:4. 
PF cells were isolated from healthy skin punch biopsies of donors. Skin samples were 
incubated in PBS containing 5% Penicillin-Streptomycin (P/S; PAA Coelbe, DE) for at least 
30 min at 4 °C. Superfluous fat was removed and skin samples were cut into 1-4 mm2 small 
pieces with a scalpel (Feather, Osaka, JP). Three to five tissue pieces were transferred into a 
175 cm2 flask, incubated at room temperature for 15 min to enhance tissue adhesion, and 
carefully flooded with 25 mL DMEM supplemented with 10% fetal bovine serum (FBS; 
Biochrom AG, Berlin, DE) and 1% P/S (culture DMEM; cf. appendix I.5). Flasks were then 
cultured in a CO2-incubator (MCO-18AlC; Sanyo, München, DE) at 37 °C, with 5% CO2, and 
90% humidity for approximately 1-2 weeks until exclusively fibroblast cells were proliferating. 
Cells were transferred into new flasks for further growth and split once a week at a ratio of 1:2. 
Passaging of fibroblasts 
Fibroblasts were divided and passaged (transposed to new flasks) at 90% confluence; with 
100% defined as the largest possible area of the flask base covered by cells. Flasks were 
rinsed with 10 mL PBS to remove any residual FBS, as well as dead cells. Cells were incubated 
with 4 mL Trypsin/EDTA (Biochrom AG, Berlin, DE) for 5 min (37 °C, 5% CO2, 90% humidity) 
to dissociate them from flask base. Trypsin activity was stopped by adding 10 mL FBS-
containing culture medium. Cells were centrifuged for 5 min at 1000 rounds per minute (rpm) 
in a centrifuge (Mikro 220; Hettich, Tutllingen, DE), the supernatant discarded, and the pellet 
re-suspended in about 30 mL of medium for transferring them into new 175 cm2 flasks. 
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Cryo-preservation of fibroblasts 
Fibroblasts had to be regularly frozen and stored in liquid nitrogen for maintenance of the cell 
culture. Therefore, cells were collected from cell culture flasks using Trypsin/EDTA as 
described above and centrifuged for 5 min at 1000 rpm. The supernatant was discarded and 
the pellet re-suspended in culture DMEM. Cell number of the cell solution was determined (cf. 
below) and adjusted to 4∙105 cells/mL by adding culture DMEM. Then, same volume of freezing 
medium (cf. appendix I.5) was added. Precooled cryo tubes (Greiner bio-one, Frickenhausen, 
DE) were filled with 1 mL solution each and stored overnight at -80 °C (Ultra low MDF-U73V; 
Sanyo, Müchen, DE) in a cryo box (Nunc; Wiesbaden, DE) filled with isopropanol to ensure a 
constant cooling rate (-1 °C/min). On the next day, the cryo tubes were transferred into a liquid 
nitrogen container (Apollo Biosafe; Messer Greisheim, Bad Siden, DE) for cryo-preservation 
at -196 °C.  
Re-culturing of fibroblasts 
In order to re-seed frozen cells, a cryo tube was held under running tap water to thaw the cells 
a little bit and subsequently wiped off with 70% ethanol (Merck, Darmstadt, DE). Then, 1 mL of 
culture DMEM was added and gently mixed to completely thaw cells. Subsequently, the cell 
solution was poured into 10 mL culture medium, centrifuged for 5 min at 1000 rpm, and the 
supernatant discarded. The pellet was re-suspended in 10 mL culture medium and transferred 
to a fresh culture flask. On the following day, culture DMEM was completely replaced with fresh 
culture medium to remove dead cells. 
Cell counting 
Cells were harvested as described above and re-suspended in culture medium. 10 µL of the 
cell suspension was mixed with 90 µL of trypan blue and 10 µL of this solution (1/10 dilution 
factor) was added to a Neubauer counting chamber (Brand, Wertheim, DE). Four 0.01 cm2 
corner squares with a depth of 0.01 cm were counted, which correspond to a volume of 
0.0001 mL. The concentration of cell number per mL is defined with: 
 concentration (cells mL⁄ ) = 
number of cells
number of squares x dilution factor x volume (mL), 
which can be simplified to 
concentration (cells mL⁄ ) = number of cells x 25000. 
Afterwards the chamber was cleaned with water and 70% ethanol. 
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3.2.2 Transient transfection of fibroblasts 
Chemical transfections of GM or PF cells were achieved by using the non-liposomal lipid 
Attractene Transfection Reagent (Qiagen, Hilden, DE). This reagent forms complexes with 
plasmid DNA that can be assimilated by eukaryotic cells via endocytosis. Cells were seeded 
in different densities depending on cell line and assay: For HCR assays 40,000 GM cells and 
30,000 PFs were seeded per well in 12-well-plates (Greiner bio-one, Frickenhausen, DE), 
whereas for the PSV assay 250,000 GMs were seeded in 35 mm cell culture dishes (Th. Geyer, 
Renningen, DE). Cells were then incubated for adhering overnight. On the next day, either 
58.4 µL or 90.5 µL of non-supplemented DMEM was mixed with either 100 ng (renilla) and 
150 ng (firefly) or 250 ng (pSP189) of plasmid DNA (cf. appendix I.7 for firefly and renilla 
plasmids; cf. 3.5.4 for pSP189 plasmid) in round-bottom tubes with snap caps (BD Bioscience, 
Heidelberg, DE), respectively. Either 0.6 µL or 4.5 µL of Attractene reagent were added to the 
DMEM-plasmid mix, instantly vortexed (on the Vibrofix VF1 Electronic; IKA Labortechnik, 
Staufem, DE) for several seconds and incubated for 15 min at room temperature. During that 
time, medium was removed from wells and cell dishes and cells covered with 500 µL or 2 mL 
of fresh culture DMEM for the HCR or PSV assay, respectively. Then, the transfection mix 
(60 µL for HCR assay and 100 µL for PSV assay) was added drop by drop into wells or dishes 
and incubated (37 °C, 5% CO2, 90% humidity) for 5 hours (h). Afterwards, the transfection 
solution was replaced by either ~1 mL or ~4 mL of fresh culture medium and the cells further 
incubated for 72 h. 
3.2.3 Plasma treatment of fibroblasts 
On the day before plasma treatment, fibroblasts were seeded in 35 mm cell culture dishes in 
2 mL of culture DMEM in a density of 250,000 for GM and 100,000 for PF cells. On the following 
day, culture medium was removed, cells were rinsed with PBS, and covered with 1 mL of PBS. 
Plasma applications were performed in a source dependent manner to achieve the best 
possible treatment. 
Plasma treatment with the kINPen® MED 
The jet was positioned centrally and exactly 8 mm above the bottom of the cell culture dish. 
The argon gas streamed out of the device with a gas flow rate of 5 slm leading to a circulation 
of the PBS in the dish like a swirl. Thus, cells in the middle of the dish were directly exposed 
to the plasma jet, while cells that were lying closer to the rim were exposed indirectly. 
Plasma treatment with the µs-pulsed volume DBD 
The nozzle of this device was placed 1 mm above the PBS surface to ensure a uniform 
discharge. For grounding of samples, a cooper strip was placed into the PBS solution, so that 
it did not touch the bottom of the dish, and connected to an earthing clip in a socket. During 
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plasma treatment, culture dishes were constantly moved with 40 rpm by an Orbital Shaker 
(Standard 1000 Orbital Shaker; VWR International bvba, Geldenaakesbaan, BE) to reach the 
largest treatment area possible. 
The next steps were performed in the same way for both plasma sources: Immediately after 
plasma application (at the most 2 min later), 3 mL of DMEM supplemented with 13% FBS 
(DMEM-13%F; cf. appendix I.5) were added to each dish and cells incubated (37 °C, 5% CO2, 
90% humidity) for different times depending on the performed assay; 48 h for MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) tests, 
72 h for PSV assays, and 24 h for flow cytometry experiments. 
It is worth noting that the PBS solution was left in the cell culture dishes after plasma exposure 
to exclude the removal of loose, but still viable, cells. Many researchers performed cell viability 
assays without taking into account that most cell types treated with low to medium plasma 
doses or short application times detach from their substrate as one of the first cell responses 
[45, 74]. Thus, loose cells float in the treatment solution. If the solution is immediately replaced 
by fresh medium, cells, which are still viable, will be removed. The here presented protocol 
avoids this circumstance. 
3.2.4 Treatment of fibroblasts with H2O2 and different radiations 
H2O2 treatment of fibroblasts 
As positive control for MTS assays, cells were incubated for 30, 60, 90, and 180 s with a 60, 
75, or 90 µM concentrated H2O2-solution (Merck, Darmstadt, DE) in PBS. Corresponding to 
plasma treatments, 3 mL of fresh DMEM-13%F was added and dishes were incubated for 48 h 
before performing the MTS assay (cf. 3.5.1).  
UVC irradiation of GM cells 
During PSV experiments, samples of GM cells were exposed to 2.5, 5, and 7.5 mJ/cm2 of UVC 
radiation at a wavelength of 254 nm as positive control using the UVC 500 crosslinker 
(Amersham Bioscience, Glattburg, CH). 
X-ray irradiation of GM cells 
For flow cytometric analyses X-ray irradiations were performed as positive control for the 
induction of double strand break (DSB) events in cells. Using the RS225 X-Ray Box (Gulmay 
Medical LTD, Camberley, Surrey, UK) GM cells were exposed to different doses of X-rays: i.e. 
1, 3, 5, 7, and 9 gray (Gy).  
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3.3 Microbiological methods 
3.3.1 Sterilization of solid and liquid consumables 
Non sterile buffers, solutions, bacterial media, plastic pipette tips, and S1 laboratory waste 
were autoclaved (in autoclave DE-65; Systec, Wettenberg, DE) for 20 min at three bar and 
121 °C. Glass pipettes and miscellaneous glassware were washed in a dish washer (Miele 
professional; Miele, Gütersloh, DE) at 40 °C. Glass pipettes were then sealed with cotton 
wadding (Brand, Wertheim, DE) using a tamping machine (Tecnomara, Tecnoplug; Integra 
Bioscience, Fernwald, DE) and subsequently sterilized at 190 °C. Other glassware and pipette 
tips were dried at 70 °C for at least 4 h (in Memmert SL 50; Willi Fischer KG, Frankfurt, DE). 
Temperature-sensitive buffers and liquids were sterilized using syringes (Braun, Melsungen, 
DE) and sterile filter paper (Sarstedt, Nümbrecht, DE). 
3.3.2 Bacterial strains 
Two different E. coli strains were used during the thesis: 
i. DH5α [139]:  
F  ̄ endA1, hsdR17 (rKˉ, mK+), glnV44 (synthetic name of supE44), thi-1, λˉ, recA1, 
gyrA96, relA1, deoR, Δ(lacZYA-argF)U169, ϕ80dlacZΔM15, nupG 
ii. MLB100 [140]:  
F+ tet r, lacZamCa7020, lacYI, hsdR ,̄ hsdM+, araD139, (araABC-leu)7679, galU, galK, 
rpsL, thi 
3.3.3 Culture and storage of E. coli 
200 µL of frozen E. coli culture (cf. storage conditions below) of the strains DH5α or MLB100 
were poured into 200 mL of fresh double yeast medium (dYT; cf. appendix I.5) without 
antibiotics and grown overnight at 37 °C in an incubator shaker (Shaker Thermotron; Infors, 
Bottmingen, SZ) at 200 rpm. On the next day, 5 mL of E. coli culture were added to 100 mL of 
dYT medium and incubated for 2 h (37 °C, 170 rpm). Then, 25 mL of this preparatory culture 
were mixed with 500 mL dYT medium and incubated until the optical density (OD) reached a 
value of about 0.5–0.6 measured at 600 nm with the DU 640® Spectrophotometer (Beckmann, 
München, DE); this indicates the logarithmic growth phase. Pure dYT medium served as 
control for the OD600 measurements. For long-term storage of the DH5α and MLB100 cells, 
850 µL of the main culture were shortly vortexed with 150 µL glycerol (Merck, Darmstadt, DE), 
shock frozen in liquid nitrogen, and then stored at -80 °C. 
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3.3.4 Preparation of chemically-competent E. coli 
The competence of bacteria describes their ability to take up DNA that is free floating in the 
surrounding medium. This requires the process of transformation, i.e. uptake of foreign DNA 
by prokaryotic cells. E. coli bacteria do not take up foreign DNA easily and, hence, the uptake 
rate (transformation rate) of plasmid DNA would be very low. By physical or chemical 
manipulation of bacteria’s membrane, plasmid DNA attaches more easily to the membrane 
and penetrates the cell through generated pores. By this method competent cells can be 
produced that are necessary for the replication of recombinant plasmid DNA, so for 
amplification of the plasmid DNA.  
First, main cultures of DH5α or MLB100 were prepared as previously described (cf. 3.3.3). All 
following steps were performed on ice and with precooled cells, solutions, and supplies. 50 mL 
of main culture were centrifuged for 20 min at 4 °C and 3000 rpm (Sorval RC 6+ centrifuge; 
Thermo Scientific, Waltham, US) and the supernatant was discarded. The pellet was 
re-suspended with 50 mL of 50 mM CaCl2-solution (Merck, Darmstadt, DE) and incubated on 
ice for 30 min. This bacterial solution was centrifuged (20 min, 4 °C, 3000 rpm) and the 
supernatant discarded, again. Afterwards, the pellet was carefully re-suspended in 10 mL of 
CaCl2-glycerol solution (cf. appendix I.5). The resulting bacterial cultures (50 µL of DH5α and 
200 µL of MLB100) were aliquoted in -20 °C precooled reaction tubes (Eppendorf, Hamburg, 
DE), shock frozen in liquid nitrogen, and frozen at -80 °C. 
3.3.5 Transformation of plasmid DNA into chemically-competent E. coli  
50 µL of chemically-competent MLB100 or DH5α cells in reaction tubes were slowly defrosted 
on ice, supplemented with 50 ng of plasmid DNA, and incubated for 30 min on ice. 
Subsequently, the reaction tubes were placed into a thermal block (Thermomixer 5436; 
Eppedorf, Hamburg, DE) for exactly 45 s at 42 °C to generate a heat shock, followed by 
incubation on ice for 2 min. Then, 450 µL of dYT or LB medium (cf. appendix I.5) without 
antibiotics was added to the cells. For recovery, the culture was transferred to 15 mL tubes 
with filter (Greiner bio-one, Frickenhausen, DE) and incubated for 1.5 h in an incubator shaker 
(37 °C, 170 rpm).  
In the course of the PSV experiments, transformed MLB100 cells with pSP189 plasmids were 
spread on LB agar plates containing IPTG (isopropyl-β-D-thiogalactopyranosid), X-Gal 
(5-Brom-4-chlor-3-indoxyl-β-D-galactopyranosid), and ampicillin (cf. appendix I.5) for 
blue/white selection (cf. 3.5.4). After recovery, 150 µL of bacterial cultures were used for 
plating. Agar plates were incubated for 20 h at 37 °C. If the blue color of the colonies was still 
very bright, plates were further incubated at room temperature in the dark for some hours or 
overnight. Then, mutation analysis was performed, starting with counting the blue and white 
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colonies on the plates, picking white and bright blue colonies for colony polymerase chain 
reaction (PCR), and further sequencing (cf. 3.5.4). 
3.3.6 Amplification and preparation of plasmid DNA in E. coli 
For plasmid amplification dYT, LB medium, and LB agar plates were supplemented with 
100 mg/L ampicillin (Sigma-Aldrich, München, DE) according to the required resistance on the 
plasmids used in this project (firefly, renilla, pUC19, and pSP189).  
Only chemically-competent DH5α cells were used to amplify firefly, renilla, and pUC19 
plasmids (cf. appendix I.7). Following the transformation of cells with the desired plasmid, 
300 mL of LB medium containing ampicillin were inoculated with transformed cells and 
incubated overnight in the incubator shaker (200 rpm at 37 °C). On the next day, cultures were 
divided into 50 mL tubes (Greiner bio-one, Frickenhausen, DE) and centrifuged for 10 min and 
4000 rpm. The supernatant was discarded and the pellets used for midi or maxi preparation of 
plasmids with the NucleoBond® Xtra MiDi/Maxi Plus Kit (Machery-Nagel, Düren, DE; cf. 3.4.1). 
For PSV experiments, stock solutions of pSP189 plasmids were produced using only MLB100 
cells. After transformation, the bacterial suspensions were plated on LB agar plates containing 
IPTG, X-Gal, and ampicillin. Here, it is very important to use at least six large LB agar plates 
(145 mm; Greiner bio-one, Frickenhausen, DE) to ensure that the variability of the signature 
sequences on the pSP189 plasmid is preserved. On the next day bacteria with ampicillin 
resistance were able to grow on plates. Colonies were collected by washing the plates with 
dYT medium. The bacterial solution was divided into 50 mL tubes, centrifuged for 10 min at 
4000 rpm, and pellets further used for midi scale preparation (cf. 3.4.1). 
3.3.7 Quality control of generated competent cells 
To guarantee an adequate transformation efficiencies a quality control was performed every 
time new competent cells were produced. 50 µL of competent cells were mixed with 5 ng native 
pUC19 or 50 ng of pSP189 plasmid DNA and transformed (cf. 3.3.5). 50, 100 and 150 µL of 
this pre-culture were spread on LB agar plates containing ampicillin (cf. appendix I.5) and 
incubated overnight at 37 °C. On the next day, colonies were counted and the colony forming 
unit (CFU) per µg DNA calculated. When the transformation efficiency was about 106 CFU/µg, 
competent cells were further used for experiments. 
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3.4 Molecular methods 
3.4.1 Isolation of plasmid DNA 
Plasmid DNA had to be isolated from E. coli after plasmid amplification (cf. 3.3.6) and also 
from GM cells during the PSV assay (cf. 3.5.4).  
Plasmid isolation from E. coli 
In general, plasmid isolation was performed using the alkaline lysis [141]. As a first step 
bacteria carrying the plasmid were grown under selective antibiotic conditions (LB or dYT 
medium supplemented with 100 mg/L ampicillin). Then, cells were centrifuged and the pellet 
re-suspended in a solution with EDTA (ethylenediaminetetraacetic acid), Tris-HCl, glucose, 
and RNase A. EDTA protects DNA from degradation by DNase and destabilizes the cell wall 
by binding bivalent cations like Mg2+ and Ca2+ that are essential for cell wall integrity and the 
activity of DNase in cells. Glucose is included in the solution to prevent cells from bursting, 
RNase to digest cellular RNA, and Tris-HCl buffers the solution. Afterwards, the lysis buffer is 
added to the cells. It contains ionic SDS (sodium dodecyl sulfate) – this destroy the murein 
sacculus and the cytoplasmic membrane – and NaOH, which generates a strong alkaline pH 
shift (to a pH of about 12). This pH shift denaturize hydrogen bonds between complementary 
DNA strands (chromosomal DNA as well as plasmid DNA). By adding a solution containing 
potassium acetate, the pH shifts back to 7. In this stage, plasmid DNA can re-nature easily due 
to their small and circular conformation, while separated strands of genomic DNA (which are 
already fragmented due to previous steps) only partially re-nature and may bind undirected 
with wrong complementary strands. This leads to a chaotic DNA accumulation that furthermore 
stick together with denatured cellular proteins and SDS due to hydrophobic interactions and 
consequently a white precipitate is formed. These complexes and NaOH can be easily 
removed by centrifugation. Double stranded plasmid DNA is now dissolved in the supernatant, 
which is transferred to a vertical glass tube packed with silica that binds the intact plasmid 
DNA.  
To isolate lager amounts of plasmid DNA (i.e. after plasmid amplification of firefly, renilla, and 
pUC19) from MLB100 or DH5α cells, the NucleoBond® Xtra MiDi/Maxi Kit was used according 
to the user’s manual. For that, bacteria were transformed (cf. 3.3.5) and overnight cultures 
prepared (cf. 3.3.3). For amplification of the pSP189 plasmid only the NucleoBond®Xtra MiDi 
Plus Kit (Machery-Nagel, Düren, DE) was used and isolation performed according to 
instructions of low-copy plasmids. Here, transformed cells were grown overnight on big agar 
plates (145 mm). At a time, colonies of at least six plates were collected and incubated for 
16-20 h in 400 mL of LB medium in an incubator shaker at 37 °C. 
  
— 32 — 
   MATERIALS AND METHODS     
Plasmid isolation from fibroblasts 
The alkaline lysis method was also used to isolate plasmid DNA from GMs. As first step, 
fibroblasts were detached from cell culture dishes by removing the medium, adding 500 µL of 
Accutase (Biochrom AG, Berlin, DE), and incubation for 5 min (37 °C, 5% CO2, 90% humidity). 
Cells were then collected in 5 mL reaction tubes and dishes washed with 500 µL of PBS to 
catch remaining cells. For one treatment condition three dishes with fibroblasts were prepared 
and cells pooled in one reaction tube. After a centrifugation for 30 s at 1300 rpm, the 
supernatant was discarded and the following steps were performed as described in the 
manual, starting with adding the lysis buffer. 
With the NucleoSpin Plasmid Kit (Machery-Nagel, Düren, DE), smaller amounts of plasmid 
DNA from GM cells were isolated according to manufacturer’s instructions for low copy 
plasmids. 
3.4.2 Purification and concentration of plasmid DNA 
Purification of plasmid DNA 
After midi or maxi preparations, eluated plasmid DNA had to be purified, which was done by 
precipitation with ethanol in mild acidic conditions (pH: 5.2) achieved by using sodium acetate. 
Ethanol is much less polar than DNA or water. By adding ethanol to the DNA solution, the 
solubility of the DNA in water is reduced [142]. The low pH further reduces solubility because 
the negatively charged DNA is partially saturated with sodium ions and partially protonated. At 
some point, when enough ethanol is added, the electrical attraction between DNA phosphate 
groups and positive ions becomes strong enough to form stable ionic bonds [143]. 
To the DNA solution, 1/10 volume of 3 M sodium acetate (Sigma-Aldrich, München, DE) and 
2.5 volumes of 96% ethanol (analytical grade) was added and intensively vortexed. The 
solution was then centrifuged for 30 min at 14000 rpm, the supernatant discarded, and 300 µL 
of 70% ethanol added to wash the pellet. The solution was centrifuged for 10 min at 14000 rpm, 
followed by removing the ethanol and drying the pellet on a thermal block for 5 min at 42 °C 
while tubes were left open. Finally the pellet is re-suspended in 250 µL water.  
To purify pSP189 plasmids isolated from GM cells, only the Wizard® SV Gel and PCR Clean-
Up System (Promega, Fitchburg, US) were used whereby adsorption of the DNA is also 
achieved with alcohol and mild acid conditions via polar interactions. Here, DNA is bound to 
silica gel and proteins are denaturized by chaotropic salts, which are then washed out of the 
matrix. Finally, DNA is eluated in 50 µL double distilled water (ddH2O).  
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DNA concentration measurements 
The DNA concentration was determined using the NanoVuePlus® (GE Healthcare, 
Buckinghamshire, UK). 2 µL of DNA sample was measured at 260 nm absorption. Autoclaved 
ddH2O (same water as used for DNA eluation) served as blank. The concentration was 
calculated by the device using the standard conversion factor for DNA (50). DNA purity was 
tested by measuring the quotient of OD260/OD280 that had to be between 1.7 and 2.0 for further 
use. 
3.4.3 Treatment of plasmid DNA 
Plasma treatment 
To analyze the direct genotoxic effect of APP only purified and isolated DNA dissolved in 
ddH2O was used. In the course of the HCR assay firefly plasmid was treated with plasma to 
induce DNA adducts and/or fragmentation. For gel electrophoresis plasma-treated firefly 
plasmid was used to investigate the fragmentation potential of the APP. Also, the pSP189 
vector was treated with plasma during performance of version 1 of the PSV assay. In all these 
cases, 300 µL of the plasmid solution were placed into one well of a 12 well-plate. Treatment 
conditions for the two sources were the same as already described in section 3.2.4. Afterwards, 
plasmid DNA solutions were stored at -20 °C until further use.  
UV irradiation of plasmid DNA 
Plasmids were exposed to UV radiation as positive control. For HCR experiments, 300 µL of 
firefly plasmid were irradiated with either UVB at a wavelength of 312 nm (BioLink BLX 312; 
LTF-Labortechnik, Wasserburg, DE) or UVC radiations (254 nm) in 12-well-plates. The 
following doses were applied to firefly plasmid solutions: 50, 100, 250, 500, 750, and 1 mJ/cm2 
of UVB and 5, 10, 25, 50, 75 mJ/cm2 of UVC.  
UVC irradiations of pSP189 plasmid solutions were equally performed; but exclusively with 
75 mJ/m2. 
3.4.4 DNA separation via agarose gel electrophoresis 
Via agarose gel electrophoresis negatively charged DNA molecules can be simply separated 
according to their conformation (supercoiled, circular, or linear) and by their size while 
migrating through an electric field. To make a 1% gel, 0.4 g of LE agarose powder (Biozym, 
Oldendorf, DE) was mixed with 40 mL of 1x Tris/Borate/EDTA (TBE) buffer (cf. appendix I.5). 
The solution was heated in a microwave (NN-5253; Panasonic, Hamburg, DE) until it boiled 
and the powder was dissolved. Afterwards, 2 µL of HDGreen Plus DNA Stain (Intas, Göttingen, 
DE) was added to gel solution that intercalates into the DNA and that can be visualized by 
exposure to UV radiation. Then, the gel was gently poured into an electrophoresis chamber 
(Hardware & service, Friedland, DE) and an electrophoresis comb was pressed into the gel 
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near the upper edge. The gel was dried for 15 min at room temperature and the whole agarose 
chamber was filled with 1x TBE buffer. Then, the comb was carefully removed, which 
generates small loading chambers in the gel. DNA samples (usually 100-200 ng DNA content) 
were mixed with 2.5 µL of 6x DNA Loading Dye (Thermo Scientific, Braunschweig, DE) and, 
together with 4 µL of two differentially large DNA weight ladders (Thermo-Scientific, 
Braunschweig, DE), i.e. 100 base pairs (bp) and 1 kilo base pairs (kb), filled into the small 
loading chambers (ad most 10 µL per chamber). Afterwards, the whole electrophoresis 
chamber was connected to a power supply (Mini Power Rack P20; Biometra, Göttingen, DE) 
generating an electric field with a voltage of about 90 V. DNA fragments were visualized by 
fluorescence of the HDGreen stain with a gel documentation system (Gel iX 20 Imager; Intas, 
Göttingen, DE). In this work, gel electrophoresis was used for analytical investigations of 
fragmentation rates of APP-treated plasmid DNA (firefly plasmid). 250 ng and 750 ng DNA 
were used per sample of DBD treated or jet-treated samples, respectively. Also, the technique 
was utilized for testing PCR products during PSV experiments. Therefore, 7.5 µL of PCR 
products were mixed with 2.5 µL 6x DNA Loading Dye. This mix and a 100 bp DNA weight 
ladder were then separated in the gel with the same settings as above. 
3.4.5 Enzymatic digestion of plasmid DNA 
BamHI 
Restriction enzyme digestion with BamHI (10 U/µL; Thermo-Scientific, Braunschweig, DE) was 
performed to verify the linearized form of the firefly plasmid in agarose gel electrophoresis. The 
firefly plasmid includes only one site at which BamHI can cut the plasmid [144] and, thus, the 
digestion solution mainly consists of the linearized form of the plasmid. When running this 
sample in a gel it should create one band at the size of the plasmid (4863 bp). According to the 
protocol recommended for BamHI, the digestion solution included 2 µL BamHI, 5 µL Tango 
Buffer 10x (Thermo-Scientific, Braunschweig, DE), 2 µg DNA (corresponded to about 8 µL), 
and 35 µL ddH2O. The solution was incubated for 1 h at 37 °C and subsequently prepared for 
gel electrophoresis.  
DpnI 
Digestion of the pSP189 plasmid was required during PSV experiments using the enzyme 
DpnI 10 U/µL (Thermo-Scientific, Braunschweig, DE). This was done after isolation of pSP189 
DNA from GM cells (cf. 3.4.1). The enzyme belongs to type II restriction endonucleases and 
recognizes methylated adenosines in the 5’-GA T̂C-3’ sequence to further catalyze the double 
strand cut at this DNA site. Only bacteria express the appropriate enzyme to methylate the 
plasmids in this form, whereas all replicated plasmids in human cells lose their methylated 
adenosines. Thus, only the originally used pSP189 DNA during transfection into GM cells was 
degraded by DpnI digestion. Thus, only replicated pSP189 plasmids were further used for 
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experiments. 44 µL of DNA samples were mixed with 1 µL of DpnI enzyme and 5 µL of the 
recommended Tango Buffer 10x. Samples were incubated for 1 h at 37 °C followed by heat 
inactivation of the enzyme at 80 °C for 20 min. Afterwards, DNA solutions were purified with 
the Wizard® SV Gel and PCR Clean-Up System by Promega according to manufacturer’s 
instructions and the DNA concentration measured (cf. 3.4.2). Purified DNA samples were 
further used for blue/white selection and sequence analysis of mutated pSP189 plasmids 
(cf. 3.5.4).  
Exo-SAP 
Before the PCR products could be sequenced in the course of PSV assays, remaining 
deoxynucleotides (dNTPs) and primers in samples had to be removed. Therefore, samples 
were digested with the Exo-SAP-mix (New England Biolabs, Ipswich, US) containing 
Exonucelase I to remove primers and Shrimp Alkaline Phosphatase to degrade unincorporated 
dNTPs. 5 µL PCR product and 2 µL Exo-SAP-mix (prediluted in a ratio of 1:4 in ddH2O) were 
mixed on ice and incubated for 30 min at 37 °C, then 15 min at 80 °C, and finally for 3 min at 
95 °C. 
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3.5 Functional methods 
3.5.1 MTS assay 
To study the cytotoxic effect of plasma on skin fibroblasts the common MTS assay was carried 
out with the use of the kit CellTiter 96® AQeuos One Solution Cell Proliferation Assay 
(Promega, Mannheim, DE). The assay is based on the MTS tetrazolium compound that can 
be mitochondrially metabolized by viable cells into a dark purple or aubergine colored formazan 
product. The product is soluble in culture medium and the amount of the metabolized product 
can be photometrically measured representing the cell viability rate. The assay is generally 
used for examining cell proliferation in response to intracellular triggers or signaling molecules 
like growth factors, cytokines, or nutrients, but also for analyzing cytotoxic effects of agents or 
pharmaceutical compounds. However, the protocol of manufacturer had to be adjusted for APP 
applications. The experimental procedure that worked best is described below. 
After seeding cells in culture dishes, they were exposed to the different plasmas (cf. 3.2.4). 
Plasma jet applications were performed for 10, 30, 60, 90, and 180 s, which corresponds to 
plasma doses of 31, 92, 184, 275, 551 J/cm2 (cf. 4.1.1). These treatment durations were 
sufficient to reach the lethal dose 50% (LD50; meaning that 50% of the cells cannot metabolize 
the tetrazolium dye anymore) and lower values of cell viability. Using the µs-pulsed DBD 
source for same treatment durations, corresponding plasma doses are 4, 11, 23, 34, and 
69 J/cm2. However, extended application times were required to reach same viability values as 
in jet treatments. Therefore, additional durations of 270 and 360 s (≙ 103 and 137 J/cm2) for 
GM cells and further 480 and 600 s (≙ 183 and 229 J/cm2) for PFs were used. For each plasma 
treatment duration, two independent culture dishes were prepared. Treated cells were 
incubated for 48 h (37 °C, 5% CO2, 90% humidity) before the PBS-DMEM mix covering the 
cells was replaced by 1 mL of fresh complete DMEM. 200 µL of MTS solution were added to 
each dish, followed by an incubation for 2 h (37 °C, 5% CO2, 90% humidity). Then, 120 µL of 
each dish were transferred into one well of a 96-well-plate (Greiner bio-one, Frickenhausen, 
DE) and the absorption measured at 450 nm with an ELISA Reader (Tecan, Männdorf, DE). 
Simultaneously, with plasma-treated samples, untreated samples were prepared as negative 
control. These cells were treated exactly the same way (washing with PBS, 1 mL PBS covering 
cells before 3 mL DMEM-13%F was added) but without the plasma treatment. As positive 
control, cells were incubated in different concentrations of H2O2-solution in PBS (cf. 3.2.4).  
To study the impact of reactive species or biologically active agents on plasma-induced 
cytotoxic effects, the same assay was performed in an indirect approach. Here, 1 mL of PBS 
solution was treated with plasma in a cell culture dish without cells. Afterwards, this PBS 
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solution was added to cells for 5 min. Then, 3 mL of fresh DMEM-13%F was added to each 
dish. 
Analysis of MTS results 
The collected raw absorption data from the ELISA reader were first corrected for background 
fluorescence by subtracting the ‘no-cell’ control (absorption data of DMEM-13%F and MTS 
solution alone) from all absorption values detected. All corrected data were averaged over the 
experiments and then normalized to the averaged negative control (untreated cells defined as 
100% cell viability). Direct and indirect experiments were repeated for several times with 
following sample sizes:  
• direct plasma treatment of GMs with n=30 
• direct plasma treatment of PFs with n=24 
• H2O2 treatments with n=24 
• indirect plasma treatment with n=18 
The standard deviation (SD) was calculated using Excel software (Microsoft Office 2010). 
Statistical analyses were performed with SigmaPlot 12.0 software. For all normally distributed 
datasets (Shapiro-Wilk with P > 0.05), the one-sided t-test for two samples with unequal 
variance was used. If the normality test failed, the Mann-Whitney U Test was used. 
3.5.2 Plasma-induced chemical changes in PBS (ROS, RNS, pH) 
The generation of reactive species in APP plays a major role for a lot of plasma-induced 
effects. Therefore, the production of certain reactive species was quantified in a 
plasma-treated PBS solution; NO2- and NO3- representative for RNS and H2O2 representative 
for ROS production. Furthermore, it was analyzed to which extent the pH of the solution 
changed after plasma treatments. 1 mL of PBS was treated with plasma in 35 mm cell dishes 
for same durations used in the MTS tests (cf. section above). Measurements of reactive 
species and pH changes in PBS using the kINPen® MED device were kindly performed for this 
thesis by Sander Bekeschus from the INP in Greifswald. For the use of the µs-pulsed DBD, 
reactive species concentrations were measured by Joanna Hirschberg from the HAWK in 
Göttingen. The pH measurements after DBD treatments of PBS were performed by me with a 
pH meter (Lab pH Electrode LE438; Mettler-Toledo AG, Schwerzenbach, CH). 
Sample sizes of these measurements are as follows: 
• reactive species measurement after jet applications with n=2 
• reactive species measurement after DBD applications with n=6 
• pH measurements after jet or DBD applications with n=2 
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3.5.3 Host cell reactivation assay 
The HCR assay is commonly used to quantify the relative DNA repair capacity of fibroblast 
cells of damaged reporter plasmid DNA. Simultaneously, genotoxic effects of substances or 
agents can be indirectly investigated with this method. The assay is based on the firefly 
plasmid, which includes a non-replicating reporter gene [145] coding for the firefly luciferase 
enzyme [144]. In this study, purified firefly plasmid DNA was dissolved in ddH2O and treated 
with plasma, UVC, or UVB radiation (cf. 3.4.3). Untreated or treated firefly plasmids were then 
co-transfected with renilla plasmids (coding for renilla luciferase) using the Attractene reagent 
(cf. 3.2.2). The co-transfection with renilla plasmid was required for normalization. After 72 h of 
incubation (37 °C, 5% CO2, 90% humidity) cells were washed with PBS and lysed for 45 min 
at room temperature with 80 µL/well of passive lysis buffer (included in the Dual-Luciferase 
Reporter Assay System; Promega, Mannheim, DE). Then, cells were scraped off and 40 µL 
solution from each well were transferred to 96 well GlomaxTM Micoplates (Promega, 
Mannheim, DE). The enzyme expressions of both luciferases were measured by the GlomaxTM 
96 Microplate Luminometer (Promega, Mannheim, DE) using substrates from the 
Dual-Luciferase Reporter Assay System. The device, one after another, adds 80 µL of 
corresponding luciferase substrates for firefly (beetle luciferine) and renilla (coelenterazine) to 
each well and quantifies the luminescence as relative light units (RLUs). This represents the 
according enzyme activity.  
Analysis of HCR results 
To analyze the reporter gene expression of firefly luciferase, firefly RLU data within each 
experiment were first normalized to renilla RLU values by dividing firefly RLU values with RLU 
data of renilla within each well. Then, the values of these corrected data were averaged over 
same treatment modalities and converted into percent, whereby averaged RLUs of the 
untreated control plasmids were defined as 100%. Finally, mean percent values of experiments 
were averaged.  
The different treatment modalities included different sample sizes: 
• jet applications of GMs with n=12 
• jet applications of PFs with n=9 
• DBD applications of GMs and PFs with n=15 
• UVC irradiations of GMs with n=15 
• UVC irradiations of PFs with n=12 
• UVB irradiations of GMs and PFs with n=12 
SD values were calculated (Excel; Microsoft Office 2010) and statistical analyses were done 
as previously described for the MTS analysis (cf. 3.5.1). 
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3.5.4 Plasmid Shuttle Vector assay 
The PSV assay was performed for a detailed analysis of plasma-induced mutagenic alterations 
and genotoxic effects. Here, the low-copy plasmid pSP189 (generous gift of Kenneth H. 
Kraemer; National Cancer Institute, Bethesda, MD, USA), including the supF-tRNA gene and 
a signature sequence, was essential (Fig. 5). 
 
Figure 5: Scheme of the pSP189 plasmid 
The plasmid includes an ampicillin resistance (ApR) for selective 
growing of successfully transformed bacteria, replication origins 
(ori) for bacterial and eukaryotic cells (SV40 ori and pBR327 ori, 
respectively), the supF-tRNA gene, and the signature sequence as 
most important units (after information given in Parris and Seidman 
[146]). 
 
In the first phase of the PSV experiments, the origin of replication (ori) for eukaryotic cells is 
important. If plasma treatment – regardless of test version – destroys this gene, GM cells will 
not replicate the pSP189 vector. In the next step, plasmid DNA was isolated from GM cells 
(cf. 3.4.1). Due to enzymatic digestion with DpnI (cf. 3.4.5), all plasmids that were originally 
used for transfection are destroyed. Thus, only plasmids that were replicated in the GM cells 
and later transformed into MLB100 bacteria, enable them to grow on plates. After 
transformation bacterial solutions had to be plated on ampicillin, X-Gal, and IPTG containing 
agar plates (cf. 3.3.6). The essential genetic sites on plasmids for bacterial growth at this point 
are the ApR and the pBR327ori for prokaryotic cells. Functional impairment of the ApR or the 
bacterial ori will prohibit the growth of MLB100 cells. X-Gal and IPTG are required for a 
classification of all grown colonies as mutated or non-mutated bacteria. The supF-tRNA gene 
(85 bp) enables the transcription of genes that carry the Amber-stop-codon [UAG] within their 
coding sequence [147]. An Amber-stop-codon mutation is located in the LacZ-gene of MLB100 
cells that enables the bacteria to transcribe the gene. Thus, they can express the enzyme β-
galactosidase. This enzyme digests the yellow dye X-Gal. The product of this process is the 
blue dye 5,5'-Dibromo-4,4'-dichloro-indigo and galactose. Thus, MLB100 cells will grow in blue 
colored colonies on agar plates containing X-Gal. However, the supF-tRNA is very sensitive; 
only a single point mutation in this gene may lead to a severely restricted enzyme expression 
or even to the total loss of the expression function. MLB100 cells with a mutation in the supF-
tRNA gene will grow in white colonies because the X-Gal dye cannot be digested anymore; 
this is called blue/white selection. 
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Following the blue/white-selection, the plasmid was isolated again and used for sequence 
analysis. It may happen that white colonies growing in close vicinity are clones carrying the 
same mutation. To identify such clones the signature sequence located next to the supF-tRNA 
is required. If the same mutation was found in two colonies with equal signature sequences, 
this implies that both mutations originated from the same bacterium. In turn, if the same 
mutations were found, but the signature sequences were different, this indicates an 
independent manifestation of the same mutation. In other words, this allows for a distinction 
between sibling and independent mutations. 
Originally, the pSP189 vector contains an 8 bp long signature sequence [146]. This sequence 
is characterized by a highly variable sequence. However, the here used plasmid carries an 
18 bp long signature sequence that leads to an even higher sequence variability. Theoretically, 
4∙1018 different signature sequences are possible and, thus, 68 billion different plasmids can 
be discriminated from each other. The chance for a false positive classification of two equal 
mutation events is, therefore, very low. Nonetheless, the variability of the signature sequence 
was proved by creating a library (cf. appendix II).  
The assay was performed in two different versions (Fig. 6) with following plasma treatment 
durations and according plasma doses: kINPen® MED applications for 10, 30, and 60 s (≙ 31, 
92, and 184 J/cm2) and µs-pulsed DBD treatments for 10, 60, and 270 s (≙ 4, 23, and 
103 J/cm2). 
Figure 6: Schematic illustration of the two versions of the PSV assay 
In version 1 pSP189 solutions were plasma treated and then transfected into GMs. In version 2, GMs were 
transfected with untreated pSP189 and then treated with plasma. Following steps were equally performed for both 
versions: Plasmids were isolated from cells and transformed into MLB100. Bacteria carrying a mutation (purple 
asterisks) in the supF-tRNA gene (marked in green) will grow as white colonies when plated. Blue colonies indicate 
non-mutated supF-tRNA. In the following analysis steps a mutation spectrum can be generated. 
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Version 1 
In this version the plasmid DNA was first treated with APP and, as positive control, with 
75 mJ/cm2 UVC (cf. 3.4.3). Then, pSP189 was transfected into GM cells (cf. 3.2.2), and 
incubated for 72 h (37 °C, 5% CO2, 90% humidity). Afterwards, plasmids were isolated from 
the fibroblasts (cf. 3.4.1) and all following steps performed as described below. 
Version 2 
Untreated pSP189 DNA was transfected into GM cells (cf. 3.2.2) and incubated for 72 h (37 °C, 
5% CO2, 90% humidity). Then, the cells were exposed to the jet and µs-pulsed DBD plasma. 
As positive control, the cells were exposed to UVC radiation at different doses (cf. 3.2.3). 
Fibroblasts were then incubated for 48 h before plasmids were isolated (cf. 3.4.1).  
Preparation of plasmid DNA and blue/white selection of MLB100 
After isolation of pSP189 from GM cells, the samples had to be digested with DpnI to degrade 
all originally transfected plasmid DNA (cf. 3.4.5). Afterwards, transformation of MLB100 cells 
was carried out using 50 ng of isolated plasmid DNA (cf. 3.3.5). On the next day, all colonies 
on the agar plates were counted and white colonies picked with toothpicks. 25 µL of ddH2O 
were inoculated with a single picked colony by shaking the toothpick in the water. The same 
toothpick was also tapped once on a new, separate agar plate containing IPTG, X-Gal, and 
ampicillin to create a backup plate.  
Polymerase chain reaction 
The PCR technique was first described by Mullis et al. [148] and used for the amplification of 
specific DNA sequences. It is based on three steps that are repeated for several times; in so 
called cycles: 1. denaturation (DNA strand separation), 2. primer annealing, and 3. elongation. 
Each PCR cycle starts with heating the samples to initiate denaturation of the template DNA 
from double stranded DNA (dsDNA) to single stranded DNA (ssDNA). Complementary 
oligonucleotides bind to these templates creating free 3’-OH ends at ds-ssDNA junctions 
(annealing). In the last step (elongation) a thermally stable polymerase synthesizes the new 
DNA strand by adding dNTPs in 5’ to 3’ direction complementary to the template strand. These 
steps are repeated about 30-40 times by which the DNA is exponentially amplified after the 
2nd cycle.  
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Colony PCR premix for one sample (25 µL): 
• 9.1 µL ddH2O 
• 4 µL of 25 mM MgCl2 (Merck, Darmstadt, DE) 
• 1 µL of 10 mM dNTPs (Thermo Scientific, Braunschweig, DE) 
• 2 µL of 10 pmol fPrimer (forward primer; cf. appendix I.8) 
• 2 µL of 10 pmol rPrimer (reverse primer; cf. appendix I.8) 
• 1.5 µL DMSO (Sigma-Aldrich, München, DE) 
• 0.4 µL Taq DNA polymerase (Thermo Scientific, Braunschweig, DE) 
• 5 µL 10x Buffer with KCl (supplied with Taq DNA polymerase) 
Prior to starting the colony PCR, inoculated bacterial solutions were incubated at 95 °C for 
5 min to denature the cell material. Then, the PCR premix was added to the samples (total 
volume: 50 µL) and the following PCR program started (Arktik Thermal Cycler; Thermo 
Scientific, Waltham, US).  
Colony PCR cycler program: 
0. initial denaturation  95 °C, 5 min 
1. denaturation   95 °C, 3 min 
2. denaturation   95 °C, 30 s  
3. primer annealing   55 °C, 20 s 
4. elongation    72 °C, 40 s 
5. remaining elongation  72 °C, 5 min 
To check for successful PCR products, some samples were separated via gel electrophoresis 
in 1% agarose gels. For this, 7.5 µL of the PCR product and 2.5 µL 6x DNA loading dye were 
mixed and loaded into the gel. Simultaneously, 5 µL of 100 bp ladder solution were loaded to 
verify fragmentation sizes. PCR products showing bands at about 500 bp were further used 
because fPrimer and rPrimer restrict the length of the amplified sequence to 493 bp. 
Purification of PCR products and sequence analysis 
Cleaning of PCR products from remaining dNTPs and primers was done with Exo-SAP-mix 
digestion (cf. 3.4.5). Afterwards, another PCR step was done with dideoxyribonucleotide 
triphosphates (ddNTPs) that are labeled with four different fluorescent dyes. The ddNTPs lack 
the 3’ hydroxyl group, which makes them deficient in polymerization. If one of the four ddNTPs 
(i.e. ddATP, ddCTP, ddGTP, or ddTTP) is incorporated during the PCR reaction, the chain 
elongation stops at this point [149]. Consequently, this results in products with different 
sequence lengths that terminally carry one of the four ddNTP with specific fluorescence 
markers. The BigDye® Terminator v3.1 Cycle Sequencing Kit (Life technologies, Darmstadt, 
37 x 
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DE) was used according to manufacturer’s instructions (except for the volume of Big Dye 
reaction mix with only 1 µL). 
BigDye reaction mix (10 µL): 
• 7 µL digested solution 
• 0.5 µL of 5 pmol sPrimer (sequencing primer; cf. appendix I.8) 
• 1 µL 10x Buffer (3.1 Seq. Kit) 
• 1 µL BigDye Ready Reaction Mix (3.1 Seq. Kit) 
• 0.5 µL ddH2O 
Cycling reaction program: 
0. initiate denaturation  95 °C, 1 min 
1. denaturation   95 °C, 15 s  
2. primer annealing   55 °C, 20 s 
3. elongation    72 °C, 4 min 
After this cycling reaction step, the DNA products were purified with sodium acetate. Therefore, 
10 µL of 3 M sodium acetate (pH: 5.6) and 250 µL ethanol (96%) were pipetted into a reaction 
tube. 10 µL of the cycling product were mixed with 90 µL ddH2O and also added to this reaction 
tube. The solution was vortexed and incubated for 10 min on ice. Then, products were 
precipitated by a 30 min centrifugation at 13000 rpm (Hereaus Megafuge 1.0R; Thermo 
Scientific, Schwerte, DE). The supernatant was discarded, the pellet dissolved in 300 µL 70% 
ethanol, again centrifuged (10 min at 13000 rpm), and the supernatant discarded. For drying, 
the reaction tubes were placed on a thermoblock for 10 to 30 min at 37 °C. Finally, the products 
were vortexed with 10 µL Hi-Di Formamide (Applied Biosystems, Foster City, US) and stored 
at -20 °C. The color codes of all DNA sequences were then analyzed by automatic separation 
of the products through capillary gel electrophoresis. The four different fluorescent ddNTPs 
were photometrically measured with a genetic sequence analyzer (3100-Avant Genetic 
Analyzer; Applied Biosystems, Foster City, US). 
Analysis of PSV results 
a) First, the total number of colonies was counted on each agar plate (CFU). The averaged 
CFU data from negative control plates (bacteria were transformed with untreated plasmid or 
plasmids were isolated from untreated GM cells) were defined as 100%. All other averaged 
CFU data from plasma treatments or UVC irradiations were normalized to the negative control. 
Untreated controls represent the overall transformation efficiency of intact plasmids. Damaged 
plasmids in which the eukaryotic ori is destructed GM cell are not able to replicate the plasmid 
leading to the loss of the plasmid for the assay. If the bacterial ori or ampicillin resistance is 
25 x 
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impaired on the plasmid MLB100 cannot grow on agar plates. Therefore, CFU values represent 
the overall genotoxicity of the respective treatment modality.  
b) The ratio between white and total CFU numbers on an agar plate represents the mutation 
frequency, thus, the mutagenicity of the underlying treatment modality. The spontaneous 
mutation frequency was calculated with CFU data of negative control plates. For version 1, the 
mutation frequency of plasma- or UVC-treated pSP189 DNA solutions were calculated, and 
for version 2 the mutation frequency of plasma- or UVC-treated GM cells carrying untreated 
pSP189 plasmids were calculated. Resulting mutation frequencies were averaged over all 
successful experiments. 
c) Mutation spectra were generated with all white colonies that were picked from the agar 
plates. Sequences were aligned to the original sequence of the supF-tRNA and the signature 
sequence with the software Chromas Lite 2.1 and the online tool MultAlin to reveal individual 
changes in genotypes of supF-tRNA and the signature sequence. Calculations of relative CFU 
values and mutation frequencies for version 1 and 2 of the PSV assay were based on different 
sample sizes. 
Sample sizes of CFU values and mutation frequencies in version 1:  
• negative control with n=12 
• jet applications with n=13 
• DBD applications with n=13 
• UVC (75 mJ/cm2) with n=12 
Sample sizes of CFU values and mutation frequencies in version 2: 
• negative control with n=14 
• jet applications with n=8 
• DBD applications with n=6 
• UVC (2.5 mJ/cm2) with n=4 
• UVC (5 mJ/cm2) with n=8 
• UVC (7.5 mJ/cm2) with n=10 
SD values were calculated with Excel (Microsoft Office 2010). Statistically significant 
differences were tested as described before with the SigmaPlot 12.0 software (cf. 3.5.1). 
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3.5.5 Flow cytometry assay 
To study the formation of DSBs induced by plasma treatments, flow cytometric analyses were 
performed based on phosphorylated H2A.X (γ-H2A.X) stain.  
In practice, a cell suspension is swept away with a rapidly streaming liquid through a thin 
channel inside the flow cytometer. Inside the channel, one cell after another passes a laser, 
that excites every single cell. The emission is detected by the forward scatter detector. 
Simultaneously, side scatter detectors record fluorescent emission wavelengths and intensities 
(Fig. 7).  
Thus, every cell in the flow channel, which was detected by the forward scatter detector, will 
be classified and counted as a distinct event with a specific emission. Furthermore, the liquid 
stream running through the flow channel is vibrated, which causes the stream to break into 
single droplets at the end of the channel. Because of this, each droplet carries only one cell in 
the ideal case. At this point a negative or positive charge is applied to each droplet depending 
on its fluorescence. Thus, droplets are diverted according to their charges into different 
vessels. 
Figure 7: Scheme of laser and light pathways in a flow cytometric device 
The scheme shows the laser and light pathways through the flow channel and towards the scatter detectors in a 
FACS device (modified after https://www.semrock.com/flow-cytometry.aspx [150]). 
Measurements of γ-H2A.X fluorescence signals 
In these experiments, γ-H2A.X histone proteins were detected as DSB markers [151]. The 
γ-H2A.X antibody binds to the phosphorylated H2A.X protein that is one variant of the H2A 
histone core protein. Together with other histone core proteins (i.e. H2B, H3, and H4), H2A 
forms the basic element of DNA packaging in eukaryotes, the nucleosome complex [152]. 
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Phosphorylation of H2A.X on Ser139 takes place immediately after SSB or DSB events occur 
and a single DSB can lead to hundreds and thousands of phosphorylated H2A.X proteins [153, 
154]. Nevertheless, in normal cells, which are in the G1 phase of their cell cycle, constitutive 
or intrinsic H2A.X phosphorylation was found. Moreover, cells in their S- and G2/M-phase of 
the cell cycle exhibit higher levels of γ-H2A.X than cells in G1 phase [155].  
Cells were first seeded in culture dishes followed by the plasma treatment on the next day 
(cf. 3.2.3). Afterwards, cells were incubated for 24 h (37 °C, 5% CO2, 90% humidity) and 
collected by adding 500 µL Accutase to each dish (5 min, 37 °C, 5% CO2, 90% humidity) and 
pipetting the cell solution into a new reaction tube. The culture dish was rinsed with 500 µL of 
PBS and this was also transferred to the same reaction tube. The cell solutions were then 
centrifuged at 1200 rpm (Hereaus centrifuge) for 15 min, the supernatant discarded, and cells 
re-suspended in 500 µL of 3.7% paraformaldehyde (PFA; cf. appendix I.5) on a vortexer for 
fixation. Again, the cells were centrifuged (2400 rpm for 15 min) and the supernatant removed. 
Then, the cells were permeabilized and unspecific binding sites of the antibody blocked by 
incubation with 500 µL of the Per/Block-solution (cf. appendix I.5) for 30 min at 37 °C. The 
primary antibody, anti-phospho H2A.X (cf. appendix I.6; Dianova, Hamburg, DE), was added 
to the Per/Block solution at a ratio of 1:4000 (1:100 prediluted in PBS containing 5% FBS) and 
incubated for 1 h at 37 °C. Subsequently, 500 µL of PBS-Tween solution (cf. appendix I.5) were 
added to the cell solution to remove unbound antibody proteins. This was followed by 
centrifugation (2400 rpm, 15 min) and removing of the supernatant. The secondary antibody, 
Alexa-Fluor® 488 (cf. appendix I.6; Dianova, Hamburg, DE) was diluted to 1:400 in PBS 
containing 5% FBS. Cells were then re-suspended in 500 µL of the second antibody solution 
and incubated for 30 min at 37 °C. Again, 500 µL of PBS-Tween solution was added and gently 
mixed before samples were centrifuged (2400 rpm for 15 min) and the supernatant discarded. 
Finally, cells were re-suspended in 500 µL PBS and the samples were analyzed with a BD 
FACS device (BD FACS CantoTMII; BD Bioscience, Heidelberg, DE).  
In addition to plasma-treated samples, cell suspensions were prepared for positive and 
negative controls. Cells were exposed to X-rays with 1, 3, 5, 7, and 9 Gy (cf. 3.2.4) as positive 
control for induced DSB events. Untreated samples were the negative control. Moreover, each 
experiment included one unstained control, one sample stained with an IgG1 isotype antibody 
(cf. appendix I.6; Dianova, Hamburg, DE) instead of the primary antibody (-1AB), and one 
sample without the secondary antibody (-2AB) as control for the binding specificity of the 
antibodies. 
Analysis of flow cytometry results 
The sum of the fluorescent signals of the -1AB and -2AB controls was subtracted from the 
unstained control, which represents the background fluorescence of γ-H2A.X proteins in GM 
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cells. This value was also subtracted from all the other recorded values (treated samples with 
plasma or X-rays) within the same experiment. Data corrected in this way, were then averaged 
across all experiments and the treated samples normalized to the negative control (defined 
as 1). Overall, γ-H2A.X fluorescence signals measured for each sample correspond to the 
number of DNA strand breaks generated by plasma or X-ray treatments. Data of four 
experiments with different sample sizes for varying treatment modalities were analyzed: 
• negative control with n=21 
• jet applications with n=15 
• X-ray irradiations with n=6 
SD values were calculated and statistically significant differences tested as described before 
(cf. 3.5.1). 
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4. Results 
In this study, test systems are presented, which are suitable for a basic evaluation of APP 
sources regarding their physical and biomedical performances. These will help to assess risk 
factors of plasma sources intended for medical use. Furthermore, test systems are presented 
to determine the genotoxic and mutagenic potential of medical plasma devices to assess 
possible long-term effects. One of the key challenges was to find suitable assays, which can 
be adjusted to a wide range of different APP devices, to ensure comparability of results. 
Therefore, two devices, a plasma jet type and a volume DBD device, were used. Moreover, 
since another focus in this project was on dermatological applications, human skin fibroblasts 
were chosen as target cells.  
The first section of this chapter presents experiments suited for a first, general characterization 
of medical plasma sources based on our published DIN-SPEC 91315 [11]. This is the first 
document that defines standards and plasma specific criteria for the general use of plasma 
devices as medical tool. However, certain data (i.e. measurements of physical efficiencies of 
the plasma sources, inhibition zone tests, and reactive species generation in PBS) had to be 
obtained by others during the close collaboration works with the INP and the HAWK. These 
data are presented in this chapter because they are necessary for comprehensive analyses of 
plasma-cell interactions.  
Descriptions of experimental procedures are only given in the materials and methods part if 
the respective test systems were established and used by myself. Otherwise, detailed 
information about methods, techniques, and assays were already published in collaboration 
with the INP (kINPen® MED source; joint first authorship Mann and Tiede et al. [138]) and with 
the HAWK (µs-pulsed DBD; joint first authorship Tiede and Hirschberg et al. [47]). Physical 
performance data and their safety in use are also discussed for both plasma sources in this 
chapter. 
The second part of this chapter presents biological test systems to evaluate the genotoxic and 
mutagenic potential of APP. This represents an important additional step towards a detailed 
characterization of medical plasma sources, which may predict their best therapeutic use. 
4.1 Basic characterization of medical plasma sources 
4.1.1 Physico-technical characterization of APPs and safety in use 
The physico-technical characterization of both APP sources was based on plasma specific 
parameters described in the DIN-SPEC 91315: electric current, plasma temperature, 
generation of artificial optical radiation, and emission of potentially unhealthy gases.  
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Mean power, maximum and mean discharge current 
Based on previously presented physical parameters of both plasma devices (cf. 3.1) mean 
power, voltage, and maximum discharge current were measured. 
Applications with the kINPen® Med device are usually performed in the way that the tip of the 
effluent is touching the surface to be treated; that is about 8 mm from the nozzle of the device 
to the treatment object. This also represents the application-oriented working distance [138, 
156]. Consequently, the interaction or exposure area on the treatment object is about 5 mm2 
(Fig. 4a). A relatively constant mean power of 145-160 mW and a current of about 50 µA were 
measured at the tip of the plasma jet [138]. According to the DIN EN 60601-1 (Medical electric 
equipment – Part 1) the kINPen® MED device was proven to be safe with the here presented 
configurations [138, 156].  
For the µs-pulsed DBD device a mean power of 274-324 mW and a maximum discharge 
current of 470 mA were measured, the latter of which is only reached for a few nanoseconds. 
As described in Tiede et al. [47], the mean discharge current averaged across one pulse 
(‘plasma-on’ time: 70 µs) is below 10 mA. According to the assumption that no current is flowing 
during the ‘plasma-off’ time within one period, the current averaged over one period is ∼0.2 mA. 
In medical therapies electric currents are widely used; e.g. during iontophoresis therapy 
continues currents of 170 mA are used [157]. Therefore, the averaged period current of 0.2 mA 
is much lower and, thus, no harm is to be expected from discharge current of the DBD device.  
In order to achieve comparability on the basis of the energy densities generated by the two 
sources in addition to the comparison based on treatment durations, energy densities of both 
sources were calculated for 1 s of treatment duration. For the kINPen® MED an energy density 
of about 3.1 J/cm2 was calculated with 153 mW mean power and the exposure area of 
approximately 5 mm2. The energy density of the DBD plasma is about 0.4 J/cm2 calculated with 
the mean power of 299 mW and an exposure area of 78.54 mm2 (diameter of electrode: 
10 mm). For extended treatment durations these factors were simply multiplied with the 
according treatment time.  
However, it has to be explained, that this comparison is not ideal. During plasma jet treatments 
of cells or solutions in petri dishes a PBS-free area is generated centrally above the jet device. 
In addition, a turbulence is produced so that the PBS is moving as swirl in the dish during 
application. This would mean that exclusively the center of the petri dish will be exposed to an 
energy density of 3.1 J/cm2 but the surrounding regions will only be treated indirectly. In case 
of µs-pulsed DBD treatment, the petri dish was horizontally moved in an orbital motion with 
40 rpm under the dielectrically covered electrode to obtain the largest exposure area possible. 
This means that locally seen even less than 0.4 J/cm2 is applied. 
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Since it is very difficult to comprehend which plasma components act with which energy in 
which area of the petri dish and, thus, the actual energy density applied to cells or solutions 
cannot be calculated exactly, results of biological assays were compared on the basis of the 
above calculated, but simplified energy densities. 
Gas temperature and thermal output 
For dermatological applications, APP temperature should not exceed 40 °C since thermal 
damage of cells, lipids, proteins as well as skin burns should be avoided. The temperature 
profile of the kINPen® MED plasma was measured using a fiber optic temperature sensor in 
the axial direction of the visible effluent (Fig. 8). Directly at the nozzle, jet temperature is about 
49 °C, but decreases with distance from the nozzle. At the tip of the visible plasma jet (7-10 mm 
from the nozzle), the temperature already fell to around 35-40 °C. Moreover, during medical 
applications, the device would rather be moved across the treatment area than being held 
above the same point. Slow movements of the jet decrease heat absorption by the skin. Thus, 
burns can be completely avoided when the jet is moved across the treatment area at the 
recommended working distance.  
Figure 8: Axial temperature profile of the 
kINPen® MED 
With increasing distance from the nozzle, plasma 
temperature decreases. At the tip of the effluent 
(grey area; also: working distance) temperatures are 




Plasma temperature of the µs-pulsed DBD were measured with two different techniques. As 
for the plasma jet, an optical fiber was held into the discharge for measuring gas temperature. 
About 300 K (26.85 °C) could be detected [47]. This technique is sufficient for measuring the 
temperature of plasma jet devices since the optical fiber does not influence the process of 
plasma ignition. In the case of a direct DBD, holding a fiber into the discharge gap alters plasma 
generation. That is why gas temperature was also indirectly determined by optical emission 
spectroscopy (OES). Maximum and mean gas temperature calculated from the emission 
spectra were about 380 K (~107 °C) and 310 K (~36.85 °C). It has to be mentioned that the 
maximum gas temperature only is reached for a few microseconds (within a pulse duration: 
70 µs) and also limited to the microdischarge volume [158]. Additionally, within some 
milliseconds the temperature declines to almost room temperature through heat transfer to the 
surrounding neutral gas [159]. Furthermore, with another but very similar DBD and a related 
— 51 — 
Basic characterization (Physico-technical parameters)     
setup, sample heating was analyzed. This revealed that one minute of plasma treatment only 
marginally increased sample temperatures [160]. Hence, no thermal injury is to be expected 
from applications with the µs-pulsed DBD. 
Optical artificial radiation (UV radiation) 
UV radiation generated by plasma represents a serious risk factor since too long exposures of 
the skin to UV radiation are attributed to aging and wrinkle formation, can cause sunburns or, 
in the worst cases, skin cancer [12, 13, 15, 16, 161, 162]. With the OES technique, emission 
bands in the UV range were detected for both sources. The calculation of the effective 
irradiance produced by the kINPen® MED was based on measurements with a calibrated optic 
spectrometer system [138]. The spectral irradiance of the µs-pulsed DBD plasma was 
calculated after detection of the irradiance with a calibrated radiometer [160].  
Figure 9: Spectral irradiance of the two plasma sources 
The spectral irradiance measured in the UV range is shown for the kINPen® MED (a; modified after Bussiahn et al. 
[156]) and the µs-pulsed DBD (b; after data provided by Joanna Hirschberg). Please note that the y-axes are 
differently scaled in figure (a) and (b). 
The results showed that no radiation in the UVC region (200-280 nm) was generated by either 
of the two APP devices [47, 138]. However, the plasma jet produced one emission peak of OH 
radicals in the UVB region (OHr at 309 nm; Fig. 9a) and three peaks of N2 molecules in the 
UVA range (Fig. 9a). In case of the µs-pulsed DBD, mainly N2 peaks in the UVA region were 
detected (at 315.6 nm, 337 nm, and 357.6 nm) and only small emission peaks in the UVB region 
(Fig. 9b). 
The plasma jet device kINPen® MED driven with argon gas demonstrable generates vacuum 
UV (VUV) radiation [156]. Due to the jet flow rate of 5 slm, an optical light path is produced, 
through which VUV radiation can likely reach the treatment object. Argon shows two intensive 
emission lines in the VUV region at 104.8 nm and 106.7 nm [163]. In Bussiahn et al. [156] the 
maximum effective irradiance of the kINPen® MED plasma in the range of 100-400 nm was 
measured to be 35 ± 5 µW/cm2, thus the two highest resonance lines of argon were taken into 
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account. As described in Mann et al. [138], if one imagine that a surface of 1 cm2 should be 
treated with the plasma jet that has an exposure area of 5 mm2, the jet must be hold onto 20 
surface points, separately. For a total treatment duration of 60 s this would lead to an exposure 
time of 3 s for every surface point. Consequently, the effective irradiation for every 3 s contact 
point can be calculated and is about 105 µJ/cm2. The International Commission on Non-
Ionizing Radiation Protection (ICNIRP) defines a maximum radiation dose of 3 mJ/cm2 in the 
range of 180-400 nm as the daily limit for UV exposure of sensitive skin phototypes [164]. 
Therefore, the effective irradiance of the plasma jet is lower than the irradiation safety value 
and, thus, safe regarding UV radiation [138]. The other way round, it can be said that one 
surface point of 5 mm2 can be treated for about 85 s before reaching the threshold value of the 
ICNIRP. Certainly, this should be considered when using the kINPen® MED plasma on human 
skin.  
Helmke et al. [165] presented a study with a very similar DBD device and similar experimental 
configuration as used during this project, where maximal exposure durations of plasma on the 
human skin were calculated. Results showed that the ICNIRP limit of 3 mJ/cm2 was reached 
after 7 h of plasma treatment. The effective irradiance of 0.12 µW/cm2 can, thus, be calculated. 
In the practical medical use treatment durations of 7 h are most unlikely, one would rather 
expose the skin for some seconds or minutes (e.g. 10 min ≙ 72 µJ/cm2). Based on this fact, 
the µs-pulsed DBD device can be considered as safe with respect to the production of UV. In 
addition, no harm is to be expected due to VUV radiation in the DBD plasma since the ignition 
in air results in the efficient absorption by N2 (< 100 nm) and O2 (< 200 nm) [166, 167].  
Gas emission 
The generation of APP is always accompanied by ROS and RNS production. The radicals will 
react with molecules in the ambient air and can lead to the formation of toxic gases like O3, 
NO. When their concentrations are too high and when these gases are inhaled, the respiratory 
tract can be harmed. Therefore, it is very important to examine O3 and NO2 as a product of 
NO not only in the immediate vicinity of the APP but also at further distances to the generated 
plasma. This can be done with spectroscopic measurement techniques like OES. For both 
sources, O3 generation in and around the ignited plasma were measured. In addition for the 
jet NO2 measurements were performed, whereas for the DBD NO concentrations were 
provided after a model system described elsewhere.  
In case of the plasma jet, gas concentrations were not only measured at different working 
distances but also at three solid angles relative to the effluent (180°, 90°, and 45°). Whereas 
NO2 was not detected near the plasma jet, high ozone concentrations were observed at all 
solid angles in the very close vicinity of the nozzle; values were between 0.1 and 6 part per 
million (ppm) at distances below 10 cm. Highest concentrations were found when the jet was 
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directed head-on to the sensor (180° solid angle). At distances of 30 cm or more and angles of 
45° and 90°, O3 concentrations were lower than 0.055 ppm = 120 µg/m3 (Fig. 10a; rough dotted 
lines). The maximum workplace concentration (MAK) for O3 is defined with 0.1 ppm 
(= 200 µg/m3) over 8 h per day [168]. Furthermore, the EU provides an exposure limit for O3 in 
directive 2002/3/EG; the value is a daily average of 0.055 ppm = 120 µg/m3 over 8 h. When the 
plasma jet is not frontally directed at the face and one is standing more than 30 cm away from 
the jet, O3 concentrations are below these threshold values. Hence, the use of the kINPen® 
MED under these conditions can be considered as safe. 
For the µs-pulsed DBD O3 concentrations were recorded directly within the interelectrode 
space, i.e. where the plasma is generated, and at different distances to the discharge gap. 
Inside the discharge 5 ppm were measured. With increasing distances to the plasma (at 15 cm), 
O3 concentration decreased to about 0.042 ppm. Concentrations below the safety limits [168] 
are already reached at a 10 cm distance from the discharge gap (Fig. 10b). NO concentration 
was measured within the discharge gap and results showed that 235 to 265 ppm were 
produced. As for ozone, the concentration in the discharge rapidly declines with increasing 
distance to the discharge gap. The calculated NO concentration for a lateral distance of 3 cm 
is 0.2 ppm which can be considered as harmless for humans which was already described 
elsewhere [47]. Taken together, no harm is to be expected when the respiratory tract is 10 cm 
away from the discharge gap of the µs-pulsed DBD.  
 
Figure 10: Ozone concentrations generated around the two 
plasma sources 
Ozone concentrations were measured in different distances to the 
jet (a) and the µs-pulsed DBD plasma (b; modified after Tiede et al. 
[47]). In addition, measurements were performed in varying solid 
angles for the kINPen® MED (modified after Bussiahn et al. [156]). 
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4.1.2 Biomedical efficiency of APP 
The knowledge about induced biological effects of APPs is required for an appropriate 
evaluation of their medical potential. The DIN-SPEC 91315 includes descriptions of very easy 
to perform test systems to study three important aspects of the biomedical efficiency of APP 
sources: the antimicrobial effect, the cytotoxic effect on human skin cells, and the chemical 
changes of liquids due to plasma treatments.  
4.1.2.1 Inactivation efficiency of APP against microorganisms 
One beneficial property of plasma applications is their strong antimicrobial effect. In medicine, 
this can be used for contact free removal of bacteria from infected wounds. 
Investigations of the inactivation capacities using the kINPen® MED were performed in 
accordance with the DIN-SPEC 91315 using the inhibition zone test and five different microbial 
strains [138]. The results revealed increasingly larger inhibition zones with extended plasma 
treatment durations (Fig. 11). This indicates the antimicrobial efficiency of the plasma jet. The 
test also revealed a strain dependent inactivation capacity of the jet. For example, the fungus 
strain Candida albicans (C. albicans) is more sensitive to the plasma application than 
Pseudomonas aeruginosa (P. aeruginosa). Such experiments were not performed with the µs-
pulsed DBD, but existing data for a similar DBD source were used to evaluate and discuss the 
inactivation efficiency against microorganisms (cf. 5.1.2.1). 
Figure 11: Microbial inhibition zone sizes produced by the plasma jet 
The microbial strains (S. epidermidis, S. aureus, P. aeruginosa, E. coli, and C. alb icans) were punctually treated on 
tryptic soy agar plates with the kINPen® MED (modified after Mann et al. [138]). 
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4.1.2.2 Cytotoxic effects of APPs on fibroblasts 
The cytotoxicity of the plasma sources were measured with the use of the MTS kit. Quantitative 
cell viability after plasma exposures were studied on two different fibroblast cell types; GMs 
and PFs. In addition, two different versions of the assay were performed: 
1) Cell viabilities of plasma-treated cells were measured to study direct plasma effects. 
2) Plasma-treated PBS was used to study the impact of reactive species formed in the PBS; 
defined as indirect plasma treatment. 
The latter was of interest, because plasma is known to “activate” liquids via interactions of 
reactive species produced in the plasma with the treated liquid, which in turn generate 
byproducts that influence cell behavior and response [21, 83, 169]. With the indirect approach 
of the assay, specific plasma components, like the electric current, UV radiation, and 
temperature that affect cells were excluded. Thus, only the chemical changes within the PBS 
solution are responsible for underlying changes in cell viabilities. Such indirect plasma tests 
were not included in the DIN-SPEC 91315. 
Figure 12: Cell viability of GM cells after H2O2 treatments 
GM viability decreased as a function of varying incubation times with different concentrations of H 2O2 (60, 75, and 
90 µM). Error bars represent SD values and statistically significant differences to the negative control are marked 
with * (p ≤ 0.05), ** (p ≤ 0.01), and *** (p ≤ 0.001). Asterisks in brackets show differences between varying incubation 
times at same concentrations. 
To demonstrate the functionality of this method, GM cells were incubated for 30, 60, 90, and 
180 s in H2O2 solutions with different concentrations (60, 75, 90 µM H2O2 in PBS). Figure 12 
shows that cell viability of GM cells significantly reduced with higher concentrations of H2O2. 
Extended incubations for 60 µM and 75 µM H2O2 solutions caused similar viability reductions, 
which were significant in only one case (Fig. 12; cf. 30 s and 180 s at 75 µM). With the strongest 
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H2O2 concentration, significant differences of cell viabilities were found between all incubation 
times. 
1) Direct plasma effects 
Independently from the plasma source used, cell viability of PF or GM cells declined with longer 
treatment times (Fig. 13). First, cell responses of PF and GM cells are compared considering 
both plasma sources separately. 
Jet applications with the kINPen® MED device led to LD50 values between 30 and 60 s (≙ 92 
and 184 J/cm2) for both cell lines. In most cases, GM cells were significantly more susceptible 
to jet treatments than PFs with only one exception at 30 s of treatment duration (Fig. 13a).  
Figure 13: Plasma treatment time dependent cell viability of fibroblasts 
With extended plasma applications with the kINPen® MED (a) and the µs-pulsed DBD (b; modified after Tiede et al. 
[47]) cell viabilities of GM and PF cells are decreasing. Error bars represent SDs. Statistically significant differences 
to the negative control (defined as 100 %) are marked with * (p ≤ 0.05), ** (p ≤ 0.01), and *** (p ≤ 0.001). Asterisks 
in brackets refer to the comparison between GM and PF cell viability at same treatment duration. 
At this point it is important to mention that plasma jet applications also affected cells due to the 
argon gas flow (5 slm). The gas stream generated a PBS-free center in cell culture dish during 
treatment. Cells in this area were directly exposed to the stream and plasma components. To 
determine the impact of the gas flow alone, additional experiments were performed with GM 
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cells. On average, the results showed a 17% reduction of cell viability due to the gas stream 
(data not shown).  
Figure 13b shows the results of direct treatments with the µs-pulsed DBD. A treatment duration 
of 180 s (≙ 69 J/cm2) resulted in a cell viability of 68.4% for GMs and 72% for PFs. Thus, longer 
application times than used for jet treatments were necessary to decrease cell viability below 
50%. The LD50 value was reached at 180-270 s (≙ 69-103 J/cm2) of DBD-treated GMs and at 
360-480 s (≙ 137-183 J/cm2) of PF cells. As for kINPen® MED applications, there was a 
difference between the sensitivity of PF and GM cells to the DBD plasma. At short treatment 
durations PFs reacted more sensitive than GMs (10-60 s ≙ 4-23 J/cm2), whereas DBD 
applications between 90-360 s (≙ 34-137 J/cm2) resulted in lower GM cell viabilities compared 
to PFs (Fig. 13b). 
Figure 14: Plasma-type dependent cell viability of GM cells 
The cell viability of GM cells is shown as a function of treatment times (a) and as a function of plasma doses (b) 
applied by kINPen® MED and DBD treatments. GM viability was in almost all cases significantly lower for same 
treatment durations with the plasma jet than the DBD plasma (exception at 10 s). In contrast, the DBD plasma tends 
to induce lower viabilities at similar plasma doses compared to the jet. Error bars represent SDs. Statistically 
significant difference at same treatment times or similar plasma doses are marked with ** (p ≤ 0.01) and 
*** (p ≤ 0.001). Non-significant differenced are marked with (#).  
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Based on these results, a direct comparison between cytotoxic effects induced by the two 
plasma sources was possible. When comparing the cell viability of GMs on the basis of same 
treatment durations, it is obvious that GM viability decreased faster for jet than DBD 
applications (Fig. 14a). In addition, if cell viability of GMs is compared at the level of plasma 
doses, the DBD plasma tends to decrease the viability stronger than the plasma jet at energy 
densities between 7-14 J/cm2. A closer look shows that e.g. 10 s ≙ 31 J/cm2 of jet application 
approximately corresponds to a 90 s ≙ 34 J/cm2 treatment with the DBD plasma, at which cell 
viability was reduced to about 82% (Fig. 14b). Another comparison on the basis of similar 
plasma doses can be made with 30 s ≙ 92 J/cm2 of jet and 270 s ≙ 103 J/cm2 of DBD 
treatments. Here, cell viability of GM cells was significantly lower for DBD (35.8%) than jet 
application (63.9%). 
2) Indirect plasma effects 
For the indirect approach, PBS solution was exposed to plasma and then cells were incubated 
for 5 min in the PBS. In figure 15 cell viabilities of the two cell lines exposed to the two different 
plasma sources are presented. Overall, cell viabilities decreased with extended treatment 
durations with the plasma jet and DBD plasma. As expected, the decrease was lower than in 
direct plasma treatment tests.  
Figure 15: Fibroblast cell viability after indirect plasma treatments 
Cell viabilities of GM and PF cells are shown as a function of different treatment durations of PBS with the kINPen® 
MED plasma (hatched bars) and the µs-pulsed DBD plasma (solid bars) following a 5 min cell incubation. Error bars 
represent SDs. Statistically significant differences to untreated controls (defined as 100%) are marked with 
* (p ≤ 0.05), ** (p ≤ 0.01), and *** (p ≤ 0.001) for indirect jet applications and asterisks in round brackets refer to 
indirect DBD treatments compared to the untreated control. Asterisks in square brackets mark significant differences 
between jet-treated and DBD-treated PBS added to GMs (purple) or PFs (blue). 
A comparison between GM and PF sensitivity revealed that, in most cases, GMs reacted more 
sensitive to the plasma-treated PBS than PF cells. As in direct MTS experiments, only short 
DBD treatments up to 60 s significantly induced stronger viability reductions of PFs compared 
to GMs. This was the other way round for DBD treatment durations of 90 s and longer 
— 59 — 
Basic characterization (Biomedical efficiency – Cytotoxicity)     
(Fig. 15; cf. solid bars). 10 s of indirect plasma jet treatment also resulted in higher cell 
viabilities of GMs than PFs, whereas extended treatment durations induced lower GM 
viabilities compared to PF viabilities (Fig. 15; cf. hatched bars). In all cases these differences 
were significant (data not shown). 
Comparing the effects of both sources on GM cells, only a tendency towards a stronger effect 
of indirect jet applications was observed (one significant difference at 30 s in Fig. 15; purple 
asterisks). In contrast, the plasma jet induced significant lower PF viabilities at all comparable 
treatment durations than the DBD plasma (Fig. 15; blue asterisks).  
After indirect jet treatment for 180 s ≙ 551 J/cm2 GM cell viability was reduced to about 75%. 
A similar viability value (74%) was reached with 360 s ≙ 137 J/cm2 of indirect DBD treatment. 
This shows that lower DBD than jet doses applied to PBS are necessary to induce the same 
GM cell viability. 
4.1.2.3 APP-dependent generation of reactive species and pH changes 
For a better understanding, which reactive species may contribute to plasma effects, the last 
test system described in the DIN-SPEC 91315 focused on the generation of ROS and RNS in 
liquids. As in the MTS assay for indirect effects, PBS was treated with either one of the two 
plasma sources followed by measurements of NO2- and NO3- concentrations (representative 
for the production of RNS), and H2O2 concentration (representative for ROS generation). In 
addition, the pH was measured after plasma treatments, because this is another important 
factor in wound healing and some skin diseases [115, 116].  
Reactive species production in PBS 
For photometrical measurements of reactive species generated by the kINPen® MED in PBS 
the very sensitive Aplex® UltraRed Reagent for H2O2 (Thermo Fisher, Dreieich DE; lower 
detection limit: ~0.08 µM) and the Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical, 
Ann Arbor, Michigan, US) for NO2- and NO3- detection (detection range: 5-35 µM) were used. 
A different test system was used for measurements of species produced by the µs-pulsed 
DBD: RQflex 10 and appropriate reflectometric test strips (Merck KGaA, Darmstadt, DE). 
Detection thresholds of this test system are much higher with 6-588 µM (0.2-20 mg/L) for H2O2, 
11-543 µM (0.5-25 mg/L) for NO2-, and 48-1452 µM (3-90 mg/L) for NO3-.  
In figure 16, concentrations of above mentioned species in plasma-treated PBS are shown. 
Both plasma sources caused concentrations to rise with longer treatment durations. Limited 
by the detection thresholds of the RQflex 10 test kit no DBD data exist for applications shorter 
than 90 s. 
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Figure 16: Plasma treatment time dependent generation of reactive species in PBS 
H2O2, NO2-, and NO3- concentrations were detected in PBS treated with the kINPen® MED (a) and the µs-pulsed 
DBD device (b; modified after Tiede et al. [47]). Error bars represent SDs. Please note the two y-axes in each 
subfigure. 
Maximum concentrations detected after 180 s ≙ 551 J/cm2 of the jet application were 73 µM for 
H2O2, 3 µM for NO2-, and 5 µM for NO3- (Fig. 16a). PBS exposure of 180 s ≙ 69 J/cm2 to the 
µs-pulsed DBD led to concentrations of 38 µM for H2O2, 21 µM for NO2-, and 215 µM for NO3- 
(Fig. 16b). Thus, at same exposure times concentrations of NO2- and NO3- were many times 
higher after DBD than after jet treatments. In contrast, H2O2 concentrations were higher in jet 
treated PBS. Similar H2O2 concentration were e.g. generated by 30 s ≙ 92 J/cm2 of jet and 
90 s ≙ 34 J/cm2 of DBD application or by 90 s ≙ 275 J/cm2 of jet and 180 s ≙ 69 J/cm2 of DBD 
treatments. 
A comparison of reactive species concentrations produced at similar plasma doses revealed 
that DBD treatments generated higher concentrations in all cases (table 1). However, the 
differences in RNS concentrations were greater between the two plasma sources than 
differences in the ROS concentration of H2O2.  
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Table 1: Reactive species concentrations in plasma-treated PBS at similar plasma doses 
Similar plasma doses applied to PBS solution led to higher concentrations of H2O2, NO2-, and NO3- when using 
the DBD source compared to the kINPen® MED device.  
Plasma dose [J/cm2] ≙  
Treatment duration [s] H2O2 [µM] NO2
- [µM] NO3- [µM] 
(jet)             31 ≙ 10 1 0.04 0.4 
(DBD)         34 ≙ 90 9 12 105 
(jet)             92 ≙ 30 9 0.6 0.8 
(DBD)         103 ≙ 270 63 30 339 
(jet)             184 ≙ 60 25 1 1.7 
(DBD)         183 ≙ 480 125 71 664 
Changes of pH in PBS 
Plasma is also known to have an impact on the pH of liquids or humid treatment objects [117, 
120]. Since in-vitro experiments on fibroblasts were always performed in PBS (pH: 7.4), plasma 
treatment time dependent pH changes of PBS were recorded. As illustrated in figure 17 both 
sources slowly decreased pH values with extended treatment durations. For longest treatment 
times with the DBD (600 s ≙ 22.9 J/cm2) and with the plasma jet source (180 s ≙ 551 J/cm2) 
the pH was reduced by 0.66 and 0.09, respectively. Furthermore, DBD plasma led to a slightly 
stronger shift towards an acidic pH at same application times than the plasma jet. Comparing 
pH changes at similar plasma doses at about 183 J/cm2 (≙ 60 s of jet and 480 s of DBD 
treatment in Fig. 17; purple arrowhead) pH decreased by 0.05 for jet treatments and by 0.54 
for DBD applications. 
Figure 17: Plasma-type dependent changes of the pH value in PBS 
The pH value of PBS solution treated with the kINPen® MED or the µs-pulsed DBD device slightly decreased with 
extended treatment duration. Error bars represent SDs and statistically significant differences to untreated PBS are 
marked with * (p ≤ 0.05), ** (p ≤ 0.01), and *** (p ≤ 0.001). Purple arrowheads mark similar plasma doses of about 
183 J/m2. 
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4.2 Evaluation of long-term damages induced by APP 
Based on the general characterization of both APP sources, additional and detailed 
experiments focus on plasma-induced genotoxic and mutagenic effects. Reproducible and 
cost-effective assays and experimental procedures were established and evaluated until the 
most practicable solutions were found. Not only resulting data and effects were of interest but 
also the ease of use and explanatory power of the assays.  
Figure 18: Reporter gene expression of fibroblasts after transfection with UV-irradiated plasmids 
GM and PF cells showed lower firefly expression rates as a function of different UVB (a) and UVC (b) doses. Error 
bars represent SDs. Significant differences to the untreated control (defined as 100%) are marked with * (p ≤ 0.05), 
** (p ≤ 0.01), and *** (p ≤ 0.001). Asterisks in brackets mark significant differences between the two cell lines 
exposed to same UV doses. 
4.2.1 Indirectly measured genotoxicity of APP on plasmid DNA 
Usually, the HCR assay is performed to quantify the repair capacity of eukaryotic cells. Here, 
the properties of this assay were used to indirectly quantify genotoxic effects.  
For this assay, plasmid DNA diluted in ddH2O was exposed to APPs or UV radiations, followed 
by transfection of plasmids into fibroblast cells. During the incubation time, cells naturally repair 
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plasma- or UV-induced damages on plasmids. The reporter gene firefly can then be expressed 
from intact plasmids and the enzymatic activity of the firefly luciferase is detectable as 
luminescence in the cell extract. Hence, the luminescence intensity represents the rate of firefly 
reporter gene expression.  
As positive control, plasmid DNA was irradiated with different doses of UVB and UVC (Fig. 18). 
As expected, expression rates in both cell lines decreased with higher UV irradiation doses; 
this indicates that the HCR assay was successfully established and performed. However, the 
expression rates of firefly depended on the used cell type. GM cells expressed higher levels 
of firefly than PF cells when same UVB or UVC doses were applied. These differences were 
significant for intermediate doses of UVB and for mediate to high UVC doses (Fig. 18; asterisks 
in brackets). UVB was additionally selected as positive control for the later discussion about 
transferability of these in-vitro effects to in-vivo effects of APP applications (cf. 5.2.1).  
Figure 19: Reporter gene expression of fibroblasts after transfection with plasma-treated plasmids 
GM and PF cells showed lower expression rates of firefly as a function of kINPen® MED (a) and µs-pulsed DBD (b) 
treatment durations. Error bars represent SDs. Statistically significant differences to the negative control (untreated 
firefly plasmid DNA transfected into fibroblasts, defined as 100%) are marked with * (p ≤ 0.05), ** (p ≤ 0.01) and 
*** (p ≤ 0.001). Asterisks in brackets refer to significant differences between different cell lines at same treatment 
durations.   
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Results of APP treatments are given in figure 19. In general, reporter gene expression rapidly 
decreased after plasma treatments of the firefly plasmid with the two devices. Applications with 
the kINPen® MED device for 10 s ≙ 31 J/cm2 reduced gene expressions to about 16.5% for 
GM cells and 24.7% for PF cells; they further decreased to 0.6% (GM) and 1.9% (PF) at 180 s 
≙ 551 J/cm2. Cell-type dependent expression rates were, however, not significantly different 
from each other (Fig. 19a). Interestingly, when the DBD device was used, GM cells tend to be 
more effective in gene expression than PF cells (Fig. 19b). 90 s ≙ 34 J/cm2 of DBD treatment 
led to significant different gene expressions of 30.4% in GMs and 16.4% in PFs. At 180 s 
≙ 69 J/cm2, expression rates were already reduced to about 15.7% (in GMs) and 3.6% (in 
PFs). For the longest treatment duration or highest plasma dose (360 s ≙ 137 J/cm2) firefly 
expression declined to 7.1% (in GMs) and 3.3% (in PFs). 
Figure 20: Plasma-type dependent expression rates of firefly in GM cells 
The firefly gene expression is shown as a function of treatment durations with the two plasmas (a) and as a function 
of plasma doses (b). Error bars represent SDs and significant differences between the two sources for same 
treatment duration or similar plasma doses are marked with * (p ≤ 0.05), ** (p ≤ 0.01), and *** (p ≤ 0.001). 
Statistically non-significant differences are marked with (#). 
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In a direct comparison between the two sources used for same treatment durations, it becomes 
apparent that the impact on firefly DNA was significantly more pronounced after kINPen® MED 
than after DBD use (Fig. 20a). A comparison between firefly expression rates in GM cells at 
similar plasma doses revealed that at around 30 J/cm2 lower expression rates were detected 
after jet (31 J/cm2) than after DBD (34 J/cm2) applications (Fig. 20b). Other than that, DBD and 
plasma jet doses between plasma doses of ~70-140 J/cm2 tend to generate similar gene 
expression rates.  
4.2.2 DNA fragmentation capacity of APPs 
Since the HCR assay indirectly demonstrated a fast and high genotoxicity of APPs on isolated 
plasmids, the question of how the DNA is affected by plasma arose. As a first step, 
fragmentation capacities of the two plasma sources were studied using a very simple method, 
i.e. gel electrophoretic separation. As in HCR experiments, firefly plasmid DNA was used.  
Figure 21: DNA fragmentation capacity of the two plasma sources 
The gel picture shows the gel electrophoretic separation of firefly plasmid DNA treated with the µs-pulsed DBD 
device (left) or the kINPen® MED (right). 1 kb weight ladder (L), untreated firefly plasmid DNA (0), and plasmid 
digested with the restriction enzyme (BamHI) are included. The plasmid is present in three different conformations: 
supercoiled conformation (SC), nicked circular conformation (NC), and linearized conformation (LC). Changes in 
bands intensity and the appearance of grey smear are indicator for the fragmentation capacity. Comparable plasma 
doses of the two APPs are marked with asterisks of the same color (blue for ∼30 J/cm2 and purple for ∼100 J/cm2). 
As seen in figure 21, untreated control samples showed a wide band between 5 and 3.5 kb 
that represents the very condensed, so called supercoiled conformation (SC) of the plasmid. 
A second very thin band was visible between 10 and 8 kb representing the nicked circular 
conformation (NC). After plasma treatment of firefly plasmid, a third band appeared at 5 kb. 
Bands at these heights represent the linearized conformation (LC), since the size of the firefly 
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plasmid is 4863 bp (cf. appendix I.7; Fig. 28). In addition, BamHI enzyme digestion verified that 
the linearized form indeed runs at about 5 kb.  
Having said this, short DBD treatments (10 s) induced a decrease in SC yields, higher amounts 
of NC plasmid, and, simultaneously, the appearance of LC plasmids. After longer treatment 
durations with the µs-pulsed DBD (30-180 s) the LC plasmid quantity increased and 
coincidently the NC yield decreased. With longest DBD exposures (270 and 360 s), both bands 
that represent NC and LC plasmids lost intensity indicating a quantitative decrease. 
Furthermore, grey, blurred smear occurred below the LC band at 60 s, which were getting 
brighter with extended treatment durations. Small DNA fragments with variable sizes create 
such smear when running through the gel and, thus, this smear indicates an excessive 
fragmentation of the plasmid DNA. 
Fragmentation was even more pronounced in kINPen® MED treated samples. It has to be 
noted, that in comparison to DBD samples, triple amounts of jet-treated DNA had to be loaded 
into the gel for visualization of bands (cf. 3.4.4). Applications of 10 s and longer, led to clearly 
visible blurred smear. With 60-180 s of APP treatments, they appeared lower and lower in the 
gel. As for DBD treated samples, two bands representing the NC and LC plasmid conformation 
were produced; the intensity of both bands decreased with extended treatments until almost 
no bands were visible after 180 s of plasma application.  
At comparable plasma doses of the DBD and the jet, fragmentation of plasmid DNA was more 
pronounced for plasma jet treatments (Fig. 21; ∼30 J/cm2 and ∼100 J/cm2 marked with blue 
and purple arrowheads, respectively). 
4.2.3 Post-plasma mutation analysis of plasmid DNA 
The PSV assay was established to examine the genotoxic and mutagenic effects of plasma 
treatments on plasmid DNA. Results provide information about mutation frequencies and 
mutation patterns induced by plasma. The assay was performed for the cell line GM, with three 
selected treatment durations each for both of the plasma sources, and in two different versions. 
In the first version, pSP189 plasmid solutions were exposed to either the plasma jet or DBD 
plasma and then transfected into GM cells. In the second version, cells were directly treated 
with plasma after transfection with untreated pSP189 plasmids. In addition, version 1 and 
version 2 experiments always included samples irradiated with UVC as positive control. 
4.2.3.1 Mutation analysis with the PSV-version 1 assay 
1a) Genotoxic effects of plasma treatments on plasmid DNA 
As illustrated in figure 22, relative CFU values decreased with longer plasma application times 
or increasing plasma doses. A comparison on the basis of same treatment durations showed 
that e.g. 10 s of plasma treatment led to a relative CFU value of 67.5% for kINPen® MED 
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applications and to 92.8% CFU for the use of the µs-pulsed DBD. Treatments for 60 s resulted 
in 60% CFU for jet and 56.7% CFU for DBD applications (Fig. 22a). However, in both cases, 
the relative CFU values were not significantly different from each other. After the longest 
treatment duration with 270 s of DBD plasma, only a few colonies could grow on plates resulting 
in a CFU value of 3.1%. The positive control – when plasmid solution was irradiated with a 
UVC dose of 75 mJ/cm2 – induced a very high relative CFU of 87.7%. Comparing the plasma-
type dependent genotoxic effect based on plasma doses, DBD treatments tend to affect 
plasmid DNA stronger than jet treatments did. Significant lower CFU values were detected at 
plasma jet doses of 31 J/cm2 (≙ 10 s) and 92 J/cm2 (≙ 30 s) compared to 23 J/cm2 (≙ 60 s) and 
103 J/cm2 (≙ 270 s) of DBD plasma (Fig. 22b). 
Figure 22: Plasma-type and UVC dependent genotoxicity recorded in the PSV assay-version 1 
The relative CFU values are given as a function of plasma treatment times and UVC irradiation (a), as well as a 
function of different plasma doses (b) for the use of the kINPen® MED and µs-pulsed DBD device. In the latter 
diagram the relative CFU value for the UVC exposure of 75 mJ/cm2 was also inserted, even though the doses of 
plasma and UVC are not comparable with each other. Error bars represent SD values. Statistical differences to 
untreated control samples are marked with ** (p ≤ 0.01). Non-significant differences are marked with (#). Asterisk 
in brackets refer to the comparison of similar plasma doses around 25 and 100 J/cm2 marked with * (p ≤ 0.05). 
  
— 68 — 
   RESULTS     
1b) Spontaneous and plasma-induced mutation frequency on plasmid DNA 
For each experiment, the mutation frequency was separately calculated and then values were 
averaged across experiments. With this, the spontaneous mutation frequency of the pSP189 
vector was calculated to be about 0.8∙10-3 (Fig. 23). Mutation frequencies steadily increased 
with expanded treatment durations of the two sources. In case of the plasma jet, 10, 30, and 
60 s of applications resulted in 2.9∙10-3, 2.1∙10-3, and again 2.9∙10-3 mutation frequencies, 
respectively. For DBD treatments mutation frequencies of 0.9∙10-3 (10 s), 2∙10-3 (60 s), and 
43.3∙10-3 (270 s) were calculated. The mutation frequency for 270 s of DBD application is very 
striking; it is about 54 times higher than the spontaneous rate and even higher than after 
plasmid exposure to 75 mJ/cm2 UVC (mutation frequency: 15.4∙10-3). This high value can be 
explained by the extremely small number of colonies on ‘270 s plates’ (on average, only about 
10 CFUs; i.e. 3.1% CFU relative to untreated control). Therefore, every single mutation has a 
high impact on the mutation frequency. Also, it is obvious that the SD values in figure 23 are 
very high at all treatment conditions. This is due to large differences in colony numbers across, 
but also within experiments. 
Figure 23: Mutation frequencies of plasma- and UVC-treated plasmid DNA 
There is a tendency towards rising mutation frequencies with extended plasma treatment times using the kINPen® 
MED and µs-pulsed DBD device. For clarity, results of 270 s of DBD treatment and UVC irradiation are shown in 
the right diagram; note that the y-axis has a different scale. Error bars represent SDs and the only statistical 
difference to the untreated control is marked with *** (p ≤ 0.001). 
1c) Mutation spectra of plasma-treated plasmid 
The sequences of the supF-tRNA genes on the pSP189 vector were examined for all white 
colonies that indicated a mutation. In table 2, the mutation spectra are shown for untreated 
control samples (spontaneous mutations), for UVC irradiation, and for the different plasma 
sources used. The analysis focused on two general questions: i) what kinds of mutations were 
induced by different plasma sources/UVC and ii) is there a source/UVC dependent mutation 
pattern?   
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Table 2: Mutation spectra of the supF-tRNA on pSP189 plasmid DNA 
The supF-tRNA sequence (grey) with the complementary strand (black) is listed and numbered (starting on position 
27 in the pSP189 plasmid). Bold and underlined bases mark positions of mutations and the respective mutations 
are listed below. Every single row represents a single bacterial colony analyzed. Insertions and deletions are 
marked by vertical lines. Sizes of deletions are provided only if they were countable. 
Spontaneous mutations 
 
27         37         47         57         67         77         87         97         107   
CCACCCCAAG GGCTCGCCGG TTTCCCTCGT CTGAGATTTA GACGGCAGTA GCTGAAGCTT CCAAGCTTAG GAAGGGGGTG GTGGT 
|||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| |||||||||| ||||| 
GGTGGGGTTC CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA GGTTCGAATC CTTCCCCCAC CACCA 
                                 A                                                            
                                                   T   T              A                       
                                                             T                                
 
 
UVC irradiation (75 mJ/cm2) 
 
GGTGGGGTTC CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA GGTTCGAATC CTTCCCCCAC CACCA 
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Jet treatment 
 
10 s (≙  31 J/cm2) 
GGTGGGGTTC CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA GGTTCGAATC CTTCCCCCAC CACCA 
       A T                                                                                    
         A                                                                                    
         T                                                                                    
           G                                                                                  
                                     G                       A                                
                                               T   T                                          
 
30 s (≙  92 J/cm2) 
GGTGGGGTTC CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA GGTTCGAATC CTTCCCCCAC CACCA 
   A                                                         T                                
         T                                                                      T             
                                 A                                                            
                                                   ------------------------------------------ 
                                                       44 bp                   -----    ----- 
                                                                                  5 and 10 bp 
 
60 s (≙  184 J/cm2) 
GGTGGGGTTC CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA GGTTCGAATC CTTCCCCCAC CACCA 
                   G                                                                          
                           T                                                                  
                                                A                                             
                                                                      G                       
                                                                      A                       
                                                                           T                  
                                                     ---------------------------------------- 





10 s (≙  4 J/cm2) 
GGTGGGGTTC CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA GGTTCGAATC CTTCCCCCAC CACCA 
   A                                                                                          
                                                   T   T     T                                
--------------------------------------------------                                            
 
60 s (≙  23 J/cm2) 
GGTGGGGTTC CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA GGTTCGAATC CTTCCCCCAC CACCA 
               T                                                                              
                T                                                                             
                                                       A     A                                
                                                                  A                           
                                                                           G                  
 
270 s (≙  103 J/cm2) 
GGTGGGGTTC CCGAGCGGCC AAAGGGAGCA GACTCTAAAT CTGCCGTCAT CGACTTCGAA GGTTCGAATC CTTCCCCCAC CACCA 
   A                                                                                          
                   T          T                                                               
                          A                                                                   
 
For UVC irradiations in total 53 mutations were detected in 44 bacterial colonies, the majority 
of which were point mutations of the type pyrimidine and purine transitions. Thus, showing a 
mutation pattern induced by UV exposure, as expected. More specifically the following 
mutations were observed: 23 pyrimidine transitions of the type CT, 19 GA purine 
transitions, one AG purine transition, six transversions (3x CA, 1x CG, 1x GT, 
1x TG, 1x TA), two complete deletions, and one insertion of only one A nucleobase. As 
expected for UVC irradiation, pyrimidine rich regions in the sequence were most susceptible 
to generate point mutations; e.g. on position 85 and 91 in the supF-tRNA sequence, seven 
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purine and pyrimidine transitions were found (GA and CT, respectively; red labeled base 
positions for UVC irradiation in table 2).  
For plasma applications, no clear mutation patterns were obvious. In total 23 (in 18 colonies) 
and 15 (in 11 colonies) mutated regions were found after treatments with the kINPen® MED 
and the µs-pulsed DBD device, respectively. In more detail, plasma jet treatments for 10, 30, 
and 60 s led to the formation of 9, 5, and 6 single base substitutions. Deletions were detected 
for 30 s (two deletions) and 60 s (one deletion) of plasma jet application. The DBD plasma 
induced 5 mutations after 10 s, 6 mutations after 60 s, and 4 mutations after 270 s of treatment. 
Only one deletion was found after a 10 s application.  
Similar to UVC irradiation, plasma applications more often caused CT and GA transitions 
than transversions: plasma jet treatments induced 7x CT (4 after 10 s, 2 after 30 s, and 1 
after 60 s) and 1x GA (after 30 s); DBD plasma induced 6x CT (3 after 10 s, 1 after 60 s, 
and 2 after 270 s) and 4x GA (1 after 10 s, 1 after 60 s, and 2 after 270 s). Spontaneous 
mutations (total: 5) were of the kind CT (3x), GA (1x) transitions and one transversion 
(1x CA). 
4.2.3.2 Mutation analysis with the PSV-version 2 assay 
2a) Genotoxic effect of APP on untreated pSP189 plasmid DNA within fibroblasts 
In most cases, the relative CFU values decreased with extended plasma treatments or with 
higher UVC irradiation doses indicating a genotoxic effect due to plasma and UVC on plasmid 
DNA within fibroblasts (Fig. 24a).  
UVC as positive control was applied in different doses than in version 1, because an irradiation 
dose of 75 mJ/cm2 would kill most GM cells in the dish. As expected, the relative CFUs 
decreased as a function of higher UVC doses (2.5 mJ/cm2: 23.3%, 5 mJ/cm2: 19.8%, 
7.5 mJ/cm2: 9.9%). 
CFU values also steadily decreased for plasma jet applications (10 s: 85.1%, 30 s: 79.3%, 60 s: 
59.6%). In contrast, applying the DBD plasma for 10 s to GM cells including untreated pSP189 
DNA resulted in an even higher CFU (166.3%) than in untreated control samples. With the 
longest treatment duration of 270 s the CFU value was reduced to 75.3%.  
When comparing the CFU values of same treatment durations for both sources (10 and 60 s), 
only a significant lower CFU was detectable at 10 s generated by the plasma jet (Fig. 24a). 
Results of the comparison based on similar plasma doses showed that plasma jet and DBD 
treatments induced very similar CFUs in the range of about 25-105 J/cm2.  
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Figure 24: Plasma-type and UVC dependent genotoxicity recorded in PSV assay-version 2 
Relative CFU values are shown as a function of plasma treatment durations (a) and plasma doses (b) for the use 
of the kINPen® MED and the µs-pulsed DBD device. In both plots CFU values induced by UVC irradiations are 
included demonstrating that UVC at these doses had the strongest impact. Error bars represent SDs. Statistical 
differences to the untreated control samples are marked with * (p ≤ 0.05) and ** (p ≤ 0.01). Asterisk in bracket refer 
to the comparison between the two plasma sources applied for 10 s. Non-significant differences are marked with 
(#). 
2b) Plasma-induced mutation frequencies of plasmid DNA transfected into fibroblasts 
In this version of the PSV assay no mutated colonies were detectable on untreated control 
agar plates. In addition, only few mutations were found in treated samples, i.e. only three 
mutated colonies of 3113 colonies, all of which were induced by DBD plasma with 10 and 60 s 
of treatment durations. Hence, the mutation frequency after 10 s of DBD treatment was 
calculated to be 1.88∙10-3 (± 0.81∙10-3) and after 60 s of DBD exposure was 0.84∙10-3 
(± 0.69∙10-3). Only the DBD plasma applied for 10 s generated a slightly higher but not 
significant different mutation frequency than spontaneously evoked (cf. 0.8∙10-3 observed in 
version 1).  
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2c) Mutation spectrum 
Only a few point mutations could be detected in DBD treated samples (table 3).  
Table 3: Mutations recorded in the PSV assay-version 2  
DBD treatment Mutation 
1. colony (10 s) 
2 x CT 
2 x CA 
2. colony (10 s) GA 
3. colony (60 s) GC 
4.2.4 Flow cytometric analyses of genomic DNA damages in fibroblasts 
Gel electrophoresis, HCR and PSV experiments already indicate genotoxic effects of plasma, 
which likely involved the formation of DNA strand breaks. To estimate the amount of DSB as 
a function of plasma treatment time, flow cytometric analyses were carried out with the DSB 
marker γ-H2A.X antibody. The antibody binds to the phosphorylated H2A.X histone protein 
that is known to be formed in high numbers by cells after a single DSB event [152, 154]. The 
assay was only performed with the kINPen® MED device and on GM cells. 
Ionized radiation known to induce DSB events [152, 170] was used as positive control. As 
expected, γ-H2A.X signals increased with higher X-ray radiation doses (upper x-axis in Fig. 
25). The relative γ-H2A.X fluorescence signals also increased with extended jet treatment 
durations (lower x-axis in Fig. 25). Similar γ-H2A.X signals were induced by 30 s and 1 Gy, 60 s 
and 3 Gy, 90 s and 5 Gy, or 180 s and 7 Gy of plasma and X-ray treatments, respectively. 
Figure 25: Plasma- and X-ray-induced DSBs measured as relative γ-H2A.X fluorescence 
The relative γ-H2A.X fluorescence signals generated in GM cells are shown as a function of plasma jet treatments 
and X-ray irradiations. For a better comparability between kINPen® MED and X-ray treatments, two x-axes are 
illustrated: jet treatment times on the lower x-axis and X-ray doses on the upper x-axis. Error bars represent SD 
values. Statistical differences to the untreated control (defined as 1) are marked with ** (p ≤ 0.01) and 
*** (p ≤ 0.001). 
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5. Discussion 
The many advantages of plasma therapy are at present still countered by the necessity of 
assessing the safety of this promising technique. Even though more and more researchers in 
the plasma medicine community perform detailed evaluations of risks and side effects, still, 
plasma specific, official guidelines for medical applications of APPs are missing.  
Such guidelines are especially important in dermatology, where the skin of patients is directly 
exposed to APP. Thus, during application, all plasma components come in contact with human 
cells and their environments, which may be of advantage but also may lead to detrimental side 
effects. Several publications already introduced plasma sources as therapeutic tool in 
dermatology mostly striving to treat highly infected or chronic wounds [5, 25, 110, 165, 171–
173]. In most of the studies, the physical properties of the plasma sources were characterized 
and potential risk factors were named and discussed. However, a comparison of their results 
is impossible since experimental settings and procedures differ greatly between studies. 
Furthermore, biomedical efficiency characterizations of the various sources often did not 
include experiments on genotoxic or mutagenic effects. However, plasma contains a number 
of biologically active particles, some of which are well known to cause genomic alterations, 
e.g. reactive species and UV radiation [12, 17, 174–177]. It was demonstrated for several times 
that plasma applications on isolated DNA induce strand breaks, which lead to DNA 
fragmentation in a dose dependent manner [178–182]. Moreover, various studies confirmed 
that genomic DNA inside the nucleus of cells is also modified due to plasma applications [80, 
182–185]. This may trigger cells to initiate the apoptotic pathway or it may result in the 
formation of mutations within the genome. If manifested mutations are induced and changes 
in the chromatin structure are permanent, the genetic integrity becomes instable and 
oncogenic transformation of cells may occur [186–189], which is a serious threat to humans.  
For these reasons, a complete, detailed characterization of medical plasma sources is of great 
importance, not only for the patients, but also for nurses, physician assistants, and medical 
doctors using the device. Furthermore, it is of quite importance that results obtained with 
different plasma sources or varying efficiency parameters can be compared. With this 
knowledge physical settings and treatment recommendations may be fine-tuned for a specific 
source in order to achieve the best application results for desired effects. 
In this thesis, test systems were developed and described, which were used for a basic 
physical characterization of two different plasma sources. Most, but not all test systems 
described in the first part of this thesis, were published in the DIN-SPEC 91315 [11]. The 
second, major part of this thesis presents procedures and assays, which were established to 
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the use of plasma sources for the assessment of the genotoxic and mutagenic effects. Long-
term damages and possible side effects can thereby be discovered. 
5.1 Basic characterization of medical plasma sources 
In cooperation with the INP, the University Medical Center in Greifswald, the IFS (‘Institut für 
anwendungsorientierte Forschung und klinische Studien’) in Göttingen, and the TU Berlin 
(chair of innovation economics) the first document describing the techniques and methods for 
a basic performance characterization based on defined plasma specific criteria for APP 
sources was developed and published [11]. Part one of the DIN-SPEC 91315 describes test 
systems for measuring generally important physical and technical parameters: i.e. plasma 
temperature, UV radiation, gas emission, and generated currents. In part two, assays to 
evaluate basic biomedical performance characteristics are introduced: i.e. microbial 
inactivation efficiency, cytotoxic effect, plasma-liquid interaction. The two APP devices used in 
this thesis – the kINPen® MED and the µs-pulsed volume DBD – were characterized as 
described in the DIN-SPEC 91315. Minor adjustments had to be made for the use of the DBD 
device because the assays in the document are based on the use of a plasma jet type, only.  
5.1.1 Physico-technical parameters and medical treatment requirements 
The results of physico-technical capacity measurements of the two APP sources indicate that 
both devices are safe in the general use. According to already existing guidelines and 
thresholds (cf. 4.1.1) no risks are to be expected from electric currents, gas temperature, UV 
radiation, and the emission of O3 and NO.  
Nevertheless, the general physical characterization also revealed that during treatments with 
the kINPen® MED device certain requirements have to be complied with. The distance between 
the nozzle and treated object should be at least 7 mm to avoid burns on the skin. As already 
mentioned, the recommended working distance for the kINPen® MED is 7-10 mm [138], which 
is in agreement with the safety aspect regarding temperature. UV radiation generated in this 
plasma should be considered in more detail. According to ICNIRP guidelines [164], thresholds 
for irradiation are reached with 85 s of a spot treatment. To avoid health risks due to UV 
irradiation spot treatments, therefore, must not exceed 85 s, or the jet must be constantly 
moved across the treatment area. The latter would also reduce the actual supplied temperature 
onto the skin. Still, the detrimental impact of highly energetic VUV radiation should not be 
neglected. Even though the effective irradiance of the plasma jet was measured in a wide 
range from 100-400 nm, VUV below 100 nm were not included. VUV radiation can induce 
strand breaks or damage proteins in cells by breaking covalent bonds between C-C or C-H 
chemical compounds [190]. However, there are no sophisticated data or studies that determine 
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exactly VUV emission in the kINPen® MED device, wherefore no reasonable statement can be 
given regarding VUV specific health risks. 
The only limit for applications with the µs-pulsed DBD refers to UV radiation; here, the total 
exposure duration of 7 h per day must not be exceeded. In all in-vivo studies where plasma 
was applied to human or animal skin, advantageous effects were observed after applications 
for less than 10 min at a time [46, 109, 110, 191]. According to the ICNIRP guidelines, 
µs-pulsed DBD applications of this duration are safe and, thus, no risk is to be expected from 
UV radiation. 
5.1.2 Biomedical efficiency of APP 
For a general and basic assessment of the medical potential of APP sources three common 
and easy to perform test systems were chosen. The first test provides information about the 
antimicrobial strength of APP treatments. In dermatological therapy this is important since 
various skin diseases are accompanied or the cause of pathogenic colonization. In wounds 
that go deeper than the epidermis, fibroblasts are uncovered and surrounded by body fluids 
that leak out of the wound. During APP treatments of such wounds fibroblasts will come in 
contact with plasma components wherefore the second test system, namely the MTS assay, 
investigates the cytotoxic effect of APPs on skin fibroblasts. The wound liquid will also be 
affected by plasma. Therefore, the last analysis deals with chemical changes of plasma-treated 
physiological solution. 
5.1.2.1 Plasma inactivation efficiency against microorganisms 
As already mentioned, the same inactivation experiments were not performed with the µs-
pulsed DBD. However, various sophisticated studies examined the antimicrobial effect of 
volume DBDs in similar settings [106, 192]. In Mertens et al. [192] a bactericidal effect on 
E. coli, P. aeruginosa, and C. albicans was already detectable after 2 s of plasma application, 
which corresponds to a low plasma dose of 0.17-0.18 J/cm2. Similarly, in the comprehensive 
work by Daeschlein et al. [106], an effective inactivation of 13 different bacterial and fungal 
wound pathogens was achieved within 3 s. Comparing the bactericidal effect of the kINPen® 
Med device with results presented in Daeschlein et al. [106], antimicrobial elimination efficiency 
was stronger for the use of the DBD source. 1 min (≙ 184 J/cm2) of jet application, e.g. 
generated an inhibition zone of about 113 mm2 in S. epidermidis samples (calculated from 
Fig. 11), whereas 3 s (≙ 0.193 J/cm2) of treatment with the DBD plasma induced an inhibition 
area of about 240 mm2 [106]. It must be noted that in Daeschlein et al. [106] two different 
plasma sources were used; the kINPen09 plasma jet and a volume DBD. The kINPen09 device 
is only in some parts comparable to the kINPen® MED due to different physical settings. 
Nevertheless, the comparison of inhibition zones generated by the two devices also showed 
– in most cases – higher inactivation efficiencies induced by DBD treatments, which is in 
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agreement with the comparison made above. Since the here used µs-pulsed DBD is 
comparable with the one used in Daeschlein et al. [106], it can be assumed that similar 
inactivation efficiencies can be obtained. Moreover, a modified version of this DBD 
(PlasmaDerm® VU-2010) was used in a clinical trial on chronic wounds of the type venous 
ulcus cruris [110]. This study revealed a significant reduction of bacterial loads in the wounds 
and a slightly enhanced wound healing when plasma was applied in addition to standard 
wound care. However, detailed analysis of the µs-pulsed DBD inactivation efficiency is 
required, before this device can be considered as effective antimicrobial toll in dermatological 
therapies. 
Suitability of inhibition zone tests 
The inhibition zone test is a simple technique to evaluate antimicrobial effects of different 
plasmas and, therefore, is appropriate for an uncomplicated assessment of inactivation 
efficiencies of APPs. However, in the DIN-SPEC 91315 we recommend to perform another 
method to estimate the inactivation efficiency. For this test, microorganisms grown in 
suspension must be exposed to plasma before plating. Then, colonies growing on these plates 
are counted and the reduction rate calculated in 10-x log steps. Disinfection is achieved when 
the CFU value was reduced at least by a factor of 10-5 and sterilization level is achieved when 
the germ reduction is at least 10-6. These definitions should be considered as rough guidelines 
for inactivation efficiency tests with plasma because even if a single plasma application of an 
infected wound does not reduce bacteria to disinfection or sterilization levels, in the practical 
medical use, multiple treatments over days or weeks will restrict bacterial overgrowth and, 
thus, continuously improve wound healing. 
5.1.2.2 Cytotoxic effects of APPs on human skin fibroblasts 
The in-vitro MTS assay was performed to quantify the cytotoxic effects of the two plasma 
sources on two different types of human skin fibroblast: i.e. immortalized GMs and PFs isolated 
from healthy skin samples. The results revealed decreasing fibroblast viabilities with extended 
application times or increasing plasma doses (Fig. 13). 
As mentioned before, reactive species generated by plasmas are most likely the main 
mediators for cell responses, followed by UV radiation and electric currents (this refers to 
biomedical APP sources only). In the same manner as ROS and RNS, UV radiation, and 
electric excitation elicit dose or power dependent effects, APP was also found to cause 
different cell responses depending on the treatment duration and on how the plasma was 
produced [21, 23, 182, 193]. This is because these parameters determine the composition of 
the plasma and the plasma dose. In the next two subsections, major mechanisms are 
presented, all of which are likely to contribute to the cytotoxic effect observed in this thesis. 
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Cell membrane damage and elevated endogenous ROS level 
The first target of plasma components in MTS experiments was the PBS covering the cells 
during treatments. PBS has a buffering property via the balanced chemical Eq. 23 that 
efficiently consume OH- and H+ ions: 
H2PO4- ↔ HPO42- + H+.    
 (23) 
In this way, the pH of PBS is effectively stabilized at about 7.4, which was verified by 
measurements of pH changes in plasma-treated PBS (Fig. 17). The same buffering system, in 
addition to some others, stabilizes the pH in intra- and extracellular fluids [194]. Nevertheless, 
if concentrations of OH- and H+ are too high and the buffering capacity is depleted, these ions 
will react with other molecules in the PBS buffer.  
Both devices, the kINPen® MED and µs-pulsed DBD, generate high concentrations of different 
ROS (ROOH, OH●, O2●-) and RNS (NO, NO2-, NO3-). Short-lived and highly reactive radicals 
like OH● will preferentially react with nearby molecules at the point of generation and may then 
be transformed into long-lived species like O3, H2O2, NO2, and O2. These long-lived species 
then diffuse through the PBS solution, reach cells and induce oxidative stress in a number of 
different ways. They can for example directly affect the cell membrane. The lipid bilayer that 
constitutes the cell membrane can be oxidized by such long-lived species or other ROS like 
alkoxyl radicals (RO●) or peroxyl radicals (ROO●), which degrade the membrane [195]. It has 
already been confirmed that plasma applications cause lipid peroxidation of cell membranes 
[196] and, thus, induces transient pores [178], which affect the fluidity and transport properties 
of the membrane. Plasma application may also lead to gaps in the lipid layer by charging the 
lipids [73, 178] due to the electric current flowing across the cells. However, pores in the cell 
membrane enhance the diffusion rate of reactive species into the cell and then, they can react 
with other cell components. UV radiation is also known to affect cell membranes. It can directly 
disrupt the lipids, which leads to the formation of pores, and/or it can oxidize lipids via photo-
generated ROS (e.g. H2O2, OH●, O3, and singlet molecular oxygen (O2 (1Δg)) in aqueous 
solutions [197]. The following equation shows the transformation of O3 and water to H2O2, 
which can be induced by UV light shorter than 330 nm (Eq. 24) [198]: 
O3 + H2O + ℎν  H2O2 + O2.    (24) 
H2O2 itself can be excited by UV light below 300 nm to form OH● radicals (Eq. 25) [198, 199]: 
H2O2+ ℎν  2 OH●.     (25) 
Nevertheless, most researchers are certain that reactive species, especially ROS are 
responsible for plasma-induced cell responses affecting the viability of cells [21, 83, 86, 184, 
200]. Not only does the plasma-mediated formation of ROS in the extracellular space play a 
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central role in triggering cellular oxidative stress, but it also causes elevated endogenous ROS 
levels [21, 114, 201]. One of the main sources of ROS in cells is the mitochondrial respiratory 
pathway, which produces nearly 90% of the cellular energy by oxidative phosphorylation of 
adenosine diphosphate (ADP) to form adenosine triphosphate (ATP) [202–204]. Mitochondrial 
dysfunction due to significantly increased ROS levels can trigger mitochondria-mediated 
apoptosis [205]. The study of Ahn et al. [88] demonstrated that plasma treatment depolarized 
the membrane potential of mitochondria, which is an early event of apoptosis. Other studies 
confirmed that mitochondria-mediated apoptosis is one effect of plasma applications [80, 200].  
DNA damages 
UV radiation produced by plasma sources was assumed to rather play a minor role; at least 
regarding its decontamination and sterilization efficiency against microorganisms [18, 206, 
207]. Even though this assumption is based on prokaryotic inactivation studies, the hypothesis 
that UV may be of minor importance in plasma-cell interactions is, unfortunately, somehow 
generally accepted. Still, since UV radiation has been shown to be a cellular stressor, potential 
medical risks and benefits of this plasma component should also be considered and explored. 
UV radiation does not only affect genomic DNA directly, but is also known to trigger the 
intracellular release and production of ROS [208, 209]. Especially ROS, like O2●- or OH● can 
oxidize DNA molecules and give rise to numerous different DNA lesions or strand breaks via 
reactions with DNA bases or sugar moieties [17–19, 182].  
UV radiation also affects DNA because photons can be directly absorbed by nucleic acids, 
which leads to the generation of photoproducts (CPD and/or 6,4PP). Especially photons from 
UVC radiation produce significant amounts of severe CPD and 6,4PP photolesions. However, 
both plasma devices used in this project do not generate emission bands in the UVC region, 
but UVB and UVA radiations. UVB radiation can directly induce CPD and 6,4PP DNA 
damages, but also other modifications of nucleobases, e.g. the oxidized form of guanine 
7,8-dihydro-8-oxoguanine (8-oxoG) [13, 16]. In contrast, UVA irradiation is thought to mainly 
indirectly evoke DNA lesions or modifications via secondary photoreactions producing ROS. 
Interestingly, some studies found evidence that UVA may also generate photoproducts directly 
[13, 16]. UV-induced injury of skin cells is attributed to aging, wrinkle formation, sunburn, and, 
in the worst, causes skin cancer [12, 13, 16, 161, 162].  
Taken together, all these described influences of separate plasma components can reinforce 
one another during plasma treatments of cells, which results in an overall synergistically 
enhanced effect. 
Cell-type dependent cytotoxic effects 
The results of the MTS assay demonstrate that cell viability of both types of fibroblasts (GM 
and PF) decreased in a cell-type dependent manner with extended plasma treatment times.  
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When using the kINPen® MED device, in all cases GM cells reacted more sensitive to 
treatments than PFs, seen as lower viability values induced after same treatment durations. In 
contrast, at short and direct DBD applications of up to one minute, PFs were more sensitive 
than GMs (Fig. 13b). This indicates that such short DBD treatments somehow are better 
compensated by GMs than PFs.  
One possible explanation could be based on the cellular nature of the two cell types. GM00637 
is a SV40 transformed and, therefore, immortalized cell line. As a consequence, these cells 
divide more frequently than normal cells due to deregulated p53 tumor suppressor proteins 
[210]. The normal cell cycle arrest at checkpoints (i.e. G1/S and G2/M phase) is bypassed, 
which leads to abnormal proliferation behavior comparable to cancer cells. It can be assumed 
that PF cells with normal cell cycle will arrest at checkpoints due to DNA damages induced by 
short DBD plasma application whereas GM cells will proliferate further on until a certain 
threshold of damage or cellular stress. This may explain that treatment durations of up to 60 s 
caused higher cell viabilities of GMs compared to PF cells.  
Extended DBD treatment times of 60 s and longer or plasma doses of 23 J/cm2 and higher 
resulted in lower viability values of GMs compared to PFs, which might be also explained by 
the fact that the proliferation behavior of GM and cancer cells is similar. Cancer cells are known 
to have defects in several signaling pathways, resulting in oncogenic stimulation, increased 
metabolic activity due to apoptosis inhibition, mitochondrial malfunction, and impaired repair 
mechanisms. This leads to an accumulation of defects in the cell, and moreover to a higher 
intracellular ROS level than normal [211–213]. As already stated, plasma applications can 
induce and increase exogenous and endogenous ROS stress for cells. Upon a certain plasma 
dose cancer cells may reach the apoptosis threshold faster than normal cells due to the 
induced ROS stress in addition to the already higher basis level of intracellular ROS [184, 212, 
214]. It might be suggested that GM cells also comprise higher basis ROS levels as a 
consequence of immortalization. Moreover, in the study of Ma et al. [184], cancer cells that 
lack functional p53 showed an exceptionally high sensitivity to repetitive plasma treatments 
compared to p53-proficient cancer cell lines. It is, therefore, quite likely that plasma treatments 
of GM cells led to a stronger cytotoxic effect upon a certain threshold compared to normal and 
intact PF cells. Another explanation can be based on the higher division rate of GMs, wherefore 
cells are more often in the S-phase of their cell cycle. DNA is generally more susceptible to 
genetic modifications in this phase of the replication process [187, 189, 215]. Hence, reactive 
species and UV radiation produced in the plasma may induce more DNA damages in GM cells 
than in PFs. Accumulation of DNA lesions, failure in repairing damages, and resulting genomic 
instability will force the cell to initiate apoptosis or it may degenerate [186, 189]. 
In consistence with these hypotheses, plasma jet treatments with doses of 31 J/cm2 (≙ 10 s) 
and higher induced stronger reductions of GM viabilities compared to PF viabilities. In 
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conclusion, this would mean that induced cell damages with low plasma doses (up to about 
30 J/cm2) do not force GM cells to arrest at cell cycle checkpoints; they proliferate further on, 
while PF proliferation is slowed down in the first instance. At doses ≥30 J/cm2 the induced ROS 
stress might be high enough that the threshold of initiating apoptosis is reached earlier in GM 
cells than in PFs. Due to the abnormal proliferation behavior of GMs the cells presumably 
accumulate more damage. This would lead to a more sensitive reaction of GM cells when they 
are exposed to such high plasma doses.  
Source dependent decrease of cell viability 
When comparing the source dependent cytotoxic effect on fibroblasts on the basis of treatment 
durations, the results clearly evidence that the plasma jet has a faster detrimental impact on 
these cells than the DBD plasma (Fig. 14a). For jet applications, the LD50 value was already 
reached with treatment durations of 30-60 s. With the DBD plasma 180-270 s and 360-480 s 
were necessary to drop GM and PF viabilities to about 50%, respectively.  
It could be assumed that the VUV emission in the plasma jet is responsible for its stronger 
cytotoxic effect. However, this can be disproved by the following experimental circumstance: 
Due to the gas flow of the plasma jet, a PBS-free area in the middle of the cell culture dish was 
produced. Consequently, middle centered cells were not covered by PBS and, thus, they 
quickly dehydrated during treatments. Even if cells were exposed to significant VUV emission 
in this area, they will eventually die anyway. Cells growing at the edge of the PBS-free area 
were likely to be directly exposed to plasma components like UV, aggressive unstable ROS, 
and other radicals, but not VUV. As soon as the effluent mixes up with air, which is at the 
peripheral region around the whole effluent, VUV photons will be efficiently absorbed by N2 or 
O2 [166, 167]. All cells at the very outside of the petri dish are only indirectly treated by the jet, 
so rather come in contact with long-lived species produced by interactions of PBS and the 
plasma. 
In contrast, cells treated with the DBD plasma were constantly covered with PBS. Hence, the 
PBS layer above the cells can buffer short-lived species and, thus, cells rather interact with 
long-lived species. Of course cells will also be exposed to UVA and UVB radiation generated 
by the DBD plasma.  
Nevertheless, since fibroblasts in the center of the petri dish will be in any case eliminated 
during jet applications there is always a certain cell reduction of cells in jet-treated samples. 
This difference in the treatment conditions may be in part one reason for the lower viability 
values after jet applications.  
Following the hypothesis that reactive species, especially ROS, are mainly responsible for 
plasma-induced effects, another explanation could be that the plasma jet device generates 
higher concentrations of reactive species in same time periods as the DBD plasma, which then 
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would lead to a stronger cytotoxic effect. Looking at the indirect plasma treatment experiments, 
this might be true; indirect plasma jet applications decreased PFs viability values significantly 
stronger in comparison to indirect DBD treatments (Fig. 15; blue asterisks).  
Concentration measurements of specific ROS and RNS (H2O2, NO2-, and NO3-) in plasma-
treated PBS revealed that the plasma jet generated higher concentrations of H2O2 but 
extremely lower concentrations of NO2- and NO3- than the DBD plasma after same time 
durations (Fig. 16; cf. 90 s and 180 s). This affirms that the plasma jet is more cytotoxic because 
of a higher ROS production. That long-lived species such as H2O2 indeed greatly influence 
cell viability was evidenced in positive control experiments; here, slightly increasing H2O2 
concentrations already significantly decreased cell viability of GM cells (Fig. 12). H2O2 can 
diffuse across cell membranes and in aqueous solutions it can react to form strongly oxidizing 
OH●. Therefore, already small changes in H2O2 concentrations have a strong impact on 
oxidative stress levels of cells. Moreover, in the close vicinity to and at further distances from 
the plasma jet, higher O3 concentrations were detected than near the DBD plasma. At a 
distance of 15 cm away from the ignited plasma, the DBD device produced 0.042 ppm O3. In 
contrast, at the same distance the plasma jet produced less than 0.2 ppm for 45° of solid angle 
and more than 0.1 ppm for 90° of solid angle (Fig. 10). O3 can react with water to form OH● 
(Eq. 26) or H2O2 (Eq. 27) and, thus, increase oxidative stress on and in cells: 
O3 + H2O  2 OH● + 2 O2,       (26) 
O3 + H2O  H2O2 + 2 O2.       (27) 
As previously mentioned, UVB and UVA radiation can trigger apoptosis via direct and indirect 
damages of cell components, like the cell membrane, proteins, or DNA. In both plasma 
sources, emission lines in the UVA and UVB region were measured showing that the plasma 
jet comprises higher UVA and UVB spectral irradiances than the DBD (Fig. 9). Thus, the power 
input of UV radiation generated by the plasma jet is much higher than in the DBD plasma. This 
could also explain why plasma jet application led to faster cell viability reductions compared to 
DBD.  
When comparing GM cell viabilities on the basis of applied plasma doses, it is obvious that 
between 30-70 J/cm2 jet and DBD plasma induced similar GM damages. At 10 s ≙ 31 J/cm2 of 
plasma jet and 90 s ≙ 34 J/cm2 of DBD application a comparable cell viability of about 82% 
was detected (Fig. 14b). Interestingly, at higher doses (>70 J/cm2) DBD plasma showed a 
tendency towards a stronger cytotoxic impact on GMs than the plasma jet; at around 90 J/cm2 
one significantly lower DBD-induced GM viability was detected. At such high doses the amount 
of deposited reactive species is tremendously higher in DBD-treated PBS than in jet-treated-
PBS (table 1), which possibly is responsible for the stronger cytotoxic effect of the DBD plasma. 
This assumption is further strengthened by statistical analysis of indirect MTS results. When 
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comparing PF viabilities at similar plasma doses of the plasma jet and DBD plasma (i.e. 10 s 
vs. 90 s ≙ ~33 J/cm2, 30 s vs. 270 s ≙ ~98 J/cm2, and 60 s vs. 480 s ≙ ~184 J/cm2) the DBD 
plasma always showed a significantly stronger cytotoxic effect (data not shown). 
Suitability of the MTS assay to investigate cytotoxic APP effects 
The MTS assay is a common cytotoxic test system and provides a simple way to gain 
fundamental information about suitable plasma treatment durations or dose ranges to be 
applied for desired biomedical effects. Based on the results, a comparison of cytotoxic effects 
on different cell types can be done quickly. Furthermore, results obtained with various physical 
settings of the same device (e.g. pulse repetition rate or voltage), as well as different plasma 
sources can be compared with each other. 
However, it should be emphasized that this in-vitro method, in which human fibroblasts were 
treated, constitutes an artificial environment and does not represent an experimental model for 
the human skin. Thus, the results cannot be completely transferred to plasma-induced effects 
on human skin. It is likely, though, that cytotoxic effects tested in-vitro are stronger than effects 
on cells growing in skin tissue, because the uppermost layers of the skin composed of dead, 
flatted keratinocytes will protect the proliferative fibroblasts below. It was, for example, 
demonstrated that penetration of reactive species into the skin is limited to the upper layers of 
the stratum corneum [191]. In addition, for the kINPen09 plasma jet – which is a previous 
laboratory version of the kINPen® MED –, low effective tissue penetration depths (at most: 
60 µm) were determined in pancreatic cancer tissue [216].  
On the other hand, if one imagines a plasma application of a wound, which is deep enough 
that the dermis is exposed, proliferative fibroblasts will be directly hit by the plasma. Therefore, 
basic experiments on fibroblast responses to plasmas on the in-vitro level are necessary to 
gain relevant information about effective dose ranges of plasma sources. 
In addition, ex-vivo or in-vivo investigations of tissue-plasma interactions that are more close 
to the natural situation mostly require expensive and more complicated equipment, animal 
farming, or skin models. Therefore, the MTS assay is a good choice to evaluate cytotoxic 
effects of plasma sources on a basic level. 
5.1.2.3 APP-induced chemical changes (choice of treatment solution) 
The choice of the medium or liquid that surrounds the cells during plasma treatment is of 
tremendous importance for the outcome of plasma-cell interaction experiments. Depending on 
the buffering property of the treatment solution, different concentrations of ROS and RNS are 
formed due to plasma application and, thus, cell responses can vary. In the study of Oehmigen 
et al. [117], for example, plasma inactivation efficiency against bacteria depended on the 
dilution liquid. Bacteria suspended in non-buffered physiological NaCl solution (0.85%) were 
more efficiently inactivated by plasma applications compared to bacteria suspended in PBS. 
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This study further showed that bacterial elimination efficiency was heavily influenced by the 
pH value of the solution. It was suggested that enhanced formation of ROS and RNS in 
non-buffered solutions significantly reduced the pH of bacterial solutions, which resulted in 
higher inactivation rates. Mammalian cell viability also depends on the treatment solution used 
during plasma application. In a study of Wende et al. [83], HaCaT keratinocytes diluted in 
different cell culture media were treated with a plasma jet. After the same treatment times, 
smaller cell numbers were found in plasma-treated RPMI medium than in IMDM medium. This 
implies that the composition of cell culture medium – that differ in organic molecules such as 
vitamins, buffer systems, sugars, and amino acids – has a strong impact on resulting 
plasma-medium interaction chemistry. However, the adherent cell line in this study was treated 
in suspension, which is not a healthy and natural condition for these cells. Therefore, one can 
assume that the HaCaT cells in general were more sensitive to the plasma jet treatment than 
under naturally adherent conditions. Another study compared cell responses of mammalian 
epithelial breast cells incubated in different plasma-treated solutions [21]. For this, 
serum-containing medium, serum-free medium, PBS supplemented with BSA, and PBS alone 
were exposed to plasma prior to cell contact. The results revealed DNA damages in the cells 
in all cases, except for plasma-treated PBS. To further analyze, which components of the 
different solutions were responsible for cell damages, 11 amino acids dissolved in PBS were 
treated with plasma and added to the cells. It was found that the peroxidation effectiveness of 
the tested amino acids directly correlates with DNA damaging rates. This strongly indicates 
the formation of organic peroxides due to reactions of plasma and culture medium compounds. 
UV radiation from the DBD plasma as well as ions and electrons were excluded as reasons 
for DNA damages [21].  
The test systems established during this project should meet the requirements of comparability 
of results obtained by using different devices and/or different cell types. As the compositions 
of different cell culture media are highly variable, a comparison of plasma-induced effects in 
different cell lines would be more difficult when the appropriate cell culture media were used. 
Here, PBS was chosen as cell solution during plasma treatments to avoid culture 
medium-mediated effects on cells and to guarantee the best possible basis for comparability. 
For both sources, pH measurements of plasma-treated PBS solutions revealed only slightly 
reduced values as a function of plasma treatment durations (Fig. 17). In comparison, the DBD 
plasma induced a stronger shift towards an acidic pH than the plasma jet for same treatment 
durations; 180 s of plasma treatment with the kINPen® MED and the DBD plasma led to a pH 
of 7.31 and 7.09, respectively. Comparing similar plasma doses applied to the PBS (e.g. at 
about 184 J/cm2), again a stronger DBD-induced acidification was achieved compared to the 
plasma jet. This difference can be explained by different gases used to operate the devices. 
The jet device produces the plasma in argon gas, whereas humid air serves as process gas 
— 85 — 
Evaluation of long-term damages      
for the DBD plasma. About 78% of the air consists of N2 molecules that can be transferred to 
NO and NO2 (Eq. 4, 13-15) and further to HNO2 and HNO3 in liquid environments (Eq. 17, 20). 
These inorganic molecules decrease the pH of solutions. In consistent with this, NO2- and NO3- 
concentrations were always higher in DBD-treated PBS for same treatment durations as well 
as at similar plasma doses (Fig. 16 and table 1). However, even the strongest decrease of 
about 0.66 found after 600 s of DBD treatment, can be considered as insignificant regarding 
the influence on the normal cell physiology [217]. 
5.2 Evaluation of long-term damages induced by APPs 
As previously said, plasma has the potential to damage isolated and cellular DNA, which 
includes strand breaks. Eukaryotic cells have well-developed defense mechanisms against 
DNA damages and well developed repair pathways that are, for example, triggered by UV 
radiation or the presence of high ROS concentrations. SSBs are most commonly, indirectly 
induced by oxidative attack at the sugar-phosphate backbone. They also are indirectly 
generated during the base excision repair (BER) of oxidative damages on bases, at abasic 
sites, and other adducts. SSB can be in addition directly formed by disintegration of oxidized 
sugar [218]. If not repaired, SSBs might lead to the formation of DSBs [219]. UV-induced 
photolesions, however, are recognized and repaired via proteins of the nucleotide excision 
repair (NER) mechanism [17, 220]. In mammalian cells, DSBs are primarily repaired via 
non-homologous end-joining (NHEJ). DSBs that cannot be repaired represent a special danger 
for eukaryotic cells, for example a single DSB in an essential gene can lead to apoptosis 
initiation. A detailed review of the different repair pathways and mechanisms of the human 
genome can be found in Christmann et al. [220]. However, depending on the amount of DNA 
damages, cells may still be alive but mutated. If the genetic integrity is completely disturbed by 
a high quantity of mutations or DSBs, cells will eventually die. 
In the dermatological use of APP, this might be of advantageous, when the desired effect is 
e.g. to eliminate skin cancer cells. Treating skin diseases with the purpose to enhance the 
wound healing process, detrimental effects like DNA alterations and cell destruction are to be 
excluded. Several groups study the physical and chemical mechanisms underlying 
plasma-induced DNA damages, because they are of crucial importance for a comprehensive 
understanding of the mutagenic and genotoxic effects caused by plasma applications. 
Experiments on isolated DNA (in most cases on plasmid DNA) were conducted to gain 
information about basic plasma-DNA interactions [179, 180, 221–223]. More 
application-orientated studies analyzed cellular DNA damages [79, 80, 183, 224–226].  
In this thesis, different assays and experimental procedures for the evaluation of DNA 
damages induced by plasma treatments were tested. In some of the assays, isolated plasmid 
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DNA was used as experimental target: HCR, gel electrophoresis, and PSV assay version 1. In 
others, cellular plasmid DNA in and genomic DNA of fibroblasts were studied: PSV assay 
version 2 and flow cytometric analysis. The latter test systems are of special interest because 
they show if APPs generate DNA damages in intact cells and, if so, which types of DNA 
damages occur. Furthermore, it is discussed if the test systems are appropriate for the 
assessment of the genotoxic and mutagenic potential of plasmas.  
5.2.1 Genotoxic effect of APP on plasmid DNA 
The HCR assay was used to study the genotoxic effect of APPs on firefly plasmid DNA 
transfected into fibroblasts. After transfection and an appropriate incubation time, the overall 
enzymatic activity of firefly luciferases was measured as luminescence intensity in cell extracts. 
When plasma treatments induce DNA damages in the firefly reporter gene of the plasmid the 
expression of the enzyme will be impeded and, thus, no luminescence signal is detectable. 
Hence, the more plasma-induced DNA damages are generated in reporter genes the lower is 
the relative reporter gene expression, which in turn indicates the genotoxic efficiency. For 
normalization of data, the base-level gene expression of fibroblasts was determined by 
co-transfection of untreated renilla plasmid DNA. 
The results of the HCR assay indicate that the plasma jet and DBD plasma induce DNA 
damages in the firefly plasmid. Already the shortest application time (10 s) dramatically 
reduced the expression of the firefly enzyme in both cell lines (Fig. 19). This demonstrates that 
both plasma sources are highly genotoxic for DNA molecules dissolved in water.  
Cell-type dependent reporter gene expression 
Results suggest a difference in reporter gene expression rates between GM and PF cells. In 
case of using the plasma jet, firefly expression only tends to be higher after transfection into 
PF than into GM cells (Fig. 19a). In contrast, DBD treatments led to significant increased firefly 
expression levels in GMs compared to PFs for 90 and 180 s of treatment durations (Fig. 19b). 
This might be explained by the altered cell cycle and metabolism of the GM cells. As previously 
stated, immortalized GM cells will more quickly leave the G1- and enter the S-phase of their 
cell cycle than healthy cells. This is due to their artificially induced genetic modifications of the 
tumor suppressor protein p53, which speeds-up the DNA replication in GM cells. Since repair 
mechanisms are still functional in these cells [227] and they are more often passing cell cycle 
checkpoints this might result in higher repair rates within the same time period. In addition, the 
elevated proliferation behavior of GM cells can lead to higher transcriptional activity and, thus, 
to higher enzyme expressions. The expression yields of renilla enzyme suggest that these 
assumptions could be true. Indeed, higher renilla RFUs were detected in GM compared to PF 
cells in all individual experiments (data not shown). Furthermore, plasmid DNA exposed to 
intermediate doses of UVB or to intermediate up to high UVC doses also expressed 
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significantly more reporter genes in GM cells than in PFs (Fig. 18), which is in agreement with 
the explanation presented above.  
Source dependent reporter gene expression 
Treatments with the kINPen® MED device reduced firefly expression in GM cells stronger than 
DBD application (Fig. 20a). This indicates a stronger genotoxic effect of the plasma jet after 
same treatment durations.  
Most probably, the same stressors, which are responsible for plasma-type dependent 
differences in cell cytotoxicity, also induce differences in reporter gene expressions in fibroblast 
cells. As introduced before, direct and extensive exposure of DNA molecules to ROS and UV 
radiation can result in DNA lesions, including strand breaks and various kinds of nucleobase 
mutations. Since the plasma jet comprises more O3 and generates higher concentrations of 
H2O2 in aqueous solution after same treatment durations, this could lead to higher amounts of 
OH● formed in water. Besides the direct alteration of bases in the DNA via oxidation, OH● can 
directly damage the deoxyribose of the DNA backbone, remove hydrogen from a deoxyribose 
carbon, and, thus, generate a base release, which further can lead to a strand break [228]. In 
addition to these oxidative damages, UVB irradiation produced in the plasmas can penetrate 
through water and, therefore, affects plasmid DNA. Since spectral irradiance measurements 
confirmed that the plasma jet comprises higher UVB radiation than the DBD plasma, CPD and 
6,4PP photolesions are probably induced in higher amounts by plasma jet treatments. This 
supports the assumption that the plasma jet acts more detrimental to DNA dissolved in water.  
Looking at the expression rates induced by similar energy densities of the sources it is obvious 
that around 30 J/cm2 the plasma jet acts more genotoxic, whereas at doses between 
70-140 J/cm2 expression rates seem to be similar for the use of both sources (Fig. 20b). Gel 
electrophoretic separations of plasma-treated firefly plasmid DNA demonstrated that the 
plasma jet stronger and faster fragments plasmid DNA compared to DBD plasma. Such 
damaged plasmid DNA is lost for the HCR assay because the fibroblasts are not able to repair 
small DNA fragments, whereas other plasma-induced damages like oxidative lesions have a 
chance to be repaired after transfection into cells. However, since the impact of reactive 
species would have to be stronger in DBD-treated samples – because they are generated in a 
considerably larger amount by DBD treatments – the question arises why doses between 
70-140 J/cm2 resulted in similar genotoxic effects. It would be conceivable that the plasma jet, 
due to its high spectral irradiance and low reactive species production, causes similar amounts 
of oxidative and other damages as the DBD plasma by the generation of high reactive species 
concentrations but low irradiation intensities. 
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Suitability of the HCR test system to evaluate genotoxicity of APPs 
The experimental procedure of this test system is not very complex and well reproducible. For 
the performance of the assay a luminometer device and a HCR kit is required. The assay is 
often used for investigations of repair capacities of deficient cells, e.g. of fibroblasts with 
mutations in xeroderma pigmentosum (XP) genes [229, 230]. XP is an autosomal recessive 
genetic disorder leading to an impaired NER pathway wherefore UV-induced DNA damages 
cannot be efficiently repaired anymore. A comparison of the reporter gene expression rates of 
XP-deficient cells and healthy fibroblasts after defined UV-induced DNA damages is, therefore, 
indicative for the severity of a specific XP mutation [230]. However, in this thesis the HCR 
assay was performed to analyze the genotoxic effect of APPs on plasmids. Since healthy cells 
with normal repair capacities were used decreasing relative reporter gene expressions 
indirectly indicate the genotoxicity of plasmas without knowing which DNA damages are 
exactly generated. Therefore, this assay is probably better suited to examine the repair 
capacities of deficient cells after induction of defined DNA lesions. Other test systems may be 
more appropriate to obtain detailed information about genotoxic effects of medical plasma 
sources. 
It should be emphasized again, that these in-vitro results are not transferable to in-vivo effects 
caused by APP application. As already declared, isolated DNA is more susceptible to direct 
APP treatments or UV irradiations than genomic DNA. In addition, similar UVB doses as 
applied in this thesis (Fig. 18a), are also used for phototherapeutic treatments of some skin 
diseases such as eczema or psoriasis [231, 232]. Hence, even though the results clearly 
demonstrate high UVB-mediated genotoxicity, these doses were defined as tolerable for the 
human skin. 
5.2.2 DNA fragmentation due to APP treatment 
A very simple way to test the fragmentation capacity of APP is to separate isolated, 
plasma-treated DNA via gel electrophoresis. Several research groups already used this 
convenient method [178–181, 223, 233, 234]. In conformity with their results, both, the jet and 
the DBD plasma caused strand breaks in plasmid DNA in a dose dependent manner (Fig. 21). 
A stronger fragmentation capacity was observed for the plasma jet compared to the DBD 
plasma after same treatment durations. The same was observed when similar plasma doses 
of the two devices were compared (at doses of ∼30 J/cm2 and ∼100 J/cm2 in Fig. 21). At this 
point it is worth repeating that triple amounts of plasma jet treated DNA had to be loaded onto 
the gel to even visualize bands. Taken together, this strongly evidences a plasma-type 
dependent fragmentation capacity, which is stronger for the kINPen® MED compared to the 
DBD device.  
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Suitability of the gel electrophoresis to study the fragmentation capacity of APP 
As said before, gel electrophoresis is the easiest way to test for plasma-mediated DNA 
degradation and is, therefore, recommended if a rapid assessment of the fragmentation 
capacity is desired. For a more precise quantitative analysis of SSBs or DSBs induced by 
plasma more complex techniques such as the comet assay, immunofluorescence microscopy 
of cells based on γ-H2A.X, immunoblotting, or flow cytometry should be performed [185, 225, 
226]. 
However, additional experiments based on this method should be conducted in different 
solutions, in this case especially in PBS. This is because the DNA degradation rates strongly 
depend on the medium or solution, in which the DNA is dissolved during plasma treatments 
[178, 180]. Cell culture medium and PBS for example protect DNA better from severe damages 
than water, while DNA damages in culture medium was less pronounced than in PBS. It was 
assumed that both, PBS and culture medium, have equal buffering potentials and that due to 
specific medium components radicals may be inactivated to a greater extent than in PBS [178]. 
Another study, demonstrated that small amounts of amino acids like glycine and arginine are 
sufficient to reduce DSB formation in plasma-treated DNA [233]. 
5.2.3 Post-plasma mutation analysis of plasmid DNA 
To guarantee the absolute safety of plasma treatments in medical applications regarding 
harmful long-term effects, experiments on the mutagenic effects of APP sources were 
conducted.  
Quickly performable and widely used, the Ames test, developed by Bruce Ames in the early 
1970s [235], is a convenient test system to examine the mutagenicity of substances, mostly 
chemicals. It is based on Salmonella typhimurium strains that are deficient in producing the 
amino acid histidine due to modified genes, which are essential for the histidine biosynthesis. 
These bacteria, therefore, require histidine presence to grow. If the test substance is 
mutagenic, previously modified genes may be re-mutated so that they regain their function 
and, thus, the bacteria will grow on histidine free medium. Such salmonella are then called 
revertants and the number of revertants correlates with the mutagenic strength of the tested 
substance. However, this assay might not be suitable to assess the mutagenic potential of 
APP sources because the strong antimicrobial effect of plasma might rather eliminate 
salmonella than induce manifested mutations.  
In this thesis the PSV assay was chosen and established to test the mutagenic potential of 
medical plasma sources on human skin fibroblasts. Based on the plasmid pSP189 including 
the mutation reporter gene supF-tRNA mutation spectra following plasma applications can be 
generated. Simultaneously, the test system provides information about the genotoxic effect. 
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Two versions of the assay were designed: In the first version, pSP189 plasmid DNA was 
exposed to plasma and afterwards transfected into GM cells to examine mutations directly 
evoked in isolated DNA. The second version is more application-oriented. Here, untreated 
plasmid DNA was first transfected into fibroblast and afterwards the transfected cells were 
treated with plasma. This was done to test if plasma still alters the plasmid DNA although it is 
protected by the components and the repair system of the eukaryotic cells.  
5.2.3.1 Mutation analysis with the PVS assay-version 1 
1a) Genotoxic effect of plasma-treated plasmid DNA 
For both tested APP sources, the relative CFU values decreased in a treatment time and dose 
dependent manner (Fig. 22). This again demonstrates the genotoxic effect of APP applications 
on isolated DNA.  
After same treatment durations (i.e. 10 and 60 s) jet and DBD applications resulted in similar 
CFU values, although the plasma jet tend to induce a smaller CFU value after 10 s of treatment 
than the DBD plasma. Most of the jet and DBD treated samples tend to be stronger genotoxic 
than UVC irradiation with 75 mJ/cm2; the only exception was 10 s of DBD treatment (Fig. 22a). 
This is similar to HCR results, where UVC exposure with the same irradiation dose generated 
a lower genotoxic effect than most APP applications (cf. Fig. 18b and 20b).  
The comparison of CFU values on the basis of plasma doses applied by the jet and DBD 
device revealed significantly lower DBD-induced CFUs at around 25 and 100 J/cm2 (Fig. 22b) 
indicating stronger damaged plasmids by DBD treatments. This is in contrast to HCR results, 
where doses around 30 J/cm2 showed a stronger jet-induced genotoxicity and around 
100 J/cm2 a comparable effect (Fig. 20b).  
For the firefly plasmids, severe plasmid fragmentation directly leads to the reduction of the 
firefly expression rate. In case of the pSP189 fragmented vectors are lost for the assay 
because they will likely be degraded in GM cells during incubation. Since the plasma jet 
showed a stronger and faster fragmentation capacity than the DBD plasma, it can be assumed 
that a considerable amount of pSP189 plasmids are not included in the resulting data of plasma 
jet treatments in the PSV assay. For transformation of MLB100 bacteria with the isolated 
plasmids from GMs always 50 ng DNA were used. Since at similar plasma doses reactive 
species are produced in higher concentrations by the DBD plasma, these might destroy 
essential genes for bacterial growth – i.e. the ori for bacterial replication and antibiotic 
resistance – to higher extents compared to the use of the jet device.  
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1b) Spontaneous and plasma-induced mutation frequencies of plasmid DNA 
The spontaneous mutation frequency was calculated to be 0.8∙10-3 for the supF-tRNA gene in 
GM cells. Considering the length of the supF-tRNA with 85 bp, a spontaneous mutation 
frequency of approximately 0.9∙10-5 mutations per base pair (mut/bp) was calculated. 
Accordingly, similar mutation frequencies were e.g. generated by jet application of 30 s 
(2.5∙10-5 mut/bp) and 60 s of DBD treatment (2.4∙10-5 mut/bp). Plasma treatments in general 
resulted in higher mutation frequencies for all treatment durations in comparison to the 
untreated control, but none of which were significantly different from the untreated control 
(Fig. 23). Hence, no precise statement can be made about the mutagenicity of the plasma 
sources.  
However, if one compare jet and DBD induced mutation frequencies after same treatment 
durations, it seems like the DBD plasma acts less mutagenic than the plasma jet 
(3.4∙10-5 mut/bp for 10 and 60 s of jet treatments vs. 1.1∙10-5 and 2.4∙10-5 mut/bp for 10 and 60 s 
DBD treatments, respectively).  
The highest mutation frequency resulted from 270 s of DBD exposure (51∙10-5 mut/bp). This 
frequency is even ~3 times higher than UVC exposure to 75 mJ/cm2 (18∙10-5 mut/bp). As 
already explained in the results part, this high value resulted from small numbers of CFUs with 
a very high standard deviation (cf. 4.2.3). In general, very high deviations in colony numbers 
were observed in this assay, which is why at this state of knowledge, precise assumptions 
regarding the mutagenicity are not possible.  
1c) Mutation spectra of plasma-treated plasmid DNA 
Mutation types and mutation patterns were analyzed only within the sequence of the 
supF-tRNA gene. Three types of mutations, i.e. single base substitution, deletion, and insertion 
were detected, the majority of which were single base substitutions. 
Point mutations 
For a better understanding, some definitions and comments regarding point mutation are 
provided. Point mutations can be induced on both strands of the DNA equally. In theory 12 
different base substitutions are possible, namely transitions of the kind CT, GA, TC, 
AG, and transversions of the kind AT, TA, GC, CG, CA, GT, AC, and TG. 
If a DNA lesion at some point leads to a manifested point mutation, e.g. a CT transition, this 
will eventually lead to a GA mutation at the same location on the complementary strand. It 
is however, not possible to identify the exact position of the premutagenic lesion that 
happened. This is why a detected CT mutation represents a GA mutation and vice versa 
(Fig. 26). The same applies to the other point mutations, too. Therefore, hereinafter the 
following designations are used only: C/GT/A, C/GA/T, C/GG/C, A/TT/A, A/TC/G, 
and A/TG/C.  
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Figure 26: Scheme of how a CT transition simultaneously represents a GA transition 
The starting point is a single DNA lesion in the form of a C-C dimer that is induced by e.g. UV radiation. After 
replication of the damaged strand, A bases might be placed opposite from the C-C dimer. After further replications 
T bases will be correctly paired with A bases. Now, depending on the DNA strand which is sequenced, either a 
CT or GA mutation is visible.  
The current understanding of the probabilities of spontaneous appearances of specific point 
mutation types in humans is presented in figure 27. The frequency of spontaneously generated 
mutations in the PSV assay match this information; the majority of point mutations were of the 
kind C/GT/A transitions followed by C/GA/T transversions. C/GT/A transitions are 
characteristic for UVC and UVB irradiated DNA, which most commonly resulted from 
misincorporation of an A on the opposite site of a pyrimidine dimer [176, 236–238]. In total, the 
highest number of such mutations was found in the UVC mutation spectrum as expected; about 
84% of all base substitutions were C/GT/A transitions that included one characteristic 
tandem double CCTT mutation and one GGAA mutation (table 4).  
Figure 27: Scheme of the probability of spontaneously occurring mutations in humans 
In decreasing order: C/GT/A transitions are most common, followed by C/GA/T transversions. C/GG/C and 
A/TT/A substitutions rarely occur, and transversions of the type A/TC/G and A/TG/C are extremely rare (after 
information given in Albrecht-Buehler [239]).  
— 93 — 
Evaluation of long-term damages (Mutation analysis with PSV assay-version 1)     
Table 4: Plasma- or UVC-induced point mutations 
The induced base substitutions after UVC or APP treatments are presented as percent values of all base 
substitutions found for according treatment modality; that are 50 for UVC and 34 for APP applications (nd: not 
detected). 
Type of lesion UVC APP 
C/GT/A transition 84% 59% 
C/GA/T transversion 8% 23% 
C/GG/C transversion 2% 15% 
A/TT/A transversion 2% 3% 
A/TC/G transversion 2% nd 
A/TG/C transition 2% nd 
UVC and plasma generated mutation spectra were different from each other. Although across 
all plasma treatment durations and both plasma sources used, base substitutions of the type 
C/GT/A accounted for the majority as seen in UVC mutation spectrum, transversions of the 
kind C/GA/T and C/GG/C were also induced in a considerable amount (table 4).  
UVB radiation generated in the two plasma sources is likely to produce photoproducts that are 
the cause for C to T transitions. However, G to A transitions also indicate for oxidative lesions. 
In addition, the high number of C/GA/T can also be explained by oxidative DNA damage 
probably mediated by ROS produced in the plasma. Furthermore, plasma generated UV 
radiation also may trigger the intracellular release and production of ROS in cells. The base G 
is a major target of ROS like e.g. H2O2, O2, or OH●. Of the many oxidative damages that modify 
guanine, the mutagenic 8-oxoG is known to most frequently cause C/GA/T mutations [240, 
241], whereas OH● oxidization products of 2’-deoxyguanosine lead to C/GG/C transversions 
[242]. Therefore, the substantial amount of both mutations detected in plasma-treated samples 
in addition to the high yields of C/GT/A transitions may be explained by high numbers of 
oxidative damaged plasmid DNA.  
Insertions and deletions 
Induced or spontaneously generated INDELs can be a severe threat to the genomic stability 
in cells when not repaired. Furthermore, when an insertion or deletion includes only one base 
pair or 3n ± 1 bp within a coding sequence of a protein this leads to a shift in the translational 
reading frame resulting in synthesis failure of a functional protein.  
In UVC exposed samples three of 54 mutations were INDEL events (one insertion of an A base 
and two complete deletions of the supF-tRNA). In comparison to that, in plasma jet exposed 
samples three deletions of 23 mutations were found; this corresponds to about 13% of all 
mutations. The DBD plasma produced only one deletion in 15 mutations (~6.7% deletions). 
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The higher percentage of deletions in jet-treated samples might suggest that deletions were 
rather plasma-induced than spontaneously generated. This would be in consistent with gel 
electrophoresis analysis, where plasma jet treatments led to much stronger fragmentation of 
plasmid DNA than the DBD plasma. 
In summary, mutations induced by UVC exposure of isolated DNA mainly generated C/GT/A 
transitions presumably due to CPD and 6,4PP formations of adjacent pyrimidines. C/GA/T 
transversions and other base substitutions and INDELs were produced to a much lesser 
extent. APP applications showed a different mutation pattern. The high yield of C/GT/A 
transitions can be explained by the combination of induced oxidative DNA lesions via ROS 
formed in APPs and UVB triggered mutations. The intermediate amount of C/GA/T and 
C/GG/C transversions were likely induced by oxidative DNA damage. The same factor may 
be responsible for deletion events in plasma-treated samples. Hence, the mutation spectra for 
plasma treatment mainly suggest oxidative DNA damage but also UVB induced DNA 
modifications. The results are, therefore, in agreement with expected DNA alterations due to 
UV or plasma treatments. 
5.2.3.2 Mutation analysis with the PSV assay-version 2 
Version 2 of the PSV assay was used to gain more information about genotoxic and mutagenic 
effects on plasmid DNA, which was already transfected in cells. For control experiments, lower 
UVC irradiation doses (2.5, 5, and 7.5 mJ/cm2) were used because 75 mJ/cm2 eliminated most 
of the cultured cells (data not shown). 
2a) Genotoxic effect of plasma on untreated pSP189 plasmid DNA within fibroblasts 
A lower genotoxic effect was expected in this version of the PSV assay, because in version 1 
isolated DNA dissolved in water was directly exposed to plasma, whereas in this version 
plasmid DNA transfected into GMs should have been protected by cell components during 
plasma applications. Moreover, plasmid DNA in GM cells might be damaged in other ways due 
to environmental differences of the intracellular space compared to DNA dissolved in water. 
The tendency to increased CFU values might indicate a lower genotoxicity in version 2 than in 
version 1 for the use of both plasma sources (table 5).  
Slightly decreasing CFUs after GM exposure to different low doses of UVC indicate increasing 
genotoxicity. Even the lowest UVC dose (2.5 mJ/cm2) induced stronger damage of the plasmid 
in the GMs than the longest plasma application. Since GM cells that were eliminated during 
plasma application are not included in PSV results and the transformation of MLB100 bacteria 
were always carried out with 50 ng of plasmid DNA, it can be assumed that plasma-induced 
genotoxicity of DNA in the cells might be very low.  
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However, it is very striking that higher relative CFU values were detected for 10 s of DBD 
applications in comparison to untreated samples. This cannot be explained. Here, again 
additional experiments are necessary to review this result. 
Table 5: Comparison of the genotoxic effect recorded in version 1 and 2 of the PSV assay 
Relative CFU values caused by plasma or UVC treatment for version 1 and version 2 of the PSV test are presented 
to quantitatively compare genotoxic effects (± SD). 
Treatment Version 1 Version 2 
Jet 10 s 67.5% (± 13.4) 85.1% (± 12.7) 
 30 s 68.3% (± 18.1) 79.3% (± 5.3) 
 60 s 60% (± 16.1) 59.6% (± 16.6) 
DBD 10 s 92.8% (± 32.7) 166.3% (± 18.3) 
 60 s 56.7% (± 28) 102.2% (± 20.9) 
 270 s 3.1% (± 1.1) 75.3% (± 15.9) 
UVC 75 mJ/cm2 87.7% (± 45.5)  
 2.5 mJ/cm2  23.3% (± 8.9) 
 5 mJ/cm2  19.8% (± 2.5) 
 7.5 mJ/cm2  9.9% (± 8.2) 
2b) Plasma-induced mutation frequencies of plasmid DNA within fibroblasts 
With this version of the PSV assay, no spontaneous mutation events could be detected. Since 
the experimental procedures for the untreated samples were equal in version 1 and 2, the 
previously calculated spontaneous mutation frequency of 0.9∙10-5 mut/bp should, in theory, 
apply to this version, too. Therefore, this value was also used for the mutation frequency 
comparisons in this section. Only in three colonies mutations were found in the supF-tRNA 
region of the pSP189 plasmid, all of which were found after DBD treatments. For 10 s and 60 s 
of plasma application the mutation frequencies were 2.2∙10-5 (± 0.95∙10-5) mut/bp and 
1∙10-5 (± 0.8∙10-5) mut/bp, respectively. The latter is comparable to the spontaneous mutation 
frequency and can be neglected. Therefore, only 10 s of DBD application induced mutations 
on plasmid DNA in GM cells, however, this value depends on the enormously high CFU value 
presented above. 
2c) Mutation spectra of plasma-treated plasmid DNA within fibroblasts 
As previously reported only a few mutations were detected in this version of the test system 
(table 3). The mutations were typical for plasma-induced mutations also found in version 1. A 
closer look at the first single colony in table 3 shows that at a time four base substitutions were 
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detected, and this at a short DNA sequence of only 85 bp. This is surprising and seems very 
unlikely. Since only the mutation frequency of 10 s DBD application is different from the 
spontaneous mutation frequency and this calculation depended on both, the surprisingly high 
CFU value generated by such treatments and the unlikely multiple mutations found in one 
colony, it is, therefore, rather assumed that plasma applications generally do not induce 
mutations in plasmid DNA within fibroblasts. More likely the plasma treatments lead to cell 
damages that trigger apoptosis. 
Suitability of the PSV assay to investigate genotoxic and mutagenic potential of APPs  
The adjustment of this test system to the kINPen MED and µs-pulsed DBD plasma sources 
was very difficult, but finally the establishment was achieved with the presented experimental 
procedure. In general, it can be said that this assay is time-consuming and complex. Every 
single step must be carried out with greatest care in order to avoid the slightest deviations. 
This could be a disadvantage, since even small variations in the experimental procedure can 
lead to high deviations of the data. Hence, this experiment should be repeated very often.  
However, the major advantage of this test is that various detailed information about genetic 
alterations can be simultaneously gained, i.e. genotoxicity rates, mutation frequencies, and 
mutation patterns.  
5.2.4 Flow cytometric analysis of DNA damages in human fibroblasts 
Flow cytometric analysis was performed based on γ-H2A.X staining to investigate DSB 
formation. For experiments, GMs were exposed to either the kINPen® MED device or to X-ray 
radiation, the latter of which is known to induce DSBs in genomic DNA [243]. The damages 
were measured 24 h after plasma or X-ray treatments to study late cell responses and residual 
DNA damages after repair. One of the earliest events following DNA damages in eukaryotic 
cells is the phosphorylation of the histone protein H2A.X [151]. Even a single DSB event 
causes immediate formation of γ-H2A.X proteins in the close vicinity. The phosphorylation then 
propagates from the site of damage to surrounding chromatin domains. By that, hundreds or 
even thousands of γ-H2A.X proteins are induced within minutes and, thus, producing a distinct 
focus within the nucleus [154, 244, 245], which can be visualized by immunofluorescence 
techniques. There is a close one-to-one relationship between DSBs and γ-H2A.X foci 
formation [154, 243]. This is why γ-H2A.X fluorescence is generally accepted as a sensitive 
marker for DNA DSBs [151, 152, 154]. Nevertheless, during specific cell cycle phases, cells 
naturally exhibit a significant amount of γ-H2A.X; higher levels of γ-H2A.X were found in S- and 
G2/M-phase compared to G1-phase [155]. Moreover, DNA fragmentation during apoptosis, 
which includes the generation of many SSBs and DSBs, also leads to high levels of 
phosphorylated H2A.X proteins [246–248]. In cancer cells plasma treatment activate the 
apoptotic pathway, which often led to cell cycle arrest in the sub-G1 phase or the G2/M phase, 
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which in turn caused increased phosphorylation of H2A.X [79–81, 90, 226]. In healthy cells, 
plasma exposure led to higher number of cells in the G2/M phase [82, 83]. It was suggested 
that reactive species play a major role in inducing DNA damages that led to cell cycle 
checkpoint arrests as natural repair response of cells [83, 90, 184, 185].  
In this thesis, γ-H2A.X fluorescence signals increased in GM cells with exposure to extended 
plasma treatment times (10-180 s ≙ 31-551 J/cm2). Due to measurements of untreated control 
samples, the background fluorescence signal of phosphorylated H2A.X histones in a GM 
population including 10,000 cells was quantified and data of treated samples (same number 
of cells included) were normalized to this untreated control. Thus, resulting data represent the 
relative amount of plasma-induced γ-H2A.X fluorescence above thresholds for untreated 
controls, which further indicate DSB formation in the genomic DNA. However, with these flow 
cytometric measurements it is not possible to discriminate if plasma directly or indirectly induce 
DSBs or if DSBs were produced due to other cellular processes like initiation of apoptosis or 
mitosis. 
A study on human epithelial cells (HeLa) claimed that DSBs were indirectly induced by APP 
applications [183]. The cells were exposed for 30 s to a DBD source (plasma dose: 
~7.94 J/cm2) and DSBs were visualized by immunocytochemical staining of γ-H2A.X. While 
immediately fixed and analyzed cells showed almost no γ-H2A.X fluorescent signals, extended 
incubations (4 h and 24 h after plasma treatment) led to increased yields of γ-H2A.X foci. In 
addition, it was suggested that stronger fluorescent signals detected 24 h after plasma 
treatments were a consequence of mitosis. This would indicate for the activation of cell 
proliferation due to 30 s plasma application [183]. Another study used primary human 
fibroblasts for same analyses [84]. It was again verified that γ-H2A.X foci formation increased 
with extended treatment duration and indirect mechanisms were attributed to DSB formation. 
More precisely, the authors suggest that DSBs were generated during the repair processes of 
directly-induced SSBs and base damages via plasma treatments, i.e. during the BER process. 
This is in accordance with another study where increasing γ-H2A.X fluorescent signals were 
also suspected to be a consequence of SSBs or replication arrest in mammalian epithelial 
breast cells [21]. 
However, in this thesis γ-H2A.X fluorescence of plasma and X-ray exposed GM cells were 
compared showing that e.g. 1 Gy and 30 s (≙ 92 J/cm2) or 7 Gy and 180 s (≙ 551 J/cm2) induced 
similar signals, which were about 1% and 42% higher than the untreated control, respectively. 
Considering X-ray doses applied in radiation therapy, daily exposure to about 1.8-2 Gy are 
commonly used; they are called fractions. During therapy, these fractions are repeated until 
the desired total dose is reached. For the treatment of e.g. epithelial tumors the total dose is 
about 60-80 Gy [249]. With these doses controlled apoptosis via the direct induction of DSBs 
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is triggered in cancer cells. If GM cells used in this thesis are similar to cancer cells and 
comparable amounts of γ-H2A.X signals were induced by 1 Gy and 30 s of plasma jet 
treatments or 3 Gy and 60 s, it might be suggested that such short plasma jet applications 
induce similar apoptotic cell numbers via presumably indirectly generated DSBs in cells. 
Suitability of flow cytometric analysis to study APP-induced DNA damages 
Beside flow cytometric analysis of DNA damages based on γ-H2A.X staining, 
immunocytochemistry and Western blot analysis were also widely used to examine cellular 
DSB formations after plasma treatments [81, 185, 226, 250, 251]. 
The immunofluorescence method provides the benefit of detecting single γ-H2A.X focus 
formation in cells. However, with increasing focus numbers it is getting more and more difficult 
to discriminate between distinct foci within the cell nucleus due to variations in the intensity 
and the size. For ionized radiation the immunofluorescence method is, therefore, limited to 
doses below 2-3 Gy. In addition, manually more than 50 cells have to be recorded per sample 
to get valid data [252]. This is why flow cytometry is the better choice for studying ionized 
radiation doses higher than 2 Gy even though single focus formation cannot be distinguished 
from each other. Moreover, additional cell staining with propidium iodide in flow cytometric 
performance would allow for quantitative analysis of the cell distribution according to their cell 
cycle and annexin-V staining would clarify, if DNA damages were the cause of apoptosis 
induced by plasma treatment of the cells. Therefore, the experimental protocol presented in 
this thesis could be improved in this way. Of course, it is also necessary to perform this test 
method with the µs-pulsed DBD source and with PF cells to enable a direct comparison 
between different plasma types, as well as between immortalized and primary skin fibroblasts 
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6. Conclusion 
The innovative field of plasma medicine develops very rapidly, which is why more and more 
plasma devices flood the health-care markets. Various devices that were developed for skin 
applications can be purchased from a number of vendors. The kINPen® MED source, for 
example, which was used in this thesis, or plasma sources from the product family 
PlasmaDerm®  (CINOGY GmbH, Duderstadt, DE). Currently, the leading German research 
groups in the field of plasma medicine, which are associated in a network called ‘Nationales 
Zentrum für Plasmamedizin’, work with public health insurance companies to establish plasma 
applications in a wider range in medicine. However, many research groups still develop their 
own unique plasma sources and, so far, the medical use of these devices is only limited by the 
acquisition of a CE certification as a medical tool. The two sources, kINPen® MED and 
PlasmaDerm®, both purchased the CE certification class IIa. However, this does not guarantee 
a risk-free application. Therefore, it depends solely on the engineers, biologists, physicists, 
and medical doctors, who develop new devices, to ensure that they are well suited for the 
target applications and that they pose no short and/or long-term health risks. 
For this reason, it is necessary to develop test systems that allow a comprehensive 
assessment of the risks associated with the practical use of any medical plasma source. 
Likewise, an evaluation of the medical potential of a plasma source is important in order to 
more reliably predict possible application fields.  
Appropriate test systems for the evaluation of medical APP sources and creation of a 
comparability basis 
In this thesis, various test systems were evaluated with regard to their applicability and usability 
for the assessment of medical plasma sources. It was very important that all the test systems 
could be easily adjusted for the use with different plasma sources. Furthermore, basic 
parameters were identified, which allow a quantitative comparison. On the one hand, plasma 
treatment duration was chosen to compare plasma-induced effects and on the other hand 
results were compared on the basis of the applied plasma doses. For this safety and efficiency 
analysis, two different devices were chosen, namely the kINPen® MED as a plasma argon jet 
device and a µs-pulsed volume DBD, which ignites in air. Because this study was aimed at 
dermatological applications of APPs, in-vitro experiments were performed using human skin 
fibroblasts.  
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Basic characterization of medical APP sources 
The first part of the thesis introduces test systems that enable a basic characterization of the 
physico-technical performances, as well as some bio-medically relevant efficiencies of plasma 
sources that are designed for medical use. Most of them were already published during my 
thesis in the first official German safety document, the DIN-SPEC 91315 [11]. This document 
is a milestone for the plasma medicine community because it represents the initial step towards 
consistent standards and scientifically defined, plasma specific safety and medical application 
criteria.  
Based on the physico-technical characterization the two plasma sources are safe for general 
use, i.e. with regard to electric currents, gas temperature and resulting thermal output, UV 
radiation, and emission of O3 and NO. However, this is only the case under certain conditions. 
For medical application with the kINPen® MED, the distance from the nozzle to the treatment 
object must be larger than 7 mm. In addition, spot treatment duration with the jet must not 
exceed 85 s. Thus, it is recommended to move the plasma jet device at constant speed across 
the surface of the treated object. Furthermore, the potential risk due to the VUV radiation 
emitted in the plasma jet needs to be quantified in more detail, since VUV radiation represents 
a health hazard for humans that cannot be underestimated. When using the DBD device for 
medical treatments, exposure must not exceed 7 h. However, such long applications are very 
unlikely, since APP treatment durations usually are in the range of only a few minutes [108–
110, 253, 254].  
Three test systems were used for a basic assessment of the bio-medically relevant plasma 
parameters.  
The first of three tests is the inactivation efficiency against defined microorganisms. This 
plasma parameter is especially relevant for dermatological therapies because various skin 
diseases are accompanied by bacterial or fungal colonization, e.g. chronic wounds, 
seborrhoeic dermatitis, or acne inversa. For the kINPen® MED device, these experiments could 
only be done during the cooperation with the INP; the results show that the plasma jet efficiently 
eliminates pathogens. Such experiments could not be done with the µs-pulsed DBD device. 
However, a similar, if not stronger, inactivation efficiency is to be expected by DBD treatments. 
This is because a very similar DBD device was proven to more efficiently inactivate pathogens 
compared to a very similar plasma jet device.  
With the use of second test system, i.e. the MTS assay cytotoxic investigations on two different 
skin fibroblast cell lines were performed and revealed a cell-type dependent decrease of 
viability due to plasma treatment. In most cases, immortalized GM fibroblasts reacted more 
sensitive to direct plasma applications than primary fibroblasts. Interestingly, PFs were more 
sensitive than GMs to short DBD treatment of up to 60 s that comprise a low plasma dose (up 
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to 23 J/cm2). The GM cells have an impaired p53 suppressor protein expression and, thus, a 
deregulated cell cycle. Therefore, these cells might accelerate higher levels of cell damages 
at low DBD applications in comparison to healthy PFs. Above a plasma dose of 23 J/cm2, GMs 
may reach the threshold to initiate apoptosis faster than PFs; probably, this is due to ROS 
stress induced by plasma treatments in addition to their increased intracellular basis ROS 
levels. This interpretation is in accordance with some experimental results. Jet applications of 
10 s and longer, which comprise plasma doses ≥ 31 J/cm2, caused stronger reductions of GM 
viabilities compared to PF viabilities, in almost all cases.  
Plasma-type dependent effects on GM viability were initially compared based on treatment 
duration. This revealed significantly lower cell viability induced by the plasma jet. This can be 
explained by two facts: i) a higher jet-induced ROS stress via H2O2 and ii) stronger UV 
irradiances of UVA and UVB, which induced more DNA damages. In indirect MTS experiments, 
i.e. when only plasma-induced chemical changes were the reasons for changes in cell viability, 
the plasma jet reduced PF viabilities more strongly than DBD plasma at same treatment times, 
which is in agreement with the assumption of a higher ROS production in the jet. Thus, ROS-
mediated damages are likely responsible for the observed differences in plasma-type 
dependent cell viabilities.  
Next, APP-mediated cytotoxicity was compared on the basis of similar plasma doses. Here, it 
was apparent that for doses around 98 J/cm2, DBD plasma acted more detrimental on cells 
than the plasma jet. Probably, this is because DBD plasma induced about 7 times higher 
concentrations of H2O2, 50 times higher NO2- and 424 times higher NO3- concentrations than 
the plasma jet at the same dose. The results of indirect MTS experiments further supported 
these data, because at similar plasma doses, i.e. at around 33, 98, and 184 J/cm2, indirect 
DBD applications induced stronger PF cell reductions than indirect jet treatments. 
The third test system describes the analysis of plasma-induced chemical changes of liquids. 
In this thesis, PBS was used since in-vitro experiments were performed in PBS solution. The 
plasma-liquid interactions were studied by measuring differences in H2O2, NO2-, and NO3- 
concentrations. Together with the other test systems, reliable statements and assumptions 
were made about mechanisms which cause cellular effects or genomic alterations, e.g. the 
cytotoxic effect as shown above.  
Chemical analysis of plasma-treated PBS also included the measurement of pH changes. Only 
slightly reduced pH values were demonstrated after treatment with both sources. The largest 
pH reduction from 7.4 to 6.74 was induced by a 600 s (≙ 229 J/cm2) long DBD treatment. Such 
pH changes may inhibit cell growth but barely affect cell physiology [217]. However, at plasma 
doses of about 184 J/cm2 (60 s of jet and 480 s of DBD treatment), acidification was stronger 
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for DBD treatments. This is, of course, due to the fact that DBD plasma generates higher 
concentrations of NO2- and NO3-.  
All of the test systems for the basic characterization of medical plasma sources were well 
adaptable to both types of APP devices used in this thesis. In addition, the test systems are 
easily reproducible without major effort.  
Evaluation of long-term damages of medical APP sources 
The second major part of the thesis focused on potential long-term damages induced by 
plasma applications on human skin fibroblasts. This is of special interest, because in 
dermatology, plasma applications will most likely be repeated in regular sessions over the 
course of some days or even weeks and months, to achieve an improvement of the symptoms 
or cure of a skin disease [109, 110]. However, regular treatments with mutagenic or genotoxic 
substances increase the risk of dramatic consequences such as tumorigenesis.  
The nature of the genotoxic effects of APP sources on isolated plasmid DNA, which is 
dissolved in water was examined with three different methods: the HCR assay, gel 
electrophoretic separation of plasma-treated plasmid DNA, and the PSV assay in version 1. 
All assays revealed that genotoxicity increased as a function of plasma treatment times and 
plasma doses. HCR results indicate a very strong and fast detrimental effect of APP 
treatments, which, at same treatment durations, was more pronounced for the jet device than 
for the DBD source. Together with the stronger and faster fragmentation capacity 
demonstrated via gel electrophoresis, this leads to the assumption that the plasma jet induced 
significantly more DNA strand breaks. Besides that, other types of plasmid DNA damages due 
to plasma treatments are most likely oxidative DNA lesions. In the PSV assay version 1, 
severely fragmented DNA is lost for the assay and, therefore, not included in results. 
Nonetheless, CFU values were significantly reduced after plasma treatments. A comparison 
of plasma doses at around 25 and 100 J/cm2 showed that the DBD plasma led to stronger 
reductions of CFU values than the plasma jet. This can, again, be explained by a higher 
production of reactive species by the DBD. Interestingly, very similar amounts of damages 
were observed in HCR assays at plasma doses between 70-140 J/cm2. Here, it can be 
hypothesized that the higher fragmentation capacity of the plasma jet leads to similarly high 
damage rates as the high concentrations of reactive species of the DBD. Therefore, the overall 
damages induced at theses doses are similar in their severity.  
Calculations of mutation frequencies revealed only a tendency towards rising mutation 
frequencies, even at the longest treatment duration and, thereby, highest plasma dose (270 s 
≙ 103 J/cm2 of DBD treatment). Still, the mutation spectra generated after plasma applications 
showed that APPs modify plasmid DNA. For treatments with both devices, various point 
mutations and deletions were found. The majority of these changes were C/GT/A transitions, 
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which are characteristic for UV-induced photoproducts, i.e. CPD and 6,4PP but also for 
oxidative DNA lesions. This indicates that UV radiation and ROS produced in the plasmas 
have a significant impact on DNA alterations. In addition, noticeable amounts of C/GA/T and 
C/GG/C transversions were generated; again, these indicate oxidative damage through 
ROS attack. A closer look on mutation types generated after same treatment durations 
revealed a higher number of C/GA/T and C/GG/C transversions in the plasma jet than in 
the DBD mutation spectrum (10 s caused 3 vs. 0 and 60 s led to 5 vs. 4 transversions, 
respectively). This suggests, again, a stronger genetic impact of the plasma jet, which probably 
is mediated by higher ROS concentrations generated by the jet plasma. At same plasma 
doses, a higher rate of UV-characteristic and oxidative C/GT/A mutations and more deletions 
were observed in plasma jet treated samples than in DBD treated samples. Both of these facts 
point to a considerable impact by UV radiation. 
Again, all three test methods are well adaptable to different plasma sources. Gel 
electrophoresis is particularly easy to perform. Adjusting the HCR assay was simple too. 
However, this test is actually better suited to examine repair mechanisms in cells, as it only 
represents an indirect measure for studying the genotoxic potential of plasma sources. In 
addition, better statements can be made if induced damages are known and definable. With 
version 1 of the PSV assay, three aspects of genetic modifications can simultaneously be 
revealed. Therefore, the PSV assay is generally better suited for genotoxic and mutagenic 
studies. But, the implementation is more complicated and requires a higher effort. 
For a more detailed analysis of how plasma acts on DNA, which is inside of cultured cells, the 
PSV assay in version 2 and flow cytometry of γ-H2A.X stained DSBs in GM cells were 
performed. In most cases, lower genotoxic effects were observed in version 2 compared to 
version 1 of the PSV assay, which was expected, because cell structures like the cell 
membrane and membrane of the nucleus, as well as the cytoplasm protect the DNA against 
direct modifications by plasma. Surprisingly, the shortest DBD application induced significantly 
higher CFU values than the untreated control, which can, so far, not be explained. However, 
point mutations were detected only in DBD treated samples, which is why mutation frequencies 
and a mutation spectrum were exclusively listed for DBD applications. Even though the 10 and 
60 s of DBD treatments induced a higher mutation frequency, both were not different from the 
spontaneously generated mutation frequency. The induced point mutations were of the type 
C/GT/A and C/GA/T and, thus, not different from mutations found in version 1 of the test. 
It has to be explicitly mentioned once again that the mutations observed here were due to an 
unlikely phenomenon: four mutations occurred at the same time in a single colony. Taken 
together, it is therefore suggested that APP sources do not induce higher mutation frequencies 
in plasmid DNA which was transfected into human fibroblasts and thus, no mutagenic effect 
was detected based on these preliminary results.  
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The flow cytometric experiments of genomic DNA from fibroblasts demonstrated elevated 
γ-H2A.X fluorescence signals, because of an increased number of DSB events due to plasma 
applications. The results were correlated with X-ray irradiations, which are known to directly 
cause DSBs and, consequently, activate apoptosis. Other plasma studies suggest that APP 
induced DSBs in cells via indirect mechanisms. However, together with the cytotoxic effects of 
plasma jet applications observed in this study, it may be hypothesized that comparable 
γ-H2A.X signals induced by e.g. 1 Gy and 30 s of plasma jet treatments or 7 Gy and 180 s 
caused similarly high numbers of apoptotic cells. It would be very interesting to repeat and 
improve these experiments to test if plasma jet and X-ray applications really induce similar 
apoptotic cell numbers. 
Although the last two assays could only be repeated a few times, which led to large standard 
deviations, both of these tests are very well suited to study plasma-induced genomic DNA 
damages. The flow cytometry test could be significantly improved when combined with 
annexin-V and propidium iodide staining.  
Final note to APP applications in medicine 
The test methods used in this thesis only included in-vitro experiments and, therefore, the 
results obtained here cannot be directly transferred to dermatological applications of the 
human skin. Nevertheless, this newly developed set of test systems provides reliable 
information about plasma treatment durations and plasma dose ranges that can be used to 
obtain the desired biomedical effect. In dermatological applications, e.g. in chronic wound 
therapy, detrimental cell and/or DNA effects must be avoided. In contrast, if detrimental effects 
are desired, for example in the cancer therapy, the test systems presented here can be used 
as well to work out the perfect plasma dose and appropriate treatment duration. The results 
from this study cannot exclude mutagenic effects induced by APP sources. Therefore, it has 
to be emphasized that plasma applications must be carefully adapted to the severity of the 
clinical picture of the disease being treated, because the potential risks of plasma treatment 
cannot and should not be neglected.  
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7. Summary 
APP sources have a great potential to be used for a variety of therapeutic purposes in 
medicine. This is because APPs comprise a number of different components that induce a 
unique mixture of biological effects. Because plasma medicine is rapidly developing and 
simultaneously gaining huge interest worldwide, the necessity of clear, official guidelines and 
criteria for medical APP sources is indispensable. It is exactly because of these high number 
of biological active components that a certain degree of risk for the human health has to be 
taken into account. To avoid or at least to limit such risks, while still achieving reliable 
bio-medical effects, test systems are necessary that allow detailed assessments of the 
physico-technical and biomedical properties of APP sources. 
In this thesis, test systems are presented, which provide a basis for testing APP sources with 
regard to both, their medical potential and their possible side effects. At the same time, 
comparability of plasma-induced effects of different sources were realized on the basis of the 
treatment duration and the plasma dose. Thereby, it is possible to fine tune APP devices so 
that they induce a desired biomedical effect within an appropriate treatment time.  
In addition to the essential physico-technical characterization of plasma sources, direct 
plasma-cell interactions and plasma-mediated long-term damages of cells and their 
components were studied. Moreover, it was demonstrated that the following test systems are 
suited for dermatology related applications. All of the tests can be easily adapted to two 
different APP types; i.e. plasma jet devices and volume DBDs. 
Direct plasma-cell interactions: 
A) Inhibition zone tests: wound related microorganisms 
B) Cytotoxicity tests: MTS assay on human skin fibroblasts  
C) Chemical changes in PBS: H2O2, NO2-, NO3-, and pH measurements 
Long-term damages: 
D) Plasmid fragmentation capacity: gel electrophoresis 
E) Genotoxic and mutagenic investigations: PSV assay on DNA in two versions; i.e. 
1. plasma-treated plasmid DNA transfected into untreated fibroblasts; 2. plasma-treated 
fibroblasts previously transfected with untreated plasmid DNA  
F) Formation of DSBs in genomic DNA: flow cytometry combined with γ-H2A.X staining (ideally 
combined with quantitative analysis of cell distribution related to cell cycle phases and 
apoptosis). 
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Appendix 
I. Complete list of materials 
I.1 Devices 
Table 6: Devices 
Description Label Supplier 
Agarose gel    
(melting) Microwave NN-5253 Panasonic, Hamburg, DE 
(trays) Blue Marine 200 Serva, Heidelberg, DE 
(chambers) Special chamber for agarose gel 
electrophoresis 
Hardware & service, Friedland, DE 
(power supply) Mini Power Rack P20 Biometra, Göttingen, DE 
Documentation system Gel iX 20 Imager Intas, Göttingen, DE 
Autoclave DE-65 Systec, Wettenberg, DE 
Bacterial culture  Erlenmeyer flask (200 mL, 500 mL) VWR, Darmstadt, DE 
Centrifuges Mikro 220, Rotor: 1189-A Hettich, Tuttlingen, DE 
 Eppendorf Centrifuge 5415C, Rotor: F 
45-18-11 
Sigma, München, DE 
 Sorvall RC 6+, Rotor: F13S-14x50cy Thermo Scientific, Waltham, US 
 Hereaus Megafuge 1.0R Thermo Scientific, Schwerte, DE 
 MC 6 centrifuge  Sarstedt, Nümbrecht, DE 
Counting chamber Neubauer cell counting chamber Brand, Wertheim, DE 
Dish washer Miele professional Miele, Gütersloh, DE 
Dispenser Multipette® plus Eppendorf, Hamburg, DE 
Drier and sterilizer Memmert SL 50 Willi Fischer KG, Frankfurt, DE 
FACS BD FACS CantoTMII BD Bioscience, Heidelberg, DE 
Refrigerators and 
freezers 
GUS 34420 Bosch, Stuttgart, DE 
 
Arctis (-20°C) AEG, Nürnberg, DE  
glassline (+4°C) Liebherr, Ochsenhausen, DE  
Ultra low MDF-U73V (-80°C) Sanyo, München, DE 
Ice machine ZBE 30-10 Ziegra, Isernhagen, DE 
Incubators CO2-Incubator, MCO-18AIC Sanyo, München, DE  
Incubator model 200 Memmer, Büchenbach, DE 
Incubator shaker Shaker Thermotron Infors, Bottmingen, SZ 
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Description Label Supplier 
Laboratory hood not specified Norddeutsche Laborbau, Quickborn, 
DE 
Liquid nitrogen container Apollo Biosafe Messer Griesheim, Bad Soden, DE 
Luminescence 
measurements 
GlomaxTM 96 Microplate Luminometer Promega, Mannheim, DE 
Microscopes Axiovert 100 fluorescence microscope Carl Zeiss, Oberkochen, DE  
Axiovert Imager.M1 Carl Zeiss, Oberkochen, DE 
Mobile pipettor Pipetboyacu Integra Biosciences, Fernwald, DE 
Orbital shaker Standard 1000 Orbital Shaker  VWR International bvba, 
Geldenaakesbaan, BE 
pH-Meter digital pH-meter, pH 525 Schütt, Göttingen, DE 
 Lab pH Electrode LE438 Mettler-Toledo AG, Schwerzenbach, 
CH 
Photometer Elisa Reader Tecan, Männedorf, DE 
Pipettes Transferpette® S (1000, 100, 20, 
10 µL) 
Brand, Wertheim, DE 
 Eppendorf®Research® (1000, 100, 
10 µL) 
Eppendorf, Hamburg, DE 
 Gilson Pipetman (1000, 200, 100 µL) ABiMED, Langenfeld DE 
 Multipipette®plus Eppendorf, Hamburg, DE 
Plasma devices kINPen® MED INP Greifswald/neoplas GmbH, 
Greifswald, DE 
 µs-pulsed DBD HAWK, Göttingen, DE 
 Power Supply 3045/15 EA-Electronic, Essen, DE 
Scales MC1 AC210S Sartorius, Göttingen, DE 
 Analytic balance BP2100 Sartorius, Göttingen, DE 
Sequence analyzer 3100-Avant Genetic Analyzer Applied Biosystems, Foster City, US 
Spectrophotometer DU 640 Spectrophotometer Beckmann, München, DE 
 NanoVuePlus® GE Healthcare, Buckinghamshire, UK 
Sterile bench Heraeus Instruments NF X 44-201 Schütt, Göttingen, DE 
Tamping machine Tecnomara, Tecnoplug Integra Bioscience, Fernwald, DE 
Thermal cycler Arktik Thermal Cycler Thermo Scientific, Waltham, US 
Thermal block Thermomixer 5436 Eppendorf, Hamburg, DE 
UV-irradiation UVC 500 crosslinker Amersham Biosciences, Glattburg, 
CH 
 BioLink BLX 312 LTF-Labortechnik, Wasserburg, DE 
Vortexer Vibrofix VF1 Electronic IKA Labortechnik, Staufem, DE 
Water bath 1003 GFL, Großburgwedel, DE 
X-ray irradiation RS225 X-Ray Box Gulmay Medical LTD, Camberley, 
Surrey, UK 
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I.2 Disposables 
Table 7: Disposables 
Label  Supplier 
96 well GlomaxTM 96 Microplate Promega, Mannheim, DE 
Cell culture flasks (75, 175 cm3) Greiner bio-one, Frickenhausen, DE 
Cell culture dish (Falcon 35 x 10 mm)  Th. Geyer, Renningen, DE 
Cell scraper 25 cm BD Biosciences, Pharmingen, Oxford, UK 
Combitips plus (0.5 mL) & advanced (5, 10 mL) Eppendorf, Hamburg, DE 
Conical polypropylene tubes (15 mL with and without filter in 
cap, 50 mL) 
Greiner bio-one, Frickenhausen, DE 
Cryo boxes Nunc, Wiesbaden, DE 
Cryo tubes 2 mL Greiner bio-one, Frickenhausen, DE 
Electroporation cuvette (2, 4 mm gap) BioRad, Hercules, US 
Glass cover slips, round, 20 mm Carl Roth, Karlsruhe, DE 
Glass pipettes (5, 10, 25 mL) Brand, Wertheim, DE 
Kimtech wipes Kimberley-Clarke Professional, Roswell, US 
Multiply µStrip Pro 8-strip Sarstedt, Nümbrecht, DE 
Object slide Thermo Scientific, Braunschweig, DE 
Parafilm® Brand, Wertheim, DE 
Petri dishes, with vents (Ø100 x 20 mm, Ø145 x 20 mm) Greiner bio-one, Frickenhausen, DE 
Pasteur pipettes (230 mm) Brand, Wertheim, DE 
Pipette tips (10, 200, 1000 μL) Sarstedt, Nümbrecht, DE 
Round-bottom polystyrene tube 12 x 75 mm (Falcon 5 mL) no 
cap & snap cap 
BD Bioscience, Heidelberg, DE 
Reaction tubes (0.5, 1.5, 2 mL) Eppendorf, Hamburg, DE 
Scalpel, disposable Feather, Osaka, JP 
Syringes, single use (2, 5, 10, 20 mL) Braun, Melsungen, DE 
Sterile filters (pore size 0.2, 0.45 μm) filtropur S (plus) Sarstedt, Nümbrecht, DE 
Tissue culture plates (6-, 12-, 24-, 96-well) Greiner bio-one, Frickenhausen, DE 
Cupper stripes CFT-25/10M Conrad Electronic SE, Hirschau, DE 
Wadding  Brand, Wertheim, DE 
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I.3 Chemicals, reagents, and gas 
Table 8: Chemicals, reagents, and gas 
Chemical/Reagent/Gas Supplier 
2-propanol JT Baker, Deventer, NL 
6x DNA Loading Dye Thermo Scientific, Braunschweig, DE 
Agarose Saekem® Fluka Chemie, Neu-Ulm, DE 
Accutase Biochrom AG, Berlin, DE 
Ammonium chloride (NH4Cl) Merck, Darmstadt, DE 
Ampicillin Sigma-Aldrich, München, DE 
Argon N46 (purity of 99.996%) Air Liquide, Düsseldorf, DE 
Bacto Tryptone  BD Bioscience, Heidelberg, DE 
BamHI 10 U/µL Thermo Scientific, Braunschweig, DE 
Boric acid Merck, Darmstadt, DE 
Calcium chloride (CaCl2) Merck, Darmstadt, DE 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, München, DE 
DpnI 10 U/µL Thermo Scientific, Braunschweig, DE 
dNTP Mix (dATP, dCTP, dGTP, dTTP) Thermo Scientific, Braunschweig, DE 
Dulbecco’s modified Eagle’s medium (DMEM) PAA, Cölbe, DE and others 
Ethanol absolute, 99.8% Merck, Darmstadt, DE 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, München, DE 
Exo-SAP PCR Clean-Up Mix New England Biolabs, Ipswich, US 
Fetal Bovine Serum (FBS) Biochrom AG, Berlin, DE 
Gene Ruler (100 bp #SM0241, 1 kb #SM0311) DNA Ladder Thermo Scientific, Braunschweig, DE 
Glycerol Merck, Darmstadt, DE 
HDGreen Plus DNA Stain Intas, Göttingen, DE 
Hoechst 33342 Thermo Fisher, Dreieich, DE 
Hi-Di Formamide Applied Biosystems, Foster City, US 
Hydrochloric acid (HCl) Merck, Darmstadt, DE 
Hydrogen peroxide (H2O2) 30% Merck, Darmstadt, DE 
IPTG Biotech Trade, Kraichtal, DE 
Isopropanol (C3H7OH) Merck, Darmstadt, DE 
Kalium hydrogen phosphate (KH2PO4) Merck, Darmstadt, DE 
LB Agar Invitrogen, Karlsruhe, DE 
LE Agarose Biozym, Oldendorf, DE 
Lennox L Broth Base  Invitrogen, Karlsruhe, DE 
Magnesium chloride (MgCl2) Merck, Darmstadt, DE 
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Chemical/Reagent/Gas Supplier 
Nonidet P40 Sigma-Aldrich, München, DE 
Paraformaldehyde (PFA) Merck, Darmstadt, DE 
Penicillin-Streptomycin (100x; P/S) PAA, Coelbe, DE 
Potassium Chloride (KCl) Merck, Darmstadt, DE 
Sodium chloride (NaCl) Merck, Darmstadt, DE 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, DE 
Sodium hydrogen phosphate (Na2HPO4 x 2 H2O) Merck, Darmstadt, DE 
Sodium hydroxide (NaOH) Merck, Darmstadt, DE 
Sucrose Sigma-Aldrich, München, DE 
Sulfuric acid (H2SO4) Sigma-Aldrich, München, DE 
Taq DNA Polymerase, recombinant (5 U/µL) Thermo Scientific, Braunschweig, DE 
Tango Buffer 10x Thermo Scientific, Braunschweig, DE 
Tris-Base Merck, Darmstadt, DE 
Triton X-100 Merck, Darmstadt, DE 
Trypanblue Sigma-Aldrich, München, DE 
Trypsin/EDTA Biochrom AG, Berlin, DE 
Tween20 Merck, Darmstadt, DE 
X-Gal Thermo Scientific, Braunschweig, DE 
Yeast Extract BioChemica Th. Geyer, Renningen, DE 
I.4 Ready to use reaction systems 
Table 9: Ready to use reaction systems 
Description Supplier 
Attractene Transfection Reagent Qiagen, Hilden, DE 
BigDye® Terminator v3.1 Cycle Sequencing Kit (3.1 Seq. Kit) Life Technologies, Darmstadt, DE 
CellTiter 96® AQueous One Solution Cell Proliferation Assay Promega Corporation, Madison, US 
Dual-Luciferase Reporter Assay System Promega, Mannheim, DE 
NucleoBond® Xtra MiDi/Maxi Plus Machery-Nagel, Düren, DE 
NucleoSpin Mini plasmid Machery-Nagel, Düren, DE 
Wizard® PCR Clean-Up Kit  Promega, Fitchburg, US 
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I.5 Buffers and solutions 
Buffers and solutions were prepared in autoclaved ddH2O or PBS. Percentage data for 
solutions are given in (v/v). Some liquids had to be additionally sterile filtrated using 0.2 µm 
filters and appropriate syringes. 
Table 10: Buffers and solutions 
Designation Recipe 
Cell culture 
Freezing medium 40% DMEM, 40% FBS, 20% DMSO 
culture DMEM 89% DMEM, 10% FBS, 1% P/S 
DMEM-13%F 86% DMEM, 13% FBS, 1% P/S 
10x PBS; pH 7.4 1.5 M NaCl, 30 mM KCl, 80 mM Na2HPO4 x 2 H2O, 10 mM KH2PO4 
diluted in ddH2O 
PBS 10x PBS diluted 1:10 in ddH2O 
Bacterial culture 
Ampicillin stock solution 100 g/L in ddH2O, sterile filtered 
IPTG stock solution 24 g/L in ddH2O, sterile filtered 
X-Gal stock solution 20 g/L in DMSO, sterile filtered 
CaCl2-glycerol solution 50 mM CaCl2, 15% glycerol 
dYT 16 g/L Bacto Tryptone, 10 g/L yeast extract, 5 g/L NaCl in ddH2O 
LB medium 20 g/L Lennox L Broth Base, 5 g/L NaCl diluted in ddH2O, autoclaved 
LB agar plates with ampicillin 20 g/L Lennox L Broth Base, 15 g/L Agar, 0.5 g/L NaCl diluted in ddH2O, 
autoclaved, when cooled under 60 °C 1 mL/L ampicillin stock solution 
added 
LB agar plates with ampicillin, 
IPTG, and X-Gal 
20 g/L Lennox L Broth Base, 15 g/L Agar, 5 g/L NaCl diluted in ddH2O, 
autoclaved, when cooled under 60 °C 1 mL/L ampicillin, 1 mg/L IPTG, and 
2 mL/L X-Gal stock solution added 
SOC medium, pH 7.0 20 g/L Bacto Tryptone, 5 g/L yeast extract, 1 M NaCl, 1 M KCl diluted in 
ddH2O, autoclaved, Mg2+-and 2 M glucose-stock solutions were added to 
a final concentration of 20 mM each, sterile filtered 
2 M glucose stock solution 360 g/L diluted in ddH2O, sterile filtered 
Mg2+ stock solution 1 M MgCl2 x 6 H2O, 1 M MgSO4 x 7 H2O diluted in ddH2O, sterile filtered 
Agarose gel electrophoresis 
Running buffer TBE (1x oder 
10x) 
89 mM TRIS, 89 mM Boric acid, 2 mM EDTA in ddH2O 
Flow cytometry assay 
Paraformaldehyde (PFA) 3.7% in ddH2O (pre-dissolved using 1 M NaOH) 
Per/Block-solution 0.1% Triton X-100, 10% FBS in PBS 
PBS-Tween 0.05% Tween20 in PBS 
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I.6 Antibodies 
Table 11: Antibodies 
Antibody Supplier Dilution 
Alexa-Fluor® 488 goat anti-mouse Dianova, Hamburg DE 1:400 
Anti-phospho H2A.X Dianova, Hamburg DE 1:4000 
Mouse IgG1 Isotype Control Dianova, Hamburg DE 1:4000 
I.7 Plasmids 
pUC19 plasmid 
The pUC19 cloning vector purchased from Carl Roth (Karlsruhe, DE) was used to determine 
the transformation efficiency in E. coli. It is a small plasmid, 2686 bp in length, and has a high 
copy number.  
Firefly and renilla luciferase plasmid 
The firefly plasmid (pCMVluc; Fig. 28) was a generous gift from Kenneth H. Kraemer, National 
Cancer Institute, Bethesda, MD, USA. Renilla plasmid (pRL-CMV) was purchased from 
Promega (Mannheim, DE). Both plasmids were used in the HCR assay (cf. 3.5.3). Firefly 
plasmid was in addition used in gel electrophoretic separations of plasma-treated DNA 
(cf. 3.4.4). 
 
Figure 28: Scheme of the firefly (pCMVluc) plasmid 
The firefly plasmid includes an ampicillin resistance 
(ApR), restriction sites for different enzymes, and the 
enhancer site and promoter site for the luciferase gene 




pSP189 used for PSV experiments 
This low-copy plasmid was first described by [146]. It includes an ampicillin resistance (ApR), 
replication origins for bacterial and eukaryotic cells (SV40 ori and pBR327 ori, respectively), 
the supF-tRNA gene, and the signature sequence as most important units. This vector was 
used in this project for mutation analysis based on the blue/white-selection of MLB100 bacteria 
(cf. 3.8.4). 
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I.8 Primer 
The primers used for PCR in the course of the PSV assay are presented in table 12. fPrimer 
and rPrimer were used in colony PCR for amplification of the sequence region of interest; that 
is 493 bp of length due to primer choice. The sPrimer was used for sequence PCR with ddNTPs 
to further analyze sequences of the pSP189 supF-tRNA gene and signature sequence 
(cf. 3.4.5). 
Table 12: Primer 
Primer Supplier Sequence 
PL_pSP189_for (fPrimer) Sigma-Aldrich, München DE 5’-CACCCAACTGATCTTCAGCA 
PL_pSP189_rev (rPrimer) Sigma-Aldrich, München DE 5’- GGGAAACGCCTGGTATCTTT 
PL_pSP189_seq (sPrimer) Sigma-Aldrich, München DE 5’- GGCGACACGGAAATGTTGAA 
I.9 Software and online tools 
• BD FACS Diva Software from BD Bioscience 
• Dual Luciferase Reporter Gene Assay: GlomaxTM Software from Promega 
• ELISA reader: MagellanTM data analysis software from TECAN 
• Fluorescence microscope: Axiovert Axiovision 100 from Karl Zeiss 
• Sequence alignment: http://multalin.toulouse.inra.fr/multalin/ 
• Sequence analysis: Chromas Lite 2.1, Technelysium 
• Statistical analysis: SigmaPlot 12.0 
• Text processing, table calculations, etc.: Microsoft Office (Word, Excel, PowerPoint) 
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II. Library of the signature sequence in the pSP189 
#  signature sequence  
1 CGTGAGCTC G ACTGACTCCG GGGTAAC GAG CTC------- ---------- --------AA 
2 CGTGAGCTC G ACTGACTCCA CGATGAC GAG CTC------- ---------- --------AA 
3 CGTGAGCTC G ACTGACTCCG AAAAACA GAG CTC------- ---------- --------AA 
4 CGTGAGCTC G ACTGACTCCA GGGAATT GAG CTC------- ---------- --------AA 
5 CGTGAGCTC G ACTGACTCCC TGCCCAT GAG CTC------- ---------- --------AA 
6 CGTGAGCTC G ACTGACTCCC CCCGACA GAG CTC------- ---------- --------AA 
7 CGTGAGCTC G ACTGACTCCA CACGACA GAG CTC------- ---------- --------AA 
8 CGTGAGCTC G ACTGACTCCT GAAAATA GAG CTC------- ---------- --------AA 
9 CGTGAGCTC G ACTGACTCCG CTTCACA GAG CTC------- ---------- --------AA 
10 CGTGAGCTC G ACTGACTCCT CCAGAAA GAG CTC------- ---------- --------AA 
11 CGTGAGCTC G ACTGACTCCA GCGGAGA GAG CTC------- ---------- --------AA 
12 CGTGAGCTC G ACTGACTCCG ACACAGA GAG CTC------- ---------- --------AA 
13 CGTGAGCTC G ACTGACTCCT ACCGTGG GAG CTC------- ---------- --------AA 
14 CGTGAGCTC G ACTGACTCCG AAGGGCA GAG CTC------- ---------- --------AA 
15 CGTGAGCTC G ACTGACTCCA AATGCCC GAG CTC------- ---------- --------AA 
16 CGTGAGCTC G ACTGACTCCA TATAGGC GAG CTC------- ---------- --------AA 
17 CGTGAGCTC G ACTGACTCCT GTATCTT GAG CTC------- ---------- --------AA 
18 CGTGAGCTC G ACTGACTCCC CTATGCT GAG CTC------- ---------- --------AA 
19 CGTGAGCTC G ACTGACTCCA CTCTGAT GAG CTC------- ---------- --------AA 
20 CGTGAGCTC G ACTGACTCCG GCTACAA GAG CTC------- ---------- --------AA 
21 CGTGAGCTC G ACTGACTCCC ACGGCTT GAG CTC------- ---------- --------AA 
22 CGTGAGCTC G ACTGACTCCT ACCTTTT GAG CTC------- ---------- --------AA 
23 CGTGAGCTC G ACTGACTCCC GAGGAAR GAG CTC------- ---------- --------AA 
24 CGTGAGCTC G ACTGACTCCC CATAATA GAG CTC------- ---------- --------AA 
25 CGTGAGCTC G ACTGACTCCG GCTACAA GAG CTC------- ---------- --------AA 
26 CGTGAGCTC G ACTGACTCCT GCGGCGA GAG CTC------- ---------- --------AA 
27 CGTGAGCTC G ACTGACTCCC GCTCCCC GAG CTC------- ---------- --------AA 
28 CGTGAGCTC G ACTGACTCCG GCGCGAA GAG CTC------- ---------- --------AA 
29 CGTGAGCTC G ACTGACTCCA ACAACCG GAG CTC------- ---------- --------AA 
30 CGTGAGCTC G ACTGACTCCA GCTCCCC GAG CTC------- ---------- --------AA 
31 CGTGAGCTC G ACTGACTCCC TTCAGCA GAG CTC------- ---------- --------AA 
32 CGTGAGCTC G ACTGACTCCC AATAAAG GAG CTC------- ---------- --------AA 
33 CGTGAGCTC G ACTGACTCCA GTATCTG GAG CTC------- ---------- --------AA 
34 CGTGAGCTC G ACTGACTCCT TAAGGGA GAG CTC------- ---------- --------AA 
35 CGTGAGCTC G ACTGACTCCT TGGGTAG GAG CTC------- ---------- --------AA 
36 CGTGAGCTC G ACTGACTCCC TTAGCAT GAG CTC------- ---------- --------AA 
37 CRKGAGCTC G ACTGACTCCG ACACAGA GAG CTC------- ---------- --------AA 
38 CGTGAGCTC G ACTGACTCCA TTATAGG GAG CTC------- ---------- --------AA 
39 CGTGAGCTC G ACTGACTCCA CGGAAGC GAG CTC------- ---------- --------AA 
40 CGTGAGCTC G ACTGACTCCC ATATACT GAG CTC------- ---------- --------AA 
41 CGTGAGCTC G ACTGACTCCT ATGAAC- GAG CTC------- ---------- --------AA 
42 CGTGAGCTC G ACTGACTCCG AAATGAG GAG CTC------- ---------- --------AA 
43 CGTGAGCTC G ACTGACTCCT AGTATAG GAG CTC------- ---------- --------AA 
44 CGTGAGCTC G ACTGACTCCG TGGGCG- GAG CTC------- ---------- --------AA 
45 CGTGAGCTC G ACTGACTCCA GTTCCTT GAG CTC------- ---------- --------AA 
46 CGTGAGCTC G ACTGACTCCA AAAATAT GAG CTC------- ---------- --------AA 
47 CGTGAGCTC G ACTGACTCCA CGATCCT GAG CTC------- ---------- --------AA 
48 CGTGAGCTC G ACTGACTCCT CCGAATA GAG CTC------- ---------- --------AA 
49 CGTGAGCTC G ACTGACTCCT ACAATTG GAG CTC------- ---------- --------AA 
50 CGTGAGCTC G ACTGACTCCG ATAAAAA GAG CTC------- ---------- --------AA 
51 CGTGAGCTC G ACTGACTCCA GCTCCCT GAG CTC------- ---------- --------AA 
52 CGTGAGCTC G ACTGACTCCA ATTGCGG GAG CTC------- ---------- --------AA 
53 CGTGAGCTC G ACTGACTCCG GTTCACC GAG CTC------- ---------- --------AA 
54 CGTGAGCTC T TGCGCAGGGA GTCAGTC GAG CTC------- ---------- --------AA 
55 CGTGAGCTC T GAAATCCGGA GTCAGTC GAG CTC------- ---------- --------AA 
56 CGTGAGCTC C AATTCATGGA GTCAGTC GAG CTC------- ---------- --------AA 
57 CGTGAGCTC T ACGTCAGGGA GTCAGTC GAG CTC------- ---------- --------AA 
58 CGTGAGCTC A CCTGGCCGGA GTCAGTC GAG CTC------- ---------- --------AA 
59 CGTGAGCTC A CAATAGAGGA GTCAGTC GAG CTC------- ---------- --------AA 
60 CGTGAGCTC T TGGCGAGGGA GTCAGTC GAG CTC------- ---------- --------AA 
61 CGTGAGCTC A CGCCGAAGGA GTCAGTC GAG CTC------- ---------- --------AA 
62 CGTGAGCTC A TTAAGCTGGA GTCAGTC GAG CTC------- ---------- --------AA 
63 CGTGAGCTC T GTCACAGGGA GTCAGTC GAG CTC------- ---------- --------AA 
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64 CGTGAGCTC A GCGGATTGGA GTCAGTC GAG CTC------- ---------- --------AA 
65 CGTGAGCTC G AGCGGGTGGA GTCAGTC GAG CTC------- ---------- --------AA 
66 CGTGAGCTC T AACTTTTGGA GTCAGTC GAG CTC------- ---------- --------AA 
67 CGTGAGCTC T ACGAAGGGGA GTCAGTC GAG CTC------- ---------- --------AA 
68 CGTGAGCTC T GCCGCGAGGA GTCAGTC GAG CTC------- ---------- --------AA 
69 CGTGAGCTC C CCAGCTCGGA GTCAGTC GAG CTC------- ---------- --------AA 
70 CGTGAGCTC T TCGATTAGGA GTCAGTC GAG CTC------- ---------- --------AA 
71 CGTGAGCTC C GCTGTTAGGA GTCAGTC GAG CTC------- ---------- --------AA 
72 CGTGAGCTC T AGAATTTGGA GTCAGTC GAG CTC------- ---------- --------AA 
73 CGTGAGCTC A GGGGTTTGGA GTCAGTC GAG CTC------- ---------- --------AA 
74 CGTGAGCTC A ATGAAAAGGA GTCAGTC GAG CTC------- ---------- --------AA 
75 CGTGAGCTC T CAGCAACGGA GTCAGTC GAG CTC------- ---------- --------AA 
76 CGTGAGCTC T TACTGCTGGA GTCAGTC GAG CTC------- ---------- --------AA 
77 CGTGAGCTC A TCTTATTGGA GTCAGTC GAG CTC------- ---------- --------AA 
78 CGTGAGCTC T ATCCCAGGGA GTCAGTC GAG CTC------- ---------- --------AA 
79 CGTGAGCTC A GACCTCAGGA GTCAGTC GAG CTC------- ---------- --------AA 
80 CGTGAGCTC G CGTCGCAGGA GTCAGTC GAG CTC------- ---------- --------AA 
81 CGTGAGCTC G GAGGCGTGGA GTCAGTC GAG CTC------- ---------- --------AA 
82 CGTGAGCTC T ATTTATGGGA GTCAGTC GAG CTC------- ---------- --------AA 
83 CGTGAGCTC T TCATCAAGGA GTCAGTC GAG CTC------- ---------- --------AA 
84 CGTGAGCTC A ATACCCTGGA GTCAGTC GAG CTC------- ---------- --------AA 
85 CGTGAGCTC T TCTTCGTGGA GTCAGTC GAG CTC------- ---------- --------AA 
86 CGTGAGCTC A GCCTGGGGGA GTCAGTC GAG CTC------- ---------- --------AA 
87 CGTGAGCTC A TCTGGGTGGA GTCAGTC GAG CTC------- ---------- --------AA 
88 CGTGAGCTC T AAGCGCCGGA GTCAGTC GAG STC------- ---------- --------AA 
89 CGTGAGCTC T TAGGTCGGGA GTCAGTC GAG CTC------- ---------- --------AA 
90 CGTGAGCTC T AGGTGGGGGA GTCAGTC GAG CTC------- ---------- --------AA 
91 CGTGAGCTC T AATTCCTGGA GTCAGTC GAG CTC------- ---------- --------AA 
92 CGTGAGCTC T MGGTCTTGGA GTCAGTC GAG CTC------- ---------- --------AA 
93 CGTGAGCTC G TGACGGGGGA GTCAGTC GAG CTC------- ---------- --------AA 
94 CGTGAGCTC G CGTGTCAGGA GTCAGTC GAG CTC------- ---------- --------AA 
95 CGTGAGCTC A CCGGAACGGA GTCAGTC GAG CTC------- ---------- --------AA 
96 CGTGAGCTC C TTCGGTCGGA GTCAGTC GAG CTC------- ---------- --------AA 
97 CGTGAGCTC A TGGCGGTGGA GTCAGTC GAG CTC------- ---------- --------AA 
98 CGTGAGCTC T AGAGCGTGGA GTCAGTC GAG CTC------- ---------- --------AA 
99 CGTGAGCTC A CGGATTAGGA GTCAGTC GAG CTC------- ---------- --------AA 
100 CGTGAGCTC A TCAGTTAGGA GTCRGTC GAG CTC------- ---------- --------AA 
101 CGTGAGCTC C AAACATGGGA GTCAGTC GAG CTC------- ---------- --------AA 
102 CGTGAGCTC C TCGTATTGGA GTCAGTC GAG CTC------- ---------- --------AA 
103 CGTGAGCTC A CGGAGAGGGA GTCAGTC RAG YTC------- ---------- --------AA 
104 CGTGAGCTC A TTACGCAGGA GTCAGTC GAG CTCGACTGAC TCC-ATGCTA A-GAGCTCAA 
105 CGTGAGCTC A CGCCTTCGGA GTCAGTC GAG CTCTGATGGC TGG-AGTCAG TCGAGCTCAA 
106 CGTGAGCTC G ACTGACTCCC TTTTGAT GAG CTCGACTGAC TCC-CACTCT CAGAGCTCAA 
107 CGTGAGCTC G GGTACCGGGA GTCAGTC GAG CTCCTAATTC GGGGAGTCAG TCGAGCTCAA 
108 CGTGAGCTC C CAGCGTTGGA GTCAGTC GAG CTC------- ---------- --------AA 
109 CGTGAGCTC A ATGGGTAGGA GTCAGTC GAG CTC------- ---------- --------AA 
110 CGTGAGCTC A TACTAACGGA GTCAGTC GAG CTC------- ---------- --------AA 
111 CGTGAGCTC T ATTGTTCGGA GTCAGTC GAG CTC------- ---------- --------AA 
112 CGTGAGCTC G TCCCTAAGGA STCAGTC GAG CTC------- ---------- --------AA 
113 CGTGAGCTC G ACTGACTCCA CATCATT GAG CTC------- ---------- --------AA 
114 CGTGAGCTC - ---------- ------- --- ---------- ---------- --------AA 
115 CGTGAGCTC - ---------- ------- --- ---------- ---------- --------AA 
116 CGTGAGCTC R ACTGACTCCT GGSTCCG GAG CTC------- ---------- --------AA 
117 CGTGGACTG A TWAGGACCTW MKAAGTC CST GAC------- ---------- --------GG 
118 CGTGGAAGG A ATTGAATCTT CGGACTC GAT GAC------- ---------- --------RG 
reference CGTGAGCTC N NNNNNNNNNN NNNNNNN GAG CTC------- ---------- --------AA 
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